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ABSTRACT 
TUNING ESTERASE ENANTIOSELECTIVITY FOR THE SYNTHESIS OF 
UNNATURAL SERINE AND TYROSINE ANALOGUES 
by 
Dale Anthony Rosado, Jr. 
December 2009 
The synthesis of disubstituted and homologated unnatural amino acids and the 
development of a mass spectrometry based assay for enantioselectivity are presented 
here. Disubstituted and homologated unnatural amino acids have proven to be effective 
for the treatment of diseases and for use as imaging agents. Peptides that contain 
unnatural amino acids have also proven to be effective treatments for various disease 
states including cancer. The potential to evaluate such unnatural amino acids for 
pharmaceutical properties is limited by the available syntheses. No method currently 
exists that will allow for the synthesis of homochirally similar unnatural amino acids 
from a common intermediate. Herein is described a method that will allow for the 
synthesis of both enantiomers of disubstituted and homologated serine and tyrosine 
analogues from a common malonate half ester intermediates via several well-known 
functional group transformations and protecting group chemistry. The described synthetic 
methodology has resulted in the synthesis of both enantiomers of a-methyl-, P ' -, and 
(33,3-serine and both enantiomers of a-methyl-, p2,2-, p3'3-, and y4'4- tyrosine analogues 
and one enantiomer of a y ' - tyrosine analogue. 
Synthesis of the aforementioned unnatural amino acids requires a chiral malonate 
half ester. To obtain this half ester intermediate, a malonate diester is enantioselectively 
ii 
hydrolyzed by Pig Liver Esterase (PLE) to give an excess of one enantiomer of a 
malonate half ester over the other. The enantiomeric composition of the unnatural amino 
acids is dependent on the enantioselectivity of the enzyme. An increase in the 
enantioselectivity of the enzyme is needed if less than 97% enantiomeric excess (ee) is 
obtained from the enzymatic hydrolysis. This process can consume a tremendous amount 
of time and materials. This dissertation also describes the development of a high 
throughput electrospray-mass spectrometry based assay for determining the 
enantioselectivity of PLE for malonate diesters. The mass spectrometry assay has been 
utilized to evaluate the hydrolysis of three malonate diesters under a variety of cosolvent, 
buffer, and pH conditions. The PLE hydrolysis of a diester that was used to synthesize 
unnatural serine analogues was improved from 70% to greater than 97% ee. The 
hydrolysis of another diester that was used to synthesize unnatural tyrosine analogues 
was improved from 63% to 85% ee. This assay has proven to be a powerful tool for the 
enhancement of the enantiomeric composition of malonate half esters that can be used for 
the synthesis of disubstituted and homologated unnatural amino acids. 
in 
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CHAPTER I 
PEPTIDOMIMETICS, UNNATURAL AMINO ACIDS, AND MASS 
SPECTROMETRY: TYING IT ALL TOGETHER 
Introduction 
The National Research Council published "Beyond the Molecular Frontier" to 
state the challenges facing chemical scientists in the 21st century. One of the stated goals 
for synthetic chemists is to develop new syntheses using enzymes as catalysts to make 
compounds and materials of value.1 The publication also states that compounds of 
pharmaceutical interest, either synthons or complete compounds, are perhaps the most 
important of the current synthetic endeavors. The overall goal of research in the 
Masterson research group is to synthesize small peptidomimetic compounds and test their 
potential for use as pharmaceutically active compounds, both in vitro and in vivo, as 
compared to the natural peptide. This dissertation will detail the efforts to create a series 
of homochirally similar unnatural serine and tyrosine analogues from a common 
intermediate (Scheme 1.1). The common intermediate is synthesized by use of pig liver 
esterase as a desymmetrization enzyme. The primary disadvantage of our proposed 
synthesis is that PLE may not yield compounds of sufficient enantiomeric composition 
(greater than 97% enantiomeric excess (ee)) for further synthesis. In an attempt to solve 
this problem, a high-throughput MS based assay that allows for the monitoring of the 
enantioselectivity of enzymes under a variety of conditions was devised. Once the 
enantioselectivity problem has been solved, synthesis of our unnatural amino acids can 
continue, which may ultimately result in a peptidomimetic compound with increased 
biological stability and activity that may be used as a receptor specific imaging or a anti-
disease compound. 
Prochiral Malonate 
1-1 o 0 
RO^>><OOR 
' R* 
R = CH3, CH2CH3 
R'= 2 
PLE 
Good % ee 
Malonic Half Acid 
0 0 1 -2 
RO-^X^OH 
/ \ > 97% ee 
\ 
OBn 
MS Probe 
O O 1.3 
RO
 (>>>S OR" 
R" = CD3, CD2CD3 
MS Assay 
(R) % ee Improvement From MS Assay 
3-(S) P-Pro 
• t f 
Peptidomimetic Synthesis 
Ar§ XArg I pr° j ( T y r ] ( I l e X L e u H ) H 
m / z Nuerotensin(8-13) 
Scheme 1.1 The development of novel unnatural tyrosine analogues for 
incorporation into neurotensin peptidomimetic compounds 
Literature Review 
Peptidomimetics 
A peptide is defined as two or more amino acids that are covalently joined by an 
amide bond. Peptides can be composed of two 
to fifty amino acids. Peptides are involved in 
many functions throughout the body including 
peptide hormones, signaling, clearing of 
xenobiotics as peptide conjugates, and as 
antibiotics. Peptides are made and / or 
released as needed and are degraded or 
deactivated as soon as their function has been 
fulfilled. The efficiency of this process is 
increased by the high level of specificity 
Figure 1.1. The primary structure of 
exhibited by receptors for specific peptides. glutathione and the TER199 
glutathione derivative 
Metabolic diseases are the result of a cell that has lost control of this regulation which can 
be caused by environmental or biological events. Peptidomimetic compounds are 
structurally similar and can be derived from natural peptides that are involved in some 
form of a disease state (up-regulation or down-regulation of genes, peptide aggregates, 
etc.). These compounds are designed to mimic the biological activity of a natural peptide 
or inhibit a receptor or enzyme. These compounds also display increased in vivo 
properties such as stability to the cellular machinery that is normally responsible for 
degradation of natural peptides. Synthesis of peptidomimetic compounds can be 
accomplished by covalent modification of the natural peptide, replacement of specific 
1.8TER199 
4 
residues with unnatural amino acids, or a combination of both. An example of a small 
peptidomimetic compound is the TER199 (y-glutamyl-5'-(benzyl)cysteinyl-i?-(2)-phenyl 
glycine diethyl ester, 1.8) glutathione (1.7) derivative of which the cysteine residue had 
been S-benzylated and glycine has been replaced by phenyl glycine (Figure 1.1). This 
compound has shown the ability to inhibit a specific isozyme of glutathione S-
transferase (GSTP1-1), which is responsible for metabolizing multiple xenobiotics, 
including anti-cancer medication, through glutathione conjugation and can be responsible 
for drug resistance. Inhibition of this isozyme with TER 199 led to prolonged uptake and 
activity of several drugs that had previously shown resistance.4 
It has been shown that cancerous cells in various tumor tissues express large 
quantities of peptide hormones and, more importantly, peptide hormone receptors.5'6 
Many of these peptide hormones and receptors are expressed in specific tissues and 
should not be expressed in normal tissues elsewhere in the body. Another important 
characteristic of peptide hormones is that after binding to their receptor, they can be 
internalized into cells.7'8 This can result in an increase in concentration of these peptides 
in tumor cells. These properties make peptide hormones promising candidates for 
evaluation as potential peptidomimetic drugs. Somatostatin (SST, 1.9) is one such peptide 
hormone that has received much attention. Naturally, SST functions to regulate the 
secretion of growth hormone, insulin, glucagon, secretin, and vasoactive intestinal 
polypeptide.9 Given the broad regulatory ability of SST, this peptide hormone was chosen 
for evaluation as one of the first peptidomimetic drugs. The initial research was focused 
on creation of an imaging agent. However, somatostatin has proven to be a very efficient 
hormone peptidomimetic at treating a variety of cancers by providing regulation of 
5 
mitosis.10 This has led to development and FDA approval of several synthetic peptide 
drugs which have comparable activity to somatostatin, but have increased half-lives in 
vivo (somatostatin half-life = 2 to 3 min, octreotide half-life = 90 min).9'11'12 They are 
available under the names octreotide (1.10), lanreotide (1.11), and vapreotide (1.12, 
Figure 1.2). The major advantage of these peptidomimetic drugs is that minimum 
chemical modification of natural peptide hormones can lead to compounds that are 
sufficiently stable to proteolysis and have high affinity and selectivity for the receptor of 
the native peptide. This is in contrast to the tremendous amount of trial and error that is 
involved in developing a new drug candidate. 
1.12 Vapreotide 
Figure 1.2. The native primary structure of Somatostatin (1.9) with protease 
cut sites indicated by arrows. Octreotide (1.10) Landtreotide (1.11) and 
Vaprotide (1.12) both with indicated modification of the active residues 
(highlighted in blue) 
Picking a Target: Neurotensin 
It is now clear that peptidomimetic compounds have a multitude of uses in the 
pharmaceutical world. With an unknown number of peptides performing various 
functions in the body, it is necessary to determine a target peptidomimetic compound. An 
ideal target will 1) be a small peptide composed of a minimum number of active amino 
acid residues and 2) contain minimum protease cut sites. The small nature of the peptides 
should make them amenable to efficient solid phase peptide synthesis. Neurotensin (NT, 
7 
1.13, Figure 1.3) is a peptide hormone which meets the desired properties. Literature has 
also shown that this peptide exhibits potential for imaging and cancer treatment.5' 
However, the short half-life of NT in the blood (1.5 minutes) limits the potential use of 
natural NT.13 As discussed earlier, this problem may be solved by the incorporation of 
unnatural amino acids into protease specific cut-sites in the peptide. It has been shown 
that replacement of several specific amino acid residues with unnatural analogues 
(unnatural side chains) has lent dramatically to the stability of these NT analogues in 
human serum. Furthermore, some of the existing NT analogues exhibit increased binding 
affinity for the NT receptor.13 
1.13 
fpGluYLeu Y Tyr Y Glu Y Asn Y Lys Y Pro Y Arg Y Arg Y Pro If Tyr ) ( lie j f Leu J—OH 
Figure 1.3 Condensed structure of Neurotensin. The protease cleavage site of interest 
between the tyr-ile bond is highlighted in red 
Neurotensin is a 13 residue peptide hormone. Neurotensin was discovered in 1973 
by Carraway et al.14 The amino acid sequence was later determined and the peptide was 
synthesized by solid-phase peptide synthesis. Neurotensin is found primarily in the 
central nervous system and the intestinal tract. In the central nervous system, NT 
functions as a neurotransmitter or neuromodulator of dopamine transmission and in 
anterior pituitary hormone secretion.15 In the digestive tract, NT functions as a local 
hormone that exerts paracrine and endocrine modulations of the digestive tract and the 
cardiovascular system in mammals.15'16 NT has also been shown to be involved in 
immune response in the gut, as well as a growth response in a variety of other tissues. 
8 
Neurotensin and the NT receptor have been found to be over expressed in 
Ewing's sarcoma (65%), mengiomas (52%), 
astrocytoma (43%), medulloblastoma (38%), 
medullary thyroid carcinoma (29%), and 
small lung cell cancer (25%).17 Additionally 
NT receptors have also been found in 
prostate cancer cell lines18, breast cancer cell 
lines , pancreatic cancer cell lines , and 
colon cancer cell lines13. In 1998, Reubi, et 
al. confirmed the presence of NT receptors in 
human exocrine pancreatic tumors (Figure 
1.4). This was accomplished by testing 24 
patients with ductal pancreatic 
adenocarcinomas, 20 with endocrine pancreatic cancers, 18 patients with chronic 
pancreatitis, and 10 healthy patients. Acetyl-NT(1-13) was labeled at 3-Tyr with l25I, 
apposed to 3H hyperfilms (Where a tissue slice containing a radioactive isotope is 
exposed to film by placing the tissue directly on the film.), and subjected to x-ray 
cassettes for seven days. Reubi was able to conclude that NT receptors were present in 
75% of the human ductal adenocarcinomas examined and up to 83% of the highly 
differentiated tumors expressed NT receptors. Equally important was the fact that NT 
receptors were not found in the pancreatic tissue of healthy patients or in the pancreatic 
tissue of patients with chronic pancreatitis (a disorder that can lead to pancreatic 
adenocarcinomas).5 The high level of specificity exhibited by NT for exocrine tumors 
Figure 1.4. A & B. Autoradiograms of a 
Haematoxylin-Eosin stained pancreatic 
tumor. C & D Autoradiodiagram of the 
same tumor with 125I-NT 5 Reproduced 
with permission from BMJ publishing 
Group Ltd 
combined with previously developed Octreoscan (a labeled somatostatin analogue 
specific for types endocrine pancreatic cancer (since NT receptors were not expressed in 
the endocrine pancreatic cancer)) could make NT a powerful therapeutic tool able to 
selectively identify the presence and type of tumors 
(Figure 1.5).5 
B 
m-m 
Neurotensin: Evaluation of Primary and Secondary 
Peptide Structure for Design of a Peptidomimetic 
Compound 
It is important to know the binding site of 
peptides when designing peptidomimetic drugs. Some 
peptide hormones may bind to several different 
subtypes of receptors; each with varying affinity. If 
peptidomimetic NT analogues exhibit internalization it 
may allow for efficient use of the analogues for 
imaging.2 ~22 To date, three subtypes of the NT 
receptor have been discovered.15'' The most important characteristic of the 3 NT 
receptor subtypes in regard to this dissertation is that they all recognize the same C-
terminal 8-13 sequence and have similar structure-function with regard to NT.16 To 
determine if NT exhibits internalization upon binding to the NTS, Chabry et al1 used a 
radio-labeled NT analogue. It was found that after 1 hour of incubation with NTS-1 
cells, at 37 °C, 56% of 125I-NT that bound to NTS-1, was internalized into cells that had 
Figure 1.5. Autoradiodiagram 
of an endocrine pancreatic 
tumor A. Haematoxylin-Eosin 
B. 125I-NTC. 125I-Octreotide 5 
Reproduced with permission 
from BMJ Publishing Group 
Ltd 
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been transfected with NTS-1. This was further confirmed by using NT labeled with a 
fluorescent tag. It has also been observed that all three subtypes of NTS participate in 
internalization.8 The internalization of the NT/NTS means that NT has potential for use 
as an imaging agent or a receptor-specific drug. The genes for NTS-1 have been shown to 
be fairly conserved in rats, mice, and humans.16 The conserved nature of these genes 
makes rats and mice ideal candidates for in vivo testing of potential NT analogues. 
When designing peptidomimetic compounds it is necessary to determine two 
properties of the peptide of interest: 1) the smallest peptide that retains biological activity 
and 2) the active residues of that segment. Once the active residues are determined, these 
residues can then be 
replaced with homologous 
1-14 unnatural amino acids or 
Figure 1.6.NT(8-13) Smallest NT analogue that 
maintains biological activity w l t h o t h e r unnatural amino 
acids that retain the properties of the residue of interest. Determination of the shortest 
active fragment of NT was performed by Carraway et al. Using native NT 1-13 as a 
control, NT fragments synthesized that were truncated at both the N and C termini. The 
biological activity of each fragment was then tested using rats and guinea pigs. It was 
determined that these NT analogues maintained their biological activity (60 to 70% of 
native NT activity) as long as the last six residues remained intact (NT(8-13), 1.14, 
Figure 1.6).2 St-Pierre et al. determined which residues were responsible for binding to 
the NTS by systematically replacing specific amino acids with either similar amino acids, 
D-amino acids, or alkylated amino acids. It was determined that 8-Arg, 9-Arg, and 10-
Pro were required for binding. Removal of 8-Arg or substitution of 9-Arg with D-Arg 
11 
resulted in significant loss of binding to the NTS-1. The same effect was seen when 10-
Pro was replaced with D-Pro. This was proof that L-Pro is required for the correct 
conformation for binding to the NT receptor. The most important finding was that 
replacement of 11-Tyr with any amino acid (D-Tyr, Phe, Z)-Phe, Ala, Leu, D-Trp, and 
Tyr(OMe)) but Trp led to a dramatic loss in activity. This led St-Pierre, et al. to conclude 
that the 11! residue must be an aromatic I-amino acid capable of H-bonding. 
The 3-dimensional structures of peptides are also important in designing 
peptidomimetic compounds. The spatial arrangement of the functional groups of a 
peptide can greatly influence binding affinity. Therefore, it is important that a 
peptidomimetic compound display a similar 3-D structure as compared to the native 
peptide. This means that it is important to know the solution and binding conformations 
of the peptide of interest. Nieto et al. were able to confirm that NT(1-13) has no stable 
secondary structure in solution. This was accomplished by a 'H-NMR study of NT(1-13), 
NT(l-8), and NT(8-13) in the presence of a temperature gradient (-5 to 38°C), denaturing 
agents (6M urea), and a pH gradient. No significant difference in conformation was seen 
for NT(1-13), NT(l-8), or NT(8-13) in the presence of any of the above conditions. 
Furthermore, no presence of peptide aggregates were found in concentrated solutions of 
NT(1-13). It was concluded that NT(1-13) assumes a random coil in solution. It is also 
necessary to determine if NT adopts a particular conformation upon binding to the NTS. 
This was accomplished by using l3C, l5N-labeled NT(8-13) peptides that were bound to 
the lipid reconstituted NTS-1.26 Two dimensional ,3C-I3C (2Q,1Q) NMR correlation 
experiments were used due to the method's ability to select for pairs of nearby 13C-' C 
nuclei (directly bonded). This study determined that the 10-Pro residue with a y/Pro 
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dihedral angle of 146 ± 15° allows NT and NT analogues to assume a P-strand 
conformation when bound to NTS-1. This means that any structural modification that 
allows the peptidomimetic compound to retain or more readily assume the binding 
conformation may increase the binding affinity of the peptidomimetic compound for the 
NTS. 
In light of the discovery that NT and NTS are over expressed in cancer tissue, 
several different approaches to adapting NT and truncated NT analogues for use as 
cytotoxic drugs and/or imaging agents have been developed. As mentioned earlier, there 
are two primary problems that must be overcome when designing NT analogues: 1) the 
NT analogue must be stable to endogenous proteases and 2) the binding affinity to NT 
receptors must be retained or improved upon. Knowledge of prior attempts to make a NT 
peptidomimetic compound is necessary to pick an amino acid residue on which to focus 
our synthetic efforts. The primary focus for the development of NT analogues is the 
NT(8-13) fragment. The labile nature of NT(8-13) has been attributed to the 8-Arg- 9-
Arg, 10-Pro- 11-Tyr, and the 11-Tyr- 12-Ile peptide bonds.13'24'27"32 Therefore, 
modification at these residues has been the primary focus of recent NT research. 
Several groups have recently shown that replacement of either the 8-Arg with a 
single basic amino acid, or both the 8-Arg -9-Arg with either two new basic amino acids 
or a single amino acid capable of mimicking both 8-Arg -9-Arg, has increased binding 
affinity to NTS-1 compared to NT(8-13) or NT(8-19).13'27"32 Some of these groups have 
also addressed the liability of the 11-Tyr-12-Ile peptide bond by replacing the lie residue 
with bulkier unnatural amino acids. Linquist et al.33 working with a proposed binding 
model of NT(8-13), developed NT analogues in which the 9-Arg residue was replaced 
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with azido acids 1.15a-e and 1.16 in Figure 1.7 that could mimic the 8-Arg- 9-Arg, but 
reduce the molecular weight of the analogue. These NT analogues were compared to 
NT(9-13)(hNTR-l 
affinity = 19.0 ± 
2.0 nM) and it was 
found that every 
analogue showed a 
higher binding 
(hNTR-1 affinity = 
Figure 1.7. 8-Arg- 9-Arg mimics synthesized by Linquist et al33 »
 Q . . . 
affinity to the hNTS-1 thanNT(9-13), with the exception of the NT(9-13) analogue 
containing compound 5, which had a comparable binding affinity (hNTR-1 affinity = 28 
±5.0nM) toNT(9-13). 
Achilefu et al. synthesized NT(8-13) analogues that contained unnatural amino 
acids to replace several specific residues (Figure 1.8). These NT(8-13) analogues 
contained a diethylene tetramine pentaacetic acid (DTPA) moiety capable of chelating 
" ' in (1.17, Figure 1.8), which was used for nuclear imaging. It was observed that 1.17 
had a IC50 value of 0.3 nM (compared to NT(1-13) IC50 = 0.2 nM and NT(8-13) IC50 = 
0.4 nM). To test stability, 1.17 was incubated in rat serum and urine for 4 hours at which 
time fractions were taken and injected into reverse-phase HPLC (RP-HPLC). It was 
observed that 1.17 was 96% intact in serum and 94 % intact in urine. It was found that 
replacement of 12-Ile with t-butyl glycine dramatically improved the stability of 1.17 
over other analogues containing 12-Ile. It was also stated that replacement of 11-Tyr 
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with D-Tyr in the same position (1.18) gave the greatest stability of the NT analogues in 
this study. However, the IC50 value for 1.18 was greater than 1000 nM confirming St 
Pierre's earlier statement that there was a decrease in binding of NT(8-13) analogues that 
contained D-Tyr.24 
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Figure 1.8. DTPA labeled NT(6-13) analogue containing a 9-Arg mimic (1.17) 
and DTPA labeled NT(6-13) analogue containing D-Tyr (1.18). The unnatural 
amino acids (1.19-1.31) incorperated into NT(6-13) analogues synthesized by 
Achilefu, et al.13 
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Kokko et al. reported that truncated analogues of NT with N-terminus azide 
moieties have the ability to cross the blood-brain barrier (BBB). These NT analogues 
were of interest as 
Leu | - n ) H P° s s i b l e anti-
psychotics. 
Figure 1.9. NT(8-13) analogue (1.32) capable ^corporation of the 
of crossing thr blood-brain barrier . , ., 
azido group, as well as 
replacement of the 12-Ile residue with a L-tert-Lue residue, was shown to dramatically 
increase the stability of the NT analogues from a half-life of 5.78 minutes (NT(8-13) 
Figure 1.14) to a half-life of 24 hours. The NTS showed no tolerance for 1.32 (Figure 
1.9) after 5 days of increased loading (5 mg / kg body weight). Furthermore, this 
compound did not induce catalepsy (a common side effect of antipsychotic drugs where 
the body becomes rigid while a person is unconscious). Compound 1.32 also exhibited a 
long half-life (t\a = 24hours) and the azido group was shown to have little or no effect on 
the binding affinity of 1.32 to the NT receptors as compared to NT(8-13).29 This example 
of the ability of an NT analogue to cross the BBB further demonstrates the invaluable 
utility of peptides like NT as tools and templates for pharmaceuticals. 
Only one group has studied the effects of replacing the 10-Pro residue on binding 
affinity. Based on the dihedral angles of the NTS-1 bound NT(8-13) deduced by Luca et 
al. , Bitterman et al. proceeded to incorporate functionalities that would allow NT 
analogues to maintain a stable binding conformation. Replacement of the 10-Pro residue 
has been approached by substitution with 4,4 spirolactams. Bitterman et al. found that 
compound 1 (Figure 1.10), which had a (//Pro dihedral angle of + 128.7°, showed a 1000 
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,3Leu 
Figure 1.10. A representation of the peptide 
backbone of NT(8-13) and spirolactam 
containing analogues 1 and 2 34 Reproduced 
with permission from the American Chemical 
Society 
ability of compound l.34 The results of this experiment specifically demonstrate the 
fold increase (Kj = 12 ± 0.73 nM) in 
binding affinity to porcine NTS-1 
when compared to the more flexible 
[ll-NMeTyr]NT(8-13) (Kj = 12 ± 
150 nM, The [1 l-NMeTyr]NT(8-13) 
was used to mimic the loss of 
hydrogen bonding due to the 
spirolactam structure of compound 
1.). Compound 2, with a i//Pro 
dihedral angle of-128.7° exhibited a 
dramatic loss of binding affinity 
(17000 ± 1200 nM). Compound 1 
does exhibit lower binding affinity for 
the NTS-1 thanNT(l-13)(Kj= 1.3 
nM). It was concluded that this was 
due to the loss of hydrogen bonding 
necessity of the correct conformation in NTS-1 binding. 
One human trial has been carried out to date using a NT analogue. Buchegger et 
al.35 conducted the first clinical trial of a 99mTc-NT(8-13) analogue with the following 
structure: [99mTc(CO)3](NaHis)Ac-Lys-(CH2-NH)-Arg-Pro-Tyr-Tle-Leu. The NT 
analogue was stabilized by replacing the 8-Arg- 9-Arg bond with a pseudopeptide bond 
and replacing the 12-Ile residue with a f-butyl Leu. This analogue was chosen due to its 
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binding ability to the NTS-1 and its long half-life. Four volunteers were used in the study, 
each having been previously diagnosed with ductal pancreatic adenocarcinomas. All 
patients were injected an average of 20 hours before a surgery was conducted to remove 
the tumors. Whole-body scintographies were conducted pre-surgery on two of the 
patients and abdominal scintographies were conducted on all four patients. Patient 4 
showed moderate tumor uptake and the tumor was visible in the abdominal scintogram. 
Presence of the radiotracer uptake by the tumor in patient 4 was seen even after 20 hours. 
The half-life of the 99mTc-NT(8-13) analogue was determined by drawing blood samples 
at various times between 17 and 383 minutes. The in vivo half-lives in humans were 
determined to be 1.7-6.3 hours. The test results were a confirmation of earlier tests 
performed in rats. 
In summary, it is clear that modification of the 8, 9 Arg-Arg bond has led to NT 
analogues with sufficient Ua and binding ability. Replacement of the 12-Ile with an 
unnatural amino has also lent to the stability of NT analogues, possibly due to the 
creation of steric bulk at the Tyr-Ile cut site. It has also been shown that NT analogues 
that maintain the binding conformation of NT have a higher binding affinity than 
analogues that contain residues that result in modified 3-D structure. 
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Description of Dissertation Research 
Synthesis of Unnatural Tyrosine Analogues 
Interestingly, with all the research done on NT analogues and all of the amino 
acids replaced to increase half-life or affinity, the question of modification of the Tyr 
residue to increase the half-life still remains somewhat ambiguous. It was concluded from 
the work of St-Pierre et ai. that the residue in this position must be the L-isomer of an 
aromatic amino acid capable of hydrogen bonding.24 Achilefu et al. later confirmed that 
binding was decreased when Tyr1' was replaced with a D-Tyr, but stability was greatly 
increased.13 However, to our knowledge, no group has explored the replacement of the 
Tyr residue with an Z)-a-methyl Tyr, P ' Tyr, or p ' Tyr. It is for this reason that our 
synthetic efforts will focus on the creation of both enantiomers of a series of unnatural 
tyrosine analogues for eventual incorporation into NT analogues for use as potential 
peptidomimetic compounds. 
Several a-methyl 
amino acids exhibit 
medicinal properties and 
potential for use as 
imaging agents.37 Several 
medicinally active 
compounds are currently 
Figure 1.11. Structure of the classes of unnatural 
available that contain P amino acids synthesized in this dissertation 
and y amino acids. " Literature has also shown that incorporation of a-methyl and 
homolongated amino acids (i.e. p and y-amino acids) can induce secondary structure and 
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increase the proteolytic stability of peptides. " Incorporation of unnatural tyrosine 
residues into NT(8-13) may result in a pharmaceutical^ active peptidomimetic 
compound. Tyrosine analogues are needed in order to synthesize these peptidomimetic 
compounds. For this reason, the primary focus of this dissertation will be the synthesis of 
the a-methyl, (5-, and y- classes of the homolongated, disubstituted unnatural amino acids 
(Figure 1.11). Each of theses classes of unnatural amino acids exhibits unique properties 
when incorporated into peptides. These properties create a need for an efficient synthesis 
of both enantiomers of each class of unnatural amino acids. Currently, synthesis of a 
variety of homolongated amino acids requires many different synthetic paths. This makes 
synthesis of a series of homologous amino acids a daunting task. This section will outline 
our approach to the synthesis of a-methyl (1.33), p2'2 (1.34), p3'3 (1.35), y2'2 (1.36), and 
y4'4 (1.37) tyrosine residues from a common intermediate. 
One popular method is to generate an unnatural amino acid from a natural amino 
acid.42'43'47 The disadvantage of this method is that the types of unnatural amino acids 
that can be synthesized are limited. This method requires careful control of reaction 
conditions without which may lead to racemization through epimerization at the a-
carbon. Another popular approach is to use chiral catalyst to generate the unnatural amino 
acids.48 This requires the use of expensive metal catalysts and may require an extensive 
amount of trial and error to select ligands that will give the desired stereochemistry and 
enantiomeric composition. Transition metal catalysts may also have significant problems 
with functional group tolerance which can limit their application. The shared 
disadvantage of both of these methods is that they draw from a pool of chiral molecules 
which can cause additional detriment to the cost effectiveness of the synthesis. 
The ideal synthetic scheme should make use of simple chemistry, use cost-
effective starting materials, have common synthetic intermediates, use common 
chemistry, and induce or conserve the configurations of the starting materials. One 
candidate that fits these criteria is malonic diesters. The acidity of the a-protons of 
malonates makes the generation of enolates efficient. The resulting enolate can then 
nucleophilically attack a variety of electrophiles to generate a tetrahedral center. This 
creates a pro-chiral compound that can be converted to a chiral compound by hydrolysis 
of one of the esters. The result is a half-ester that can be transformed to a variety of 
functional groups. If the starting material is a 2-methyl malonate diester (1.38), the 
derivatives will contain a neopentyl-like framework that does not racemize through 
epimerization. Saponification of the malonate diester with one equivalent of base results 
in a racemic half-ester that can be used in synthesis, but would have to be resolved into 
enantiomers at some point. Resolution of the racemic half-ester results in a maximum 
yield of 50 % for each enantiomer. A better approach is to use a stereoselective synthesis. 
One possible solution to the aforementioned problem of obtaining good chemical yields 
with high enantioselectivity is the use of an enzyme for desymmetrization of a malonate. 
Esterases are enzymes that are involved in the metabolism of the various dietary esters.49 
In organic chemistry, esterases have found use in hydrolysis of the alkoxy groups of 
esters to form an acid and an alcohol. Pig Liver Esterase (PLE) is an esterase that has 
proven to be fairly indiscriminate toward substrates. Depending on the substrate and the 
conditions, the hydrolysis of a malonate has the potential to yield a chiral half ester of 
significant enantiomeric enrichment. The chiral half-ester can then be modified via 
several well known reactions to yield both enantiomers of a-methyl, p2'2-, p4'4-, y2'2-, and 
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y ' - amino acids (Scheme 1.2). The acid can be converted to an amine by use of the 
Curtius rearrangement (Scheme 1.2, path A).30 Manipulation of protecting groups, 
followed by sequential utilization of the Ardnt-Eistert synthesis, Wolff rearrangement 
and Curtius rearrangement yields (322, p3'3 amino acids (Scheme 1.2, Paths B). 7 Synthesis 
of the j2'2- and y4'4- amino acids can be accomplished through use of protecting group 
manipulation, reduction of the acid to an aldehyde, a Wittig reaction, a reduction, and a 
Curtius rearrangement (Scheme 1.2, Paths D).42 
Prochiral Malonate Malonic Half Acid 
1-38 Q Q
 p L E 1-39 0 Q 
RO ^X. OR 
R' 
R — CH3, CH2CH3 
R' = Alkyl 
NH, 
Scheme 1.2. Proposed synthesis of the unnatural amino acid analogues 
High Throughput Assay for Enantioselectivity 
The major problem encountered with enantioselective synthesis using enzymes is 
that the enzyme does not always yield a high enantiomeric excess. In this case, a mixture 
of enantiomers is obtained which is not useful for further synthesis when the target 
compound is of pharmaceutical interest. Several solutions are currently available. An 
enzyme can be modified by site-directed-mutagenesis to yield hydrolysis products in 
higher % ee.51"53 This approach requires mutations through modification in the DNA that 
code for specific amino acids. This method requires knowledge of the DNA that codes 
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for the enzyme. To further complicate this method, knowledge of the active site and 
mechanism must be known. This can be very time consuming and requires a great deal 
of biochemical experience. A simpler method to tune the enantioselectivity of enzymes is 
solvent engineering.54 This process uses various organic cosolvents to change some 
characteristic of the enzyme such as the conformation of the active site. Although the 
exact cause of the change in enantioselectivity may not be known, the effect is well 
documented.3>57 The following will outline the efforts that have been made in the area of 
termed "combinatorial asymmetric catalysis" and our proposal of a method that will 
greatly contribute to the evaluation of malonate substrates for current and new enzymes, 
under a variety of conditions. 
The rate limiting steps in determining if an enzyme is stereoselective with regard 
to a particular substrate is the hydrolysis time and purification of the product. Typical 
rates of enzymatic hydrolyses can in buffer alone vary greatly from a few hours to a few 
weeks. Since chiral analytical GC and HPLC columns are sensitive to contaminants, the 
product of an enzymatic hydrolysis must be at least partially purified to remove buffer, 
salts, and protein. It is now clear that this method is not efficient; neither in materials nor 
time. To compound this problem, use of organic cosolvents has been shown to slow the 
rate.5 'ii'sl Problems like these must be solved in order for further development of 
syntheses that incorporate the use of enzymes. For us, the challenge lies in determining a 
method that will allow for the efficient analysis of the enantiomeric composition of the 
products from enzymatic reactions. The method should include 1) the ability to analyze 
of a large range of cosolvent conditions with various enzymes, 2) be applicable to 
multiple substrates, and 3) ideally be automated. 
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Mass Spectrometry (MS) offers an ideal solution. Each sample can be acquired in 
a short period of time. Very small quantities of material are needed for MS analysis, so 
small quantities of probes are needed for each assay. Since the structures of the molecules 
of interest are very similar, this method would also be applicable to multiple substrates. 
Most mass spectrometers are equipped with auto samplers that would allow for 
automated analysis. Several mass spectrometry based assays have been developed to 
monitor the enantiomeric composition of the products from enzymes or chiral 
organometallic catalysts. However, none have been used to monitor the 
desymmetrization of malonic diesters. The primary strength displayed in our assay is that 
the probes need only be enantiomerically enriched, not enantiomerically pure. This 
allows for recycling of material from enzymatic hydrolysis that yield good % ee but that 
is not synthetically useful. After the assay is complete, the % ee obtained from the 
hydrolysis can be corrected to give the actual % ee. We have used this assay to 
significantly improve the enantioselectivity of PLE for two malonate diesters. Once 
conditions have been determined that give high enantioselectivity for the malonate 
acid/esters, they can be used for further synthesis. The unnatural amino acids obtained 
from these syntheses can then be incorporated into NT(8-13) analogues. These 
peptidomimetic NT analogues can then be evaluated for biological activity and stability. 
Conclusions 
The success seen in SST and NT analogues has proven the potential for the 
therapeutic use of peptidomimetic drugs. In order to advance this area of research, new 
developments in synthetic methodology for unnatural amino acids must be developed and 
optimized. This will require an adequate supply of cost effective, chiral synthons. It 
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seems quite likely that enzymes will fulfill these two requirements. However, discovery 
of new and more efficient enzymes will require a significant amount of work. Methods 
will have to be developed that will allow chemist to efficiently determine the types of 
substrates that each enzyme may accept. If chiral products are obtained from these 
enzymes, additional work will be needed to efficiently assay the resulting 
enantioselectivity. With this all in mind, this dissertation will focus primarily on A) the 
development of methodology for synthesis of a series of homochirally similiar a-methyl, 
P-, and y-unnatural amino acid analogues B) Application of that methodology for 
synthesis of an series on unnatural tyrosine analogues and C) the development of a mass 
spectrometry based enantioselectivity assay for substrate specific, cosolvent engineering 
for the PLE hydrolysis of malonate diesters. 
Hypotheses 
Hypothesis 1 of this dissertation states that a series of homochirally similar serine 
and tyrosine analogues may be synthesized from a common malonate half ester 
intermediate by the utilization of several well known organic transformations and 
protecting group chemistry. The syntheses of the unnatural serine and tyrosine analogues 
will be divided into three parts and described in Chapters II-IV. Chapter II will detail part 
A of hypothesis 1: the efforts to synthesize a-methyl serine and a-methyl tyrosine. 
Chapter III will detail part B of hypothesis 1: the efforts to synthesize (32'2-serine, p3'3-
serine, P ' -tyrosine, and P ' tyrosine. Chapter IV will details part C of hypothesis 1: the 
efforts to synthesize y ' -tyrosine and y4'4-tyrosine. 
Hypothesis 2 of this dissertation states that a mass spectrometry assay may be 
devised to determine the enantiomeric composition of malonate half esters that are 
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yielded as the result of an enantioselective enzymatic hydrolysis. Chapter V will detail 
the efforts to create and validate such an assay. Chapter VI will conclude this dissertation 
with future work that may be used to solve the encountered synthetic problems and 
outline future directions for the mass spectrometry assay for enantioselectivity. 
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CHAPTER II 
a- METHYL AMINO ACIDS 
Literature Review 
Introduction 
The previous chapter contains a discussion of the properties that unnatural amino 
acids can produce in peptidomimetic compounds. The need for an efficient synthesis of 
unnatural tyrosine analogues for incorporation in neurotensin peptidomimetic compounds 
was also outlined. This chapter will focus on part A of hypothesis 1, which is the 
development of synthetic methodology for both enantiomers of a-methyl tyrosine from a 
common intermediate. Discussed within Chapter 2 is the synthesis of both enantiomers of 
a-methyl serine with subsequent application of this methodology for the synthesis of both 
enantiomers of a-methyl tyrosine. To accomplish this, a malonate diester that contains a 
substituent that is analogous to a protected a serine side-chain was synthesized. The 
enantioselectivity of Pig Liver Esterase (PLE) was evaluated for this substrates, and the 
resulting malonate half ester that was obtained from the hydrolysis was used to 
synthesize both enantiomers of a-methyl serine. The same methodology was utilized to 
synthesize both enantiomers of a-methyl tyrosine with the long term goal of 
incorporation into neurotensin peptidomimetic compounds. This chapter will illustrate the 
current syntheses of a-methyl amino acids, our proposed methodology, and the results 
and conclusions of our work. 
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Properties ofa-Methyl Amino Acid 
i 
Recent research into a-methyl amino acids has shown promise for use in many 
different areas. Several a-
methyl amino acids (Figure U K,H J? 
HO\X, 2 HCO 
2.1) such as a-methyl 
aspartic acid (2.1) are 
potent enzyme inhibitors 
(aspartate amino transferase 
is inhibited by 2.1).' 
Literature has shown 123T 
Figure 2.1. a-methyl amino acids that have seen use as 
imaging agents,enzyme inhibitors, or as conformation 
inducers in peptidomimetics. The blue (a-methyl 
tyrosine) and red (a-methyl serine) are the 
methyl-Z-tyrosine (2.2) as a residues of interest for this chapter. 
application of I- a-
123T potent tumor imaging agent. Flamen et al. observed I- a-methyl-Z-tyrosine 
scintography was able to identify 
previously confirmed tumors in the 
head and neck of 10 out of 11 
patients (91%).2 Other a-methyl 
amino acids (Figure 2.1) such as a-
mefhylalanine (2.3), a-methylvaline 
2.8 Tachykinin Receptor 
AntagonistPD 154075 
Figure 2.2. Structures of a receptor antagonist Q.4), a-methylphenylalanine (2.5), 
containing a-methyl tryptophan 
a-methylleucine (2.6), and a-methylserine (2.7) have shown the ability to induce specific 
secondary structures (i.e. helices and (3-turns) in peptides that are not observed in peptides 
containing natural amino acids.1'3'4 The presence of unnatural a-amino acids that induce 
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binding conformation results in an increase in the affinity of the receptor for the peptide.5 
In this manner, these a-methyl amino acids may be used to improve the binding affinities 
of peptidomimetic compounds for specific receptor targets. Several pharmaceutically 
active compounds, including some antibiotic peptides, contain a-methyl amino acids that 
increase the stability of the compound (Figure 2.2).5 Our interest in a-methyl amino acids 
arises from the ability of a-methyl amino acids to increase the stability of peptidomimetic 
compounds and to induce conformation changes that facilitates binding of 
peptidomimetic compounds. 
Synthesis of a-Methyl Amino Acids 
Asymmetric synthesis of a-methyl amino acids is not a trivial task. Much work 
has been done to develop synthetic methodology that is efficient and cost effective 
enough to use on an industrial scale. Based on the numerous uses of this class of 
unnatural amino acids already established, commercially available quantities of a-methyl 
amino acids could prove to be invaluable synthetic and as pharmacological tools. 
Cativiela stated in his review of the synthesis of quaternary a-amino acids that the 
extensive use of quaternary a-amino acids was limited only by the availability of 
enantiomerically pure compounds in large quantities. There are several methods 
currently used to synthesize a-methyl amino acids. Direct methylation of an amino acid 
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Scheme 2.1. Azalactones Synthesis of ot-methyl-Asp and Glu amino acids 
i: L-Phe-cyclohexylamide 
ii: CF3SO3H, MeOH, reflux 
iii: 25% HC1 (aq), dioxane 
Schiff s base would lead to racemic a-methyl amino acids, and is therefore not of suitable 
utility in methyl amino acid synthesis. Previous synthetic methodologies have made use 
of auxiliaries to confer chirality to the a-methyl amino acids or the a-methyl amino acid 
was synthesized racemically and later resolved as a pair of diastereomers using a chiral 
auxiliary.1 Obrecht et al. synthesized enantiomerically pure a-methyl aspartic acid and a-
methyl glutamic acid via racemic azlactones (Scheme 2.1), which were later resolved into 
enantiomers by reaction with Z-Phe-cyclohexylamide.3 The diastereomers formed were 
separable by flash chromatography. The amide bond of the diastereomers was cleaved by 
CF3SO3H, yielding the free a-methyl aspartic acid and a-methyl glutamic acid. The major 
disadvantage of this method is that 50% chemical yield is the maximum chemical yield 
35 
possible for each enantiomer. This 
2.16 \ / - " V 
2 > N o^2' 
N. . N = \ 
2.19 
Hp '^COoR synthesis is problematic in that low 
yields are obtained and a chiral 
compound had to be used for 
NaOH/R'X
 2 1 g 
2% Catalyst ^ \ >C resolution of the racemates. One 
A r ^ N C02R " Ar XN C02R 
possible solution to the problems 
Scheme 2.2 . Use of copper(salen) catalyst for 
synthesis of a-methyl amino acids present with resolutions is the use 
of stereoselective transition metal catalysis. Belokon et al. have made extensive use of 
copper(salen) complexes (2.16) to synthesize a variety of a-dialkyl amino acids from 
alanine enolates (Scheme 2.2).7"10 The chemistry is mild and results in up to 92% ee. 
Once the alkylation has been achieved, the protecting groups can be cleaved by treatment 
with aqueous acid. Both enantiomers could be obtained in these syntheses by changing 
the chiral ligand. The disadvantages of this methodology are 1) the amount of time that is 
required to tune the enantioselectivity of the catalyst, 2) chiral ligands are required for 
asymmetric induction which can be expensive, and 3) transition metal catalyst can be 
sensitive to atmospheric conditions. 
Enzymes offer a solution to the majority of the aforementioned problems with the 
asymmetric synthesis of a-methyl amino acids. They are catalytic, generally tolerant to 
variety of experimental conditions, tolerate a variety of functional groups, and can result 
in highly enantioselective products (> 97% ee).n Kedrowski reported the synthesis of 
both enantiomers of a-methyl cysteine (Scheme 2.3) by a procedure that involved 
enzymatic hydrolysis, using PLE, of 2.20 to 2.21 in 97 % chemical yield and 91% ee. 
The half-ester was subjected to a Curtius rearrangement to give the protected (R)-a-
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methylcysteine (2.22) in 87% yield. Furthermore, 2.21 was tert-buty\aXed to give 2.23. 
The methyl ester of 2.23 was saponified with LiOH and subjected to a Curtius 
rearrangement to give the protected (5)-a-methylcysteine (2.25) in 92% yield. This 
synthesis demonstrates a method that allows the synthesis of both enantiomers of a-
methyl cysteine in good enantiomeric and chemical yields from a common intermediate. 
This synthesis demonstrates the careful manipulation of orthogonal protecting groups that 
is necessary in this type of synthesis. The use of a common intermediate, orthogonal 
protecting group strategies, and enzymes utilized in this synthesis are appealing. The 
malonate half ester intermediate has the potential to be used in the synthesis other classes 
of unnatural amino acids. The synthetic work discussed in this dissertation is our efforts 
to extend this methodology to synthesize a class of a-methyl and homolongated unnatural 
amino acids from a similar intermediate. 
Curtius 
2.22 Q 
^ N H ^ / O P M B 
O 
2.25 
H O Curtius PMBO. M S 
— - Y A o 
O 
s 
Scheme 2.3. Synhesis of (i?)-a-methyl Cysteine (2.22) and 
(S)-a-methyl Cysteine (2.25)12 
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It was decided to begin our synthesis with a prototype amino acid. It was found 
that a-methyl serine would be an interesting target. Literature has shown that a-methyl 
serine has found significant use as a synthetic intermediate for the production of other a-
methyl amino acids. ' As an example, a-methyl serine can be converted to an aziridine 
2-methyl carboxylate derivative.14 With these substrates, nucleophilic attack occurs 
regioselectively ^
 T s ^ 
O ' Nu u M 
II *• N - n , I N 
attheC3 H 2 N v ^ - 0 H *• L\/ 
. . , , // Nu 
position when OH O 
organocuprates N u = PhCH2NH2, IPrMgCuBr, PhMgCuBr, 
Scheme 2.4 . Conversion of a-methyl seine (2.26) into an 
and other mild aziridine (2.27) followed by nucleophilic attack of the (3-carbon to 
yield a new a-methyl amino acid (2.28) 
nucleophiles 
are used. The result is an a-methyl amino acid with a side chain that corresponds to the 
nucleophile that was used (Scheme 2.4). This means that an efficient synthesis of a-
methyl serine may lead to the synthesis of multiple classes of a-methyl amino acids with 
moderate to good yields (48-84 %). The primary interest of this chapter is the synthesis of 
the a-methyl tyrosine series. However, we evaluated our synthetic methodology on 
synthesis of the serine series due the significant synthetic potential of the analogues. To 
accomplish this, diesters which contain protected amino acid side chains were 
synthesized. These diesters were subjected to a hydrolysis with PLE which yielded a half 
ester. This half ester was converted to both enantiomers of our desired a-methyl amino 
acids by careful manipulation of protecting groups and by use of the Curtius 
rearrangement. The starting materials for a 2.31a with a protected serine side chain 
(2.30a) are commercially available and there is literature precedence for synthesis and 
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PLE hydrolysis.13 Although synthesis of the tyrosine diester (2.31b) has been previously 
accomplished, the side chain is not commerically available and was synthesized.16 
However, the PLE hydrolysis of 2.31a has not been previously accomplished. 
Considering these factors, it was clear that the synthesis of the tyrosine analogues would 
be more tedious. It is for this reason that we decided to evaluate our methodology by 
synthesis of both enantiomers of a-methyl serine. 
Results and Discussion 
The first step in synthesis of a-methyl serine is the synthesis of diethyl 2-
(benzyloxymethyl)-2-methylmalonate (Scheme 2.5, 2.31a). To accomplish this, the 
enolate of 2.29 was generated upon addition to a suspension of NaH in anhydrous THF. 
Alkylation with Benzylchloromethylether (2.30a) gave compound 2.31a in 77% yield. 
Generation of the half ester intermediate (2.32a) took place through a PLE hydrolysis in 
0.1 N pH 7.4 phosphate buffer. The hydrolysis was based on previous literature and was 
11 1 9 1 7 1 S 
monitored by titration of the acid with a Titrino® in pH stat mode. ' ' ' The reaction 
was complete after one equivalent of NaOH was consumed (approximately 24 hours). 
Compound 2.32a is the common intermediate for synthesis of our unnatural serine 
analogues. Chiral HPLC showed that compound 2.32a exhibited 70% ee as compared to 
the racemic material that was generated by saponification with one equivalent of NaOH. 
Polarimetry was used to verify that the enzyme showed selectivity of the R enantiomer of 
2.32a. Both the enantiomeric composition and the absolute configuration was consistent 
with literature values.13 
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Scheme 2.5. Synthesis of the 2.31a and 2.31b with subsequent PLE 
hydrolysis to 2.32a and 2.32b 
To synthesize the protected (5)-a-methyl serine (Scheme 2.6, 2.36a), 2.32a was 
treated with a slight excess of diphenylphosophoroazide (DPPA) at room temperature to 
generate an acyl azide (2.33a). Heating of this acyl azide resulted in a Curtius 
rearrangement to an isocyanate (2.34a) which was quenched with an excess of p-
methoxybenzyl alcohol (PMB-OH) to give the 2.36a in 70% yield. The synthesis of the 
protected (7?)-a-methyl serine (2.39a) required manipulation of the protecting groups. 
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Compound 2.32a was treated with isobutylene (IBE) in the presence of catalytic amounts 
sulfuric acid to give a 93% yield of 2.37a. Saponification of the ethyl ester with NaOH 
resulted in a tert-buty\ half ester (2.38a, 75% yield) that was subjected to a Curtius 
rearrangement under the aforementioned conditions to give 2.39a in 78% isolated yield. 
Chiral HPLC was conducted on both the protected 2.35a and the 2.38a proved that the 
enantiomeric composition of 2.32a was retained throughout the synthesis. 
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Scheme 2.6. Curtius rearrangement of the malonic half esters to 
protected amino acids. The chiral HPLC chromatograms of 2.34a (red) and 238a 
(blue ) prove that the composition of enantiomers is retained during synthesis 
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The positive results seen with the synthesis of a-methyl serines were encouraging, 
so it was decided to proceed with the synthesis of both enantiomers of a-methyl tyrosine. 
The first step was to synthesize the desired side chain. The phenol of the tyrosine 
analogue was protected as a benzyl ether due to stability and ease of removal by 
hydrogenolysis.20 A suitable method for preparation of the benzylchlorobenzylether 
(2.30b) was found in the literature.21 The preparation of 2.30b followed the literature 
preparation with the exceptions that we used a methyl ester (2.41) instead of an ethyl 
ester and generated an alkylchloride instead of an alkylbromide (Scheme 2.7). This alkyl 
chloride was added dropwise as a THF solution to a stirring solution of the enolate of 
diethyl methyl 
2.39 2 - 4 0 2.41 J J 
H 0 ^ ^ ^ ° + (~^y~\ KzC°3 , \ J / \ _ / — V - / > malonate that was 
o-
\ / ^ \=/ x x = / b 
X = = /
 O - ^ ^ Br DMF U generated as 
LiAIH4 | THF 
< ^ A 2 '30b SOCl2 /T\ 2A2 described above. 
\ = / XC| CH2ci2 \r=:/ X0H This gave 2.31b in 
Scheme 2.7. Synthesis of 2.30b 9 1 % Y i e l d a f t e r 
precipitation from pentane. To facilitate the PLE hydrolysis, 2.31b was crushed into a 
fine powder and dispersed in buffer. Although hydrolysis of 2.31b has not been 
previously accomplished, there is literature precedence for the PLE hydrolysis of similar 
diesters yielding good enantioselectivity. The crystal structure for PLE has yet to be 
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determined, so we made use of a model of the active site of PLE proposed by Jones 
(Figure 2.3 with compound 2.31b imposed) and the PLE hydrolysis of similar substrates 
to predict that the R configuration would be obtained.23 It was found that a large ratio of 
buffer to starting material (800 mL for 
4 grams of diester) is necessary for the 
hydrolysis of this substrate to proceed. 
The hydrolysis was complete after 5 
days and resulted in 76% yield of 
2.32b. This is the common 
intermediate needed for synthesis of 
He 
o 
^iffi 
P /=\ H, 
' p p 
4 /r
°^D 
(Ser 
Figure 2.3 . Active site model of PLE proposed by 
Jones with compound 2.31b imposed 
both enantiomers of a-methyl tyrosine. The enantiomeric composition of 2.32b was 
determined by chiral HPLC to be 63% ee. Compound 2.32b was converted to the 
protected (5)-a-methyl tyrosine (2.35b, 67% yield) by means of the Curtius arrangement 
discussed above. The amino ester was then deprotected by hydrogenolysis with Pd on 
carbon black. A biphasic extraction was performed using methanol and pentane to 
remove the £>-mefhoxy anisole byproduct to give 84% yield of the deprotected amino 
ester 2.36b. The specific rotation of this amino ester was compared to that of an authentic 
sample to determine that the absolute configuration of 2.32b was R. The synthesis of (R)-
a-methyl tyrosine was similar to the synthesis of (R)- a-methyl serine. It was initially 
thought that the activated aromatic ring of 2.32b might lead to fert-butylation at the ortho 
position from the benzyl ether. However, we were able to obtain 65%) isolated yield of 
2.37b without any detectable presence of over alkylated byproducts. Saponification with 
NaOH led to 87% yield of half ester 2.38b. Curtius rearrangement yielded the protected 
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(7?)-a-methyl tyrosine (2.39b) in 65% isolated yield. Chiral HPLC of both the R and S Di-
methyl tyrosine proved that the enantiomeric composition was retained throughout the 
syntheses. 
Conclusions 
The above chapter outlined the synthesis for both enantiomers of a-methyl serine 
and a-methyl tyrosine. The PLE hydrolysis of the starting diesters yielded good 
enantioselectivity for both to yield common intermediates that were used to synthesize 
both enantiomers of the a-methyl amino acids. Workup of the tyrosine half ester (2.32b) 
has proven to be to be quite tedious due to the tremendous amount of buffer necessary for 
PLE hydrolysis and the emulsions that forms during extraction. Kedrowski's 
methodology was extended to include the synthesis of both enantiomers of a-methyl 
serine and a-methyl tyrosine from a common malonate half ester. It was proven that the 
protecting groups used can be removed and replaced selectively without racemization. It 
was also shown that the Curtius rearrangement proceeds without any change in 
enantioselectivity. The a-methyl serine analogues have potential to be a synthetic 
intermediate of both enantiomers of other a-methyl amino acids. The a-methyl tyrosine 
analogues have potential use in peptidomimetic drug synthesis. The primary problem 
with our current synthesis is that the PLE hydrolysis of both 2.31a and 2.31b does not 
result in great enantioselectivity. Although the half ester discussed in this chapter will be 
used to prove the remainder of our synthetic methodology (Chapters III and IV), we have 
developed an assay that we hope to use to solve the enantioselectivity problem. This 
assay is will be discussed thoroughly in Chapter V. 
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Experimental 
General 
Tetrahydrofuran was distilled over sodium, under a nitrogen atmosphere, prior to use. 
Methylene chloride and 1,2-dichloroethane were distilled from calcium hydride under a 
nitrogen atmosphere prior to use. Triethylamine was distilled from sodium hydroxide 
pellets under a nitrogen atmosphere prior to use. Diphenylphosphorylazide was prepared 
using a literature procedure. All other chemicals and enzymes were obtained from 
Aldrich Chemical and used as received unless otherwise noted. Benzylchloromethyl ether 
(2.30a) was purchased from Sigma and distilled over calcium chloride before use. 
Diethyl 2-(benzyloxymethyl)-2-methylmalonate (1) was synthesized according to a 
literature procedure.19 All NMR spectra were acquired with a Varian Mercury 300 MHz 
spectrometer and referenced to either residual solvent protons or to TMS. IR spectra were 
acquired with a Thermo-Nicolet Nexus 470-FT-IR using a diamond anvil ATR accessory. 
UV/Vis spectra were acquired with an HP 8452 spectrophotometer. Optical rotation 
measurements were acquired with a Rudolph Research Autopol III autopolarimeter using 
a 1dm cell at ambient temperature. TLC analysis was performed on EMD science silica 
coated aluminum plates and visualized using UV or phosphomolybic acid stain. Flash 
chromatography was performed using Silicycle silica gel (Silia-P). Radial 
chromatography was performed using a Harrison Research Chromatotron with Analtech 
precoated plates. Chiral HPLC was performed using a LabAlliance Series III isocratic 
pump coupled to a LabAlliance Model 500 UV/Vis detector. HPLC chromatograms were 
recorded using the Peaksimple® data acquisition system and software. Chiral HPLC was 
performed using a Chiralcel OJ-H analytical column or a Chiralcel AD-H column from 
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Chiral Technologies, Inc. All HPLC retention times are listed in minutes. HRMS analysis 
was performed at Old Dominion University on an Apex FT-MS using a 1:1 THF:MeOH 
solvent system with added NaCl to observe sodium adducts of the compounds of interest. 
Melting points were determined in an open capillary tube using a Hoover melting point 
apparatus and are uncorrected. 
Diethyl 2-(benzvloxvmethvD-2-methvlmalonate (2.31a): A 1.60 g (46 mmol) portion 
of NaH (60% dispersion in mineral oil) was dispersed in 50 mL of dry THF and a 
solution of diethyl methylmalonate (6.67 g, 38.3 mmol in 5 mL anhydrous THF) was 
added dropwise to the NaH suspension at 0 °C. The solution was allowed to stir at 0 °C 
until no further gas evolution was observed. The reaction mixture was removed from the 
ice bath and allowed to stir at ambient temperature for 90 minutes. A solution of 2.30a 
(6.00 g, 38.3 mmol, in 5 mL anhydrous THF) was added dropwise and the solution was 
heated to solvent reflux for 12 hours. The resulting suspension was diluted with 50 mL of 
ether and placed in a separatory funnel. The suspension was then washed three times with 
brine and three times with 10% HC1. The organic layer was dried over MgSCU, filtered, 
and concentrated by rotary evaporation. The crude material was purified by column 
chromatography (30% EtOAc / 70% hexanes) to give 8.63 g (29.3 mmol, 77% yield) of 
2.31a as a clear and colorless viscous liquid. 
(ffi-2-(4-(benzvloxvmethvl)-3-ethoxv-2-methvl-3-oxopropanoic acid (2.32a): An 
amount of 7.09 g (24.1 mmol) of 2.31a was dispersed in 450 mL of rapidly stirring 
phosphate buffer (0.1 N pH 7.4). 90.4 mg of PLE (24 units / mg, 90 units / mmol of 
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substrate) was dissolved in 1.0 mL of 3M (NfLj^SC^ and added to the buffer solution and 
the pH of the reaction mixture was maintained using a 798 MPT Titrino® in the pH stat 
mode. The Titrino® was set to titrate to a volume of 19.9 mL (24.1 mmol) of 1.21 M 
NaOH. The hydrolysis proceeded for 20 hours, after which NaOH was added to make the 
solution sufficiently basic. The aqueous solution was then extracted with three 300 mL 
volumes of ether. The aqueous layer was acidified using concentrated HC1 to a pH of 2. 
The aqueous layer was then extracted with three volumes of ether. The organic layer was 
dried over MgSOa, filtered, concentrated via rotary evaporation, and placed under high 
vacuum to yield 4.42 g (16.6 mmol, 69% yield, 70% ee) of a viscous, clear liquid. The 
absolute stereochemistry was determined by optical rotation and comparison to literature 
values. [a]D22= +7.69° (c =0.208, MeOH). The % ee was determined by analytical chiral 
HPLC (Chiracel OJ-H, 257 nm, flow rate = 1 mL / minute, 4% /PrOH / 96% hexane) 
Rt(/?)= 16.90, Rt(S) 19.20. 
(iSr)-Ethvl3-(benzvloxv)-2-((4-methoxvbenzyloxv)carbonvlamino)-2-
methvlpropanoate (2.35a): An amount of 0.67 g (2.51 mmol) of 2.32a was dissolved in 
10.00 mL of 1,2-dichlrorethane followed by addition of 596 uL (2.77 mmol) of DPP A 
and 739 uL (5.30 mmol) of Et3N was added and the solution was brought to reflux 
solvent for 1.5 hours, at which time 432 uL (3.48 mmol) of PMB-OH was added and the 
solution was heated to reflux solvent for 12 hours. The solution was concentrated by 
rotary evaporation. The protected amino ester was then purified by silica chromatography 
using 5% MeOH / 95% CHC13 (Rf= 0.60). This gave 0.70 g (1.74 mmol, 70% yield, 
70% ee) of a transparent, viscous oil. A.max = 286 nm, [a]o = -1.8° (c = 0.164 ,CH2CL:), 
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IR (cm"1) 3420 (br), 1717 , !H-NMR (300 MHz, CDC13) 1.22 (3H, t, J= 7 Hz), 1.54 (3H, 
s), 3.70 (1H, d, J= 9 Hz), 3.78 (4H, m), 4.18 (2H, m), 4.48 (2H, q, J= 12 Hz), 5.01 (2H, 
s), 5.77 (1H, bs), 6.87 (2H, d, J= 9 Hz), 7.30 (7H, m) 13C-NMR (75 MHz, CDC13) 14.2, 
20.3, 55.3, 60.4, 61.9, 66.3, 72.7, 73.3, 113.9, 127.6, 127.8, 128.4, 128.7, 130.0, 137.8, 
155.2, 159.6, 172.7. HRMS: [C22H27N06Na] +Calcd = 424.1736 Obsd = 424.1739. The 
% ee was determined by analytical chiral HPLC (Chiracel, OJ-H, 286 nm, 1 mL / minute, 
4% /PrOH / 96% hexane) Rt(S) = 46.42 Rt(R) = 61.45. 
(S)-l-tert-But\l 3-ethyl 2-(benzvloxvmethyl)-2-methvlmalonate (2.37a): An amount of 
1.26 g (4.73 mmol) of 2.32a was dissolved in 5 mL of dry CH2CI2 and placed in a 20 mL 
sealable pressure tube at -10 °C. 300 uL of cone. H2SO4 and 3 mL of condensed 
isobutylene were added, the vial was capped and the reaction was allowed to stir 
overnight a room temperature. The flask was then placed in an ice bath for 15 minutes. 
The tube was opened and allowed to stir at room temp for 2 hours to allow evaporation of 
any remaining IBE. The solution was diluted with 25 mL of CH2CI2 and washed three 
times with 1.0 M NaOH, dried over MgSC>4, filtered, and concentrated by rotary 
evaporation to give a clear, viscous oil. 1.42 g (4.4 mmol 93 % yield, TLC (10% /PrOH / 
90% hexane) Rf = 0.536 [a]D21= + 0.60° (c = 0.100 , CH2C12). IR (cm-1) 1725, 'H-NMR 
(300 MHz, CDCI3) 1.24 (3H, t, J= 7 Hz), 1.42 (9H, s), 1.49 (3H, s), 3.77 (2H, m), 4.17 
(2H, q, J= 7 Hz), 7.30 (5H, m). 13C-NMR(75 MHz, CDC13) 14.3, 18.6, 28.0, 55.6, 61.3, 
73.0,73.6,81.8, 127.7,127.8,128.5, 138.3 169.9, 171.2. HRMS [Ci8H2605Na] + calcd = 
345.1672, obsd = 345.1683. 
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(5V2-(benzvloxvmethvO-3-fer£-butoxv-2-methvl-3-oxopropanoic acid (2.38a): An 
amount of 2.03g (6.30 mmol) of 2.37a was dissolved in 50 mL of EtOH. 0.50 g (3.30 
mmol) of LiOH was dissolved in three mL of water and added to the reaction flask. The 
reaction mixture was allowed to stir at room temperature for 48 hours. Then, 150 mL of 
1.0 M NaOH was added to the reaction mixture and the basic aqueous layer was then 
washed three times with 150 mL portions of Et20. The aqueous layer was acidified to pH 
1.0 using cold 10% HC1 and extracted with three portions of Et20. The organic layer was 
then combined, dried over MgSCU, filtered, and concentrated by rotary evaporator to give 
1.38g (4.70 mmol, 75% yield) of a clear viscous liquid which crystallized upon standing 
to a white solid. Mp = 70-76°C, TLC (10 % /PrOH / 90% hexane), Rf = 0.24, [a]D24= -
3.8° (c = 0.03 ,CHC13) IR (cm"1) 3250, 1708 'H-NMR (300MHZ, CDC13) 1.45 (9H, s), 
1.48 (3H, s), 3.49 (2H, s), 3.77 (1H, d, J= 11 Hz), 3.80(1H, d, J= 11 Hz), 4.56 (2H, s), 
7.30 (5H, m) 13C-NMR(75 MHz, CDC13) 18.7, 27.9, 55.4, 73.1, 73.7, 82.8, 127.7, 127.8, 
128.5, 137.8, 170.3, 176.2. HRMS [C16H2205Na] + calcd = 317.1365, obsd = 317.1355. 
(/?)-rgr?-butvl-3-(benzvloxv)-2-((4-methoxvbenzvloxv)carbonylamino)-2-
methvlpropanoate (2.39a): An amount of 0.150 g (0.51 mmol) of 2.38a was dissolved 
in 10 mL of 1,2-Dichloroethane followed by addition of 155 uL (0.56 mmol) of DPP A 
and 300 uL (2.13 mmol) of Et3N was added and the solution was heated to reflux solvent 
for three hours, at which time 95 uL (0.77 mmol) of PMB-OH was added and the 
solution was allowed to reflux overnight. The mixture was then cooled and diluted with 
50 mL of CHCI3 and washed three times with 1.0 M NaOH. The organic layer was 
passed through a small plug of silica gel, dried over MgS04, filtered, and concentrated by 
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rotary evaporation to give an orange, transparent, viscous oil. This was purified by radial 
chromatography (Silica, 50 % Et20 / 50% hexane) to give 0.170 g (0.40 mmol, 78 % 
yield, 70% ee) of a clear viscous oil. TLC (50% Et20 / 50% hexane) Rf = 0.36, [a]D240 = 
+0.80° (c = 0.05 ,CH2C12),IR 3419, 1717. 'H-NMR (300 MHz, CDC13) 1.43 (9H, s), 1.50 
(3H, s), 3.67 (1H, d, J= 9 Hz), 3.79 (1H, d, J= 9 Hz), 3.79 (3H, s), 3.85 (1H, d, J= 9 
Hz), 4.44 (1H, d, J= 12 Hz), 4.54 (1H, d, J= 12 Hz), 5.01 (2H, s), 5.80 (1H, bs), 6.86 
(2H, d, J = 9 Hz), 7.30 (7H, m) 13C-NMR (75 MHz, CDC13) 20.3, 28.0, 55.4, 60.7, 66.2, 
72.9, 73.5, 82.2, 140.0, 127.7, 127.8, 128.5, 128.9, 130.0, 138.0, 155.2, 159.6, 171.9. 
HRMS: [C24H3iN06Na]+ calcd= 452.2049 obsd = 452.2033. The % ee was determined 
by analytical chiral HPLC (Chiralcel AD-H, 257 nm, 4% /PrOH / 96% hexane, 1 mL / 
minute) Rt(S) = 11.72, Rt(R) =13.73. 
Benzvlchlorobenzvl ether (2.30b): Methyl 4-(benzyloxy)benzoate was prepared by an 
established synthesis, with the exception that the ethyl ester is used in the literature. An 
amount of 6.40 g (168.5 mmol) of LiAlH4 was suspended in 200 mL of dry THF in a 
1000 mL RBF and placed in an icebath. 27.22g (112.4 mmol) of methyl 4-
(benzyloxy)benzoate (2.41) was dissolved in 200 mL of dry THF and added dropwise to 
the stirring LiAlH4 solution over 40 minutes. The reaction was allowed to stir overnight 
at ambient temperature, and heated to reflux solvent for 2 hours. The reaction was 
allowed to cool and 20 mL of ddH20 was added to the reaction mixture to remove any 
unreacted LiAlH4. Then, 20 mL of 1M NaOH was added to quench the LiAlH4 and 
precipitate the Al as A12C>3. The solution was decanted, diluted with 200 mL Et20 washed 
three times with brine, dried over MgSC>4, concentrated with a rotary evaporator, and 
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placed under reduced pressure to give 23.95 g (111.8 mmol, 99% yield) of 2.42 as a 
solid, white powder. TLC (10% MeOH / 90% CDC13) of benzyloxybenzyl alcohol Rf= 
0.56. Then, 8.23 g (38.4 mmol) of 2.42 was dissolved in 150 mL of dry CH2C12 at 0 °C. 
Then, 26.70 mL (384 mmol) of SOCI2 was added slowly. The solution was heated to 
reflux solvent for 17 hours. The excess CH2CI2 and SOCI2 was removed by a rotary 
evaporation, and placed under reduced pressure for 4 hours to give (2.30b) as a white 
powder, which was used in the next step without further purification. 
Diethyl 2-(4-(benzvloxv)benzvl)-2-methvlmalonate (2.31b): A 250 mL 3-neck round-
bottom flask was charged with 100 mL of dry THF and 1.70 g (41.9 mmol) of NaH (60% 
dispersion in mineral oil) under a N2 atmosphere. A solution of diethyl methylmalonate 
(6.07 g, 34.9 mmol in 5 mL dry THF) was added dropwise to the NaH suspension at 0 °C. 
The solution was allowed to stir at 0 °C until no further gas evolution was observed. The 
reaction mixture allowed to stir at ambient temperature for 90 minutes. A solution of 
2.30b (6.00 g, 38.3 mmol, in 30 mL dry THF) was added dropwise and the resulting 
solution was heated to reflux solvent for 17 hours. The resulting suspension was diluted 
with 100 mL of ether and placed in a separatory funnel. The suspension was then washed 
three times with brine and three times with 10%> HC1, dried over MgS04, filtered, and 
concentrated in by rotary evaporation. The crude material was dissolved in warm pentane 
and cooled to -25 °C for 5 hours. The resulting white solid was isolated by vacuum 
filtration and washed with three 20 mL portions of cold pentane to give 11.73 g (31.7 
mmol, 91%> yield) of 2.31b as a white amorphous solid. TLC (20% EtOAc / 80% hexane) 
Rf=0.30. Mp = 49°C,IR(cm"1) 1727, 1H-NMR(300 MHz, CDCI3) 1.25 (6H, t, J= 1 
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Hz), 1.33 (3H, s), 3.17 (2H, s), 4.19 (4H, q,J= 7 Hz), 5.02 (s, 2H), 6.92 (2H, d, J= 9 
Hz), 7.04 (2H, d, J= 9 Hz) 7.38 (5H, m). I3C-NMR (75 MHz, CDC13) 14.3, 19.9, 40.5, 
55.1,61.5,70.2, 114.7, 127.7, 128.1, 128.7, 128.8, 131.4, 137.2, 158.0, 172.2. HRMS: 
[C22H2605Na]+ Calcd = 393.1678, Obsd = 393.1672. 
(±)-2-(4-(benzvloxv)benzvl)-3-ethoxv-2-methvl-3-oxopropanoic acid (±2.32b): An 
amount of 1.00 g (2.70 mmol) of 2.31b was dissolved in 5 mL of 100% EtOH. To this 
0.151 g (2.70 mmol) of KOH was added and allowed to stir for 24 hours at room 
temperature. The reaction was then diluted 50 mL of Et20 and extracted three times with 
60 mL portions of NaOH, which were then combined and acidified using 12.1 M HC1. 
This acidic solution was then extracted three times with Et20. This organic solution was 
dried over MgS04, filtered, concentrated by rotary evaporator, and placed under high 
vacuum to give 0.51 g (55% yield, 1.50 mmol) of a white solid. 
(i?)-2-(4-(benzvloxv)benzvl)-3-ethoxv-2-methvl-3-oxopropanoic acid (2.32b): An 
amount of 4.00 g (10.8 mmol) of 2.31b was dispersed in 600 mL of rapidly stirring 
phosphate buffer (0.1 N, pH 7.4). 100 mg of PLE (2100 units) was dissolved in 1.0 mL of 
3M (NH4)2S04 and added to the buffer solution. The pH of the reaction mixture was 
maintained using a 798 MPT Titrino® in the pH stat mode. The Titrino® was set to 
titrate to a volume of 10.2 mL (1 eq of 1.06 M NaOH). The hydrolysis proceeded for 20 
hours, after which time 40 mL of 1.06 M NaOH was added to make the solution 
sufficiently basic. The aqueous solution was then extracted three times with 300 mL 
portions of ether. The aqueous layer was acidified using concentrated HC1 to pH = 2. The 
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aqueous layer was then extracted three times with CH2CI2. The organic layer was dried 
over MgS04, filtered, and concentrated by rotary evaporation to give 2.81 g (8.21 mmol, 
76% yield, 63% ee) of a white, amorphous solid. TLC (20% EtOAc / 80% hexane) Rf = 
0.25. [a]D22= -1.00° (c =0.07, CH2C12). Mp = 99.0 °C 'H-NMR (300 MHz, CDC13) 1.22 
(3.0 H, t, J= 7 Hz), 1.40 (3H, s), 3.15 (1H, d,J= 14 Hz), 3.25 (1H, d, J= 14 Hz), 4.21 
(2H, q, J= 7 Hz), 5.02 (2H, s), 6.88 (2H, d, J= 8 Hz), 7.08 (2H, d, J= 8Hz ), 7.36 (5H, 
m), 11.50 (1H, bs). I3C - NMR (75 MHz, CDC13) 14.2, 20.1, 40.1, 55.2, 62.0, 70.1, 114.8, 
127.7, 128.1, 128.2, 128.8, 131.4, 137.1, 158.1, 172.8, 178.0. HRMS: [C2oH2205Na]+ 
Calcd = 365.1365 Obsd = 365.1359. Chiral HPLC (Chiracel AD-H, 282 nm, flow rate = 
1 mL / minute, 4% /PrOH / 96% hexane) Rt(/?) = 20.87, Rt(51 30.18. 
(5r)-ethvl-3-(benzvloxv)-2-((4-methoxvbenzvloxv)carbonylamino)-2-
methvlpropanoate (2.35b): An amount of 0.310 g (0.90 mmol) of 2.32b was dissolved 
in 10 mL of Dichloroethane followed by addition of 215 uL (0.996 mmol) of DPPA and 
409 uL (2.72 mmol) of Et3N was added and the solution was heated to reflux solvent for 
1.5 hours, at which time 169 uL (1.36 mmol) of PMB-OH was added and the solution 
was allowed to reflux for 15 hours. The mixture was then cooled and diluted with 20 mL 
of chloroform and washed with 10% HC1. The organic layer was dried, concentrated by 
rotary evaporation and purified by flash chromatography (Si02, 50% Et20 / 50% Hexane) 
to give 0.29 g (0.61 mmol, 67% yield, 63% ee) of a clear viscous oil. TLC (50% Et20 / 
50% hexane) Rf = 0.35. [oc]D178 = +24.2° (c = 0.07, CH2C12). IR (cm"1) 3426, 3354, 1716. 
'H-NMR (300MHz, CDCI3) 1.27 (3H, t,J= 7Hz), 1.61 (3H, s), 3.09 (1H, d, J= 13 Hz), 
3.36 (1H, d, J= 13 Hz), 3.80 (3H, s), 4.18 (1H, m), 5.00 (2H, s), 5.00 (1H, d, J = 12 Hz), 
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5.10 (1H, d ,J = 12 Hz), 5.44 (1H, bs),6.78 (2H, d,J= 9 Hz), 6.89 (4H, m), 7.37 (7H, m). 
l3C-NMR(75MHz, CDC13) 14.3, 23.8, 41.0, 55.5, 60.9, 61.9, 66.4, 70.1, 114.0, 114.7, 
127.7, 128.1, 128.6, 128.8, 128.9, 130.3, 131.1, 137.2, 154.9, 157.9, 159.7, 173.8. 
HRMS: [C28H3iN06Na]+ calcd= 500.2049 obsd = 500.2044. The % ee was determined 
by analytical chiral HPLC (Chiralcel AD-H, 282 nm, 1 mL / minute, 4% /PrOH / 96% 
hexane) Rt(S) = 34.38, Rt(R) = 39.35. 
(SVoc-Methvl Tyrosine Ethyl Ester (2.36b): An amount of 0.500 g of Pd/C was placed 
in a 50 mL RBF and carefully wetted with 3 mL of THF. Then, 0.270 g of 2.35b was 
dissolved in 8 mL of dry THF and slowly added to the flask. The solution was degassed 
with hydrogen gas for 15 minutes and then placed under a Hydrogen blanket for 20 
hours. The disappearance of 2.35b was monitored by TLC (50% Et20 / 50% hexane). 
The reaction was filtered through a celite pad to remove the Pd/C and concentrated by 
rotary evaporation. The material was then dissolved in 10 mL of 3N methanolic HC1 and 
washed twice with pentane and concentrated by rotary evaporator to give 0.124 g (0.477 
mmol, 84% yield) a white hygroscopic amorphous solid. Polarimetry was performed in 
1.21 M HC1. Due to the hygroscopic nature of 2.36b, an accurate mass of the sample was 
difficult to obtain. The levorotary direction of rotation (a0bs21'7 = -0.10°, 1.2 M HC1) of 
2.36b matched that of an authentic sample. 'H-NMR (300 MHz, CD3OD) 1.26 (3H, t, J = 
7 Hz), 1.54 (3H, s), 2.95 (1H, d,J= 14 Hz), 3.15 (1H, d, J= 14 Hz), 4.23 (2H, m), 6.73 
(2H, d, J = 9Hz), 6.97 (2H, d, J = 9Hz). 
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l-tert-But\l 3-ethyl 2-(4-(benzvloxv)benzvl-2-methyimalonate (2.37b): An amount of 
0.568 g ( mmol) of 2.32b was dissolved in 5 mL of dry CH2CI2 and placed in a 20 mL 
pressure vial at -10 °C (NaCl/icebath). Then, 150 uL (2.70 mmol) of concentrated H2SO4 
and 3 mL of condensed isobutylene was added, the vial was capped and the reaction was 
allowed to stir overnight a room temperature. The flask was then placed in an icebath at 0 
°C for 15 minutes and opened to allow evaporation of any remaining IBE. The solution 
was diluted with 25 mL of CH2CI2 and washed three times with 1.0 M NaOH, dried over 
MgS04, filtered, and concentrated by rotary evaporation to give a clear, viscous oil. The 
material was purified by centrifugal chromatography (Silica, 30% Et20 / 70% hexane) to 
give 0.419 g (1.10 mmol, 65% yield) of a clear, viscous oil. TLC Rf = 0.41, IR (cm'1) 
1724 cm-1, 'H-NMR(300 MHZ, CDC13) 1.26 (3H, X,J= 12 Hz), 1.28 (3H, s), 1.44 (9H, 
s), 3.09 (3H, d, J= 14 Hz), 3.16 (1H, d,J= 14 Hz), 4.18 (2H, q,J= 7 Hz), 5.02 (2H, s), 
6.86 (2H, q, J= 9 Hz), 7.06 (2H, d, J = 9 Hz), 7.37 (5H, m).13C-NMR (75 MHz, CDCI3) 
14.3, 19.8,40.2,55.5,61.2,70.1,81.7, 114.6, 127.6, 128.15, 128.76, 128.9, 131.4, 137.2, 
157.8, 171.2, 172.4. HRMS: [C24H30O5Na] +calcd= 421.1985 obsd = 421.1972. 
2-f4-(Benzvloxv)benzvl)-3-tert-butoxv-2-methvl-3-oxopropanoic acid (2.38b): An 
amount of 2.62g (6.58 mmol) of 2.37b was dissolved in 20 mL of 95% EtOH. 1.58 mL 
(19.72 mmol) of 12.50 M NaOH solution was added to the reaction flask. The reaction 
mixture was allowed to stir at room temperature for 48 hours. The reaction was diluted 
with 30 mL of 1.0 M NaOH, washed three times with Et20, acidified to pH 1.0, extracted 
into Et20 and concentrated by rotary evaporator to give 2.12 g (5.72 mmol, 87% yield) of 
a clear, viscous, liquid which later crystallized to a white solid. Mp = , TLC (20% z'PrOH 
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/ 80% hexane) Rf = 0.48, IR (cm"1) 3230, 1750, 1698. 'H-NMR (300 MHz, CDC13) 1.35 
(3H, s), 1.45 (9H, s), 3.13 (1H, d,J= 14 Hz), 3.19 (1H, d, J= 14 Hz), 5.01 (2H, s), 6.88 
(2H, d,J = 9 Hz), 7.10 (2H, d,J = 9 Hz), 7.36 (5H, m), 10.4 (1H, bs), 13C-NMR (CDCI3) 
20.1, 27.9, 40.5, 55.6, 70.0, 82.6, 114.6, 127.6, 128.1, 128.4, 128.7, 131.4, 137.1, 157.9, 
171.4, 178.2. HRMS: [C22H2605Na] +calcd = 393.1678, obsd = 393.1668 
(i?)-fer?-Butvl-3-(4-(benzvIoxv)phenvl)-2-((4-methoxvbenzvloxv)carbonylamino)-2-
methylpropanoate (2.39b): An amount of 0.300 g (0.81 mmol) of 2.38b was dissolved 
in 10 mL of Dichlrorethane in a 50 mL RBF and 192 uL (0.89 mmol) of DPPA and 739 
uL (4.90 mmol) of Et3N was added and the solution was heated to reflux solvent for 3 
hours, at which time 151 uL (1.20 mmol) of PMB-OH was added. The solution was 
allowed to reflux overnight, diluted with 50 mL of CHCI3, washed three times with 1.0 M 
NaOH, filtered through silica gel, and concentrated by rotary evaporation to give a 
orange, transparent, viscous oil that was purified by centrifugal chromatography (Silica, 
50% Et20 / 50% hexane) to give 0.266 g (0.53 mmol, 65% yield, 60% ee) of a clear, 
viscous oil. TLC (50% Et20 / 50% hexane) Rf = 0.31. IR (cm"1) 3350, 1708. 'H-NMR 
(300 MHz, CDCI3) 1.43 (9H, s), 1.59 (3H, s), 3.05 (1H, d, J= 14 Hz), 3.37 (1H, d, J= 14 
Hz), 3.79 (3H, s), 4.97 (1H, d,J= 12 Hz), 4.99 (2H, s), 5.01 (1H, d, J= 12 Hz), 5.51 
(1H, bs), 6.78 (2H, d,J= 9Hz), 6.89 (2H, d, J= 9 Hz), 6.93 (2H, d, J= 9Hz), 7.32 (2H, J 
= 9 Hz), 7.40 (5H, m), 13C-NMR (75 MHz, CDCI3) 24.1, 28.0, 40.5, 55.4, 61.0, 66.1, 
70.0,82.4, 113.9, 114.5, 127.6, 128.0, 128.7, 128.9, 129.0, 130.2, 131.2, 137.2, 154.8, 
157.8, 159.6, 172.8.. HRMS: [C30H35N 06Na]+ calcd = 528.2357, obsd = 528.2342. The 
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% ee was determined by analytical chiral HPLC (Chiralcel AD-H, 282 nm, 4% /PrOH / 
96% hexane, lmL / minute) Rt(S) = 20.63, Rt(R) = 23.97. 
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CHAPTER III 
p2'2-AND p33-AMINO ACIDS 
Literature Review 
Introduction 
In the previous chapter, the synthesis of a-methyl serine and a-methyl tyrosine 
analogues from a common intermediate was discussed. Part B of hypothesis 1 states that 
both enantiomers of two classes of p-amino acids may be synthesized from a malonate 
7 7 
half-ester intermediate. This chapter will detail the synthesis of both enantiomers of P ' 
and (3 ' serine and tyrosine 
analogues from the same 
malonate half ester 
common intermediate that 
was used to synthesize the 
a-methyl serine and a-
methyl tyrosine amino 
P2 
0 
H 2 N ' ^ X 1 ~ 0 H 
R 3.1 
XX 
H 2 N ' " y C } H 
R' 3.4 
p2,3 
Figure 
P3,3 
0 
RXRX 
3.2 
R 0 
H2N ^ ^ OH 
3.5 
P3 
P2,2 
0 
H 2 N ^ X ^ O H 
3.3 
1 1 H2N > > < O H 
1
 R' R" 
3.6 
p2,2,3 
3.1. Various P-amino acids 
acids. Beta amino acids differ from a-amino acids by an additional methylene group in 
the carbon backbone between the amine and carboxylic acid groups. There are several 
different types of [3-amino acids (Figure 3.1). The two of interest in the context of this 
dissertation are the P ' - amino acids (3.2) and the p ' -amino acids (3.3). The P ' - amino 
acids have a (HOOC-CR,R'-CH2-NH2) connectivity, while the p3'3 amino acids have a 
(HOOC-CH2-CR,R'-NH2) connectivity. There are a limited number of available 
syntheses for both classes of p-amino acids that will be discussed here in. 
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Properties ofP-Amino Acids and /^-Peptides 
Interest in P-amino acids can be found in literature references dating back to at 
least 1948.'Generally, p -amino acids are considered to be 
l_l 0 unnatural amino acids, but many examples exist where p-
>^<; Q u 
amino acids are present in peptides found in various 
3.7 > NH natural sources including prokaryotes and eukaryotes. One 
Figure 3.2 . L-Carnosine specific example of a P-amino acid present in humans is 
with highlighted P-glycine 
the dipeptide carnosine (P-Gly-His, Figure 3.2, 3.7), 
which is present in muscle tissue and has potent anti-oxidant properties. ' Currently 
marketed drugs have also made use of P-amino acids. The anti-tumor drug taxol® (Figure 
3.3, 3.8) contains a 2-hydroxy P-phenylglycine substituent.1 
P-Amino acids, like their a-methyl 
amino acid counterparts, have shown very 3.8 C \ /f OH 
NHBzO 
interesting properties as peptidomimetics. 
It has been established that common 
proteolytic enzymes can degrade P-amino Figure 3.3. Taxol® with highlighted 
a-hydroxy-P-phenylglycine 
acids, but at a much slower rate than a-
amino acids. ' These properties have made P-amino acids a lucrative research avenue for 
peptidomimetic research.1 Seebach et al. have synthesized a series of P-peptides 
T -1 0 0 0 ~1 T i l 
composed entirely of P-amino acids of different types (p-, p - , p z ' - , pz' -, pAZ' - and 
alternating p2- and p3-amino acids, examples are in Figure 3.1, 3.9-3.13).3 They tested 
these P-peptides in mixtures of enzymes, of high specific activity that would degrade the 
analogous a-peptides quickly. The enzymes were chosen to represent the member of the 
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major classes of peptidases such as serine, aspartic, and metallo- proteases. To 
accomplish this, a commercially available mixture of enzymes called Pronase (EC 
3.4.24.4) that is derived from fungus was used. Pronase has been well documented in the 
literature to cleave most types of peptide bonds. Other select enzymes also used were 
proteinase K, amidase, penicillin amidase, and (3-lactamase. Once the enzymatic 
degradation tests were started, aliquots were taken at predetermined times and analyzed 
by HPLC and MS to determine the degradation times and the products of the enzymatic 
degradation. It was observed that several of the P-peptides were intact after 48 hours 
whereas the analogous a-peptides had degraded within one hour (results shown in Table 
3.1). This stability has been confirmed in mammals, insects, plants, and microorganisms.4 
Xx xx liTjCXi xx 
H H H H H 
3.9 (P3) 
H H H H H H T ^ f 
3.10 (p3) 3.11 (P2) 
NH2 NH2 NH2 NH: 
H H H H H H H H H H H 
3.12 (P3) 
Figure 3.4. p-Peptides tested for stability to proteases (see Table 3.1) 
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Table 3.1. (3-peptide stability to enzymatic degradation 
Entry 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Enzyme 
Pronase 
proteinase K 
pepsin 
chymotrypsin 
elastase 
trypsin 
carboxypeptidase 
A 
leucyl 
aminopeptidase 
proteinase 
peptidase 
pronase E 
penicillin amidase 
(3-lactamase 
amidase 
20 S proteasome 
Origin of the enzyme 
Streptomyces griseus 
Tritirachium album 
hog stomach 
bovine pancreas 
hog pancreas 
hog pancreas 
bovine pancreas 
porcine kidney 
Bacillus substilis var. biotecus A 
porcine intestinal mucosa 
Streptomyces griseus 
Eschericha coli 
Enterobacter cloacae 
Pseudomonas aeruginosa 
human erythrocytes 
a 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
3.9 
-
-
-
-
3.10 
-
. 
-
-
-
-
-
-
-
3.11 
-
-
-
-
-
-
-
-
-
3.12 
-
-
-
-
-
-
-
-
-
-
-
-
-
Results of the peptidase degradation studies conducted on a- and P- peptides from Figure 
3.4. Each substrate was incubated with the enzyme for 48 hours. A (+) indicates 
degradation had taken place. A (-) sign indicates that no detectable degradation had taken 
place. 
It has been shown that (3-amino acids induce secondary structure. Recently, 
Seebach et al. have shown that a peptide composed of as few as four (3-amino acid 
residues can form stable secondary structures in solution.5'6 Literature has also shown that 
simple acyclic P-peptides are capable of forming stable secondary structures found in a-
peptides such as helices, parallel and anti-parallel P-pleated sheets, and hairpins. It has 
also been observed that P-peptides form unique secondary structures such as tubular 
stacking, ribbons, and alternative helices. The unique secondary structure and stability 
has yielded unique pharmacological properties in peptidomimetic compounds that 
contain (3-amino acid residues.4 Inhibition of cholesterol binding has been observed in 
cyclic (3-peptides that was not observed in peptides composed of the L-enantiomer of 
natural amino acids.7 Cyclic somatostatin mimics that are composed entirely of (33-amino 
acids have been shown to bind to the somatostatin receptor by mimicking the P-turn 
structure of the natural peptide.4'8 Cyclic P-peptides have shown anti-proliferate effects 
on leukemia, ovarian cancer, breast cancer, renal cancer, lung cancer, and cancer of the 
central nervous system. Peptides composed of P-amino acids have been designed that 
can interact with DNA in the same fashion as the natural DNA replication enzymes. It 
has even been shown that small cationic P-peptide oligomers such as octa-arginine can 
carry unnatural cargo such as magnetic beads into the nucleus of a cell and interact with 
the DNA directly.4 The properties outlined above clearly illustrate the need for efficient 
syntheses of p-amino acids. The following section will outline the methods that are 
currently used to synthesize this class of unnatural amino acids. 
Synthesis offi-Amino Acids 
The properties of p-amino acids and P-peptides outlined above clearly 
demonstrate the need for synthetic methodology that will allow for efficient synthesis of 
a variety of classes of P-amino acids. There are many different strategies that have been 
developed to synthesize P-amino acids. Many of these methods draw from the "chiral 
pool" to introduce chirality into the P-amino acids.11"13 Davies et al. reported the 
synthesis of p3-amino acids by Michael-type addition of chiral lithium amides to an a,P-
unsaturated ester.14 To accomplish this, the chiral lithium amide (3.13) was added to an 
a,P-unsaturated ester (3.14), which yielded the tertiary amine (3.15). This tertiary amine 
(3.15) was then treated with Pd/C in MeOH/formic acid to deprotect the amine. The 
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crude (3-amino ester (3.16) was then purified by crystallization with D-tartaric acid. Using 
this methodology, this group synthesized p3-Ala and p3-Tyr in moderate chemical yields 
with 99% - 100% ee. This methodology was adopted by several other groups to 
synthesize several different (33-amino acids.15 The main disadvantage of this methodology 
is the use of chiral reactants and a chiral resolving agent, which can be expensive and 
hamper the possibility of industrial application. Furthermore, this methodology is limited 
to the synthesis of a single class (p3) of (3-amino acids. 
.C02Me ^ C °2 M e 1)MeOH/HCOOH ^C0 2Me 
N "rf ^ i + -
C0 2 Me 1 } M e O H /  A 
J ^ 10% Pd/C „ J 
Li ' \ ^ J R' 7 ° ° ( f ^ T ^ N R 2) D-TartaricAcid H,N R 
3.13 3.14 \l J ^ 3)NaHC03 
R = Me J — < \ / > - O H 3.15 3.16 
Scheme 3.1. p-Amino acid synthesized by Davies et al. 
The synthesis of (3 - amino acids requires a different synthetic methodology. The 
addition of the -CH2- must take place between the amine functional and the a-carbon. 
Several approaches to the synthesis of P -amino acid using the enolate of an N-acyl-
oxazolidin-2-ones to perform a Mannich reaction to a XHC=NHZ+ equivalent (Z = 
benzyloxycarbonyl, X = CI, OH, OMe).16"19 As an example, gram quantities of p2-amino 
acids with proteinogenic and unnatural side chains have been conducted using the 4-
isopropyl-5,5-diphenyloxazolidin-2-one (DIOZ) chiral auxiliary (Scheme 3.2). Since 
both enantiomers of the DIOZ auxiliary are commercially available, both enantiomers of 
the p2-amino acids can be synthesized using this method. To accomplish the synthesis, 
the DIOZ auxiliary was N-acylated with an acyl chloride that contains the desired side 
chain. The Ti, B, or Li enolate was generated followed by addition of the appropriate 
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electrophile (CH3OCH2NHZ). The DIOZ auxiliary can then be cleaved using base and 
hydrogenolysis to give the free P -amino acid. Yields of 55-90 % and 
diastereoselectivities of 80 to > 97 % were achieved with 16 P-amino acids using this 
method (Scheme 3.2). The ability to synthesize both enantiomers of the P -amino acids in 
good to excellent yields and selectivity make this method a powerful technique. The 
disadvantage of this method, like the Davies method, is that expensive chiral materials 
(the N-acyl DIOZ auxiliary cost $ 685,000 / mol!) are required to induce the desired 
chiral center. 
3.17 1)TiCI4/Et3N 3 1 8 3 1 9 
~ 2)MeOCH2NHZ/ _ 3) LiOH 
ll ft T i C '4 U 9 4)Pd/C,H2 0 
O N ' ^ -
 0 ' > j ^ \ ^ HO' " " R p h
^ V CH2C'2 ^ ' v L -
Ph [ Ph | NH^ 
R = Me, MeCH2, MeCHCH2, PHCH2, MeS(CH2)2, BocNHCH2, BocOCH2, (1-trityl-1H-imidazole-4-yl)CH2 
Scheme 3.2 . Synthesis of P2-amino acids via the nucleophilic addition of 
a Ti, B, or Li enolate to an imine (Mannich Reaction). 
A popular method to synthesize p3-amino acids that has been widely applied and 
is inspiration for the work contained in this dissertation is the /zomo-elongation of N-Boc 
protected a-amino acids. ' Several different classes of P -amino acids have been 
synthesized using this methodology (Scheme 3.3). This method uses Ardnt-Eistert 
methodology, which is considered by most to be the best method for elongation of a 
carboxylic acid by one carbon. ' This method involves activation of the acid (3.20) to 
an acid-anhydride, which is then treated with CH2N2 to give a diazoketone (3.21). The 
diazoketone is heated in the presence of a silver catalyst to give the free acid (3.22). 
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There are two main problems with this synthetic route that make it of limited utility: 1) 
the products are generally in low yields due to formation of a cyclic byproduct11, and 2) 
this method yields only the (3 -amino acids. 
3.21 
1.Et3N 0 
2. CIC02Et »J j f OH 
0 3CH2N2 
H 
58% Yield 
O 
O N 
H 
3.23 
C02H 
^ X 
3.25 
O N 
H 
36% Yield 
C02H 
^COOH 
Boc 
80% Yield 
O 
. A 
O N 
H 
3.27 
3.29 
C02H 
58% Yield 3
 3 1 
^OBn 
O N 
H 
44% Yield 
CF3C02Ag/Et3N 
H,0 
A A^C02H 
H 
46% Yield 
3.24 
>LX O J^SMe O N 
H 
58% Yield 
A ^ C 0 2 H 
3.26 
NHCbz 
^ ^ „ ^ ^ C 0 2 H O N 
H 
3.28 32% Yield 
>L A f -- •• A ^ C O 2 H 
3.30 
C02H 
58% Yield 
Scheme 3.3 . p-Amino acids synthesized by Arndt-Eistert/ Wolff rearrangement of natural and 
unnatural oc-amino acids 
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All of the methods described above require the presence of chiral center to 
facilitate asymmetric synthesis, either in the reactant or as an auxiliary. In Chapter II, the 
desymmetrization of a 
HO 
O 
NH2 *2,2 H2N , OH prochiral malonate 
diester with PLE was 
introduced. The chiral 
half-ester product served 
as a common synthetic 
intermediate that was 
H,N x^Y0H 13,3 H O y ^ N H j 
O 
converted to both 
enantiomers of a-methyl 
Scheme 3.4 . Generation of both enantiomers of p2,2- and serine and a-methyl 
P3,3- amino acids from a common malonate half ester 
intermediate tyrosine by means of 
protecting group manipulation and a Curtius rearrangement of the acid functionality. Our 
group has contributed to the synthesis of P-amino acids by utilizing the same malonate 
half-ester to synthesize both enantiomers of p2'2- and p3'3- amino acids.23 To accomplish 
this, the acid functionality is used to homologate the carbon backbone via an Ardnt-
Eistert synthesis followed by a Wolff rearrangement. ' If water is a component of the 
Wolff rearrangement, the result is a carboxylic acid that has a new methylene spacer 
between the acid and the a-carbon. This carboxylic acid can be converted to an amine by 
use of the Curtius rearrangement to yield a protected p2,2-amino acid. Manipulation of the 
protecting groups with subsequent application of the Curtius and Wolff rearrangements 
results in the synthesis of the enantiomer p2'2-amino acid and both enantiomers of the 
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(33'3-amino acids. The following will describe the development of the synthesis of both 
enantiomers of p ' - and p ' - serine and tyrosine analogues from the same common 
malonate half-ester intermediates (2.32a and 2.32b) that were discussed in Chapter II. As 
discussed in Chapter II, the serine analogues functioned as a prototype for the 
development of the needed synthetic methodology. After synthesis of the serine 
analogues had been achieved, the same methodology was applied to the synthesis of 
tyrosine analogues. 
Discussion and Results 
To synthesize the (S) enantiomer of p2,2-serine the half-ester intermediate 2.32a 
was treated with thionyl chloride to generate an acid chloride. Addition of diazomethane 
yielded a diazoketone 3.32a (Ardnt-Eistert synthesis). Our initial attempts of a Ag+ 
catalyzed Wolff rearrangement failed. One possible explanation of this failure is that the 
diazoketone functionality is in close proximity to a neopentyl backbone and the catalysis 
can not proceed due to steric congestion. Literature findings support this hypothesis and 
note that the Wolff rearrangement of sterically hindered diazoketones can be 
accomplished by photolysis.21 Synthesis of the desired compound was accomplished 
when the diazoketone was subjected to intense UV light in the presence of water. This 
resulted in a new half acid (3.33b, 63% yield) that has been homologated by one 
methylene group. Analysis by chiral HPLC proved that there was no racemization of the 
chiral center during the Ardnt-Eistert synthesis and the Wolff rearrangement (Scheme 
3.5). This half-ester was subjected to a Curtius rearrangement and quenched with PMB-
OH to yield the protected (5)-p2'2-serine (3.34a, 55% yield). The (i?)-p2'2-serine 
enantiomer was generated using a similar synthetic sequence with the exceptions that 
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half-ester 2.38a (Synthesis of 2.38a from common intermediate 2.31a is detailed in 
Chapter II) was used as the starting acid and a different method to activate the acid was 
required. The acid sensitive nature of the tert-butyl ester of 2.38a did not allow for 
activation of the acid with thionyl chloride due to the HC1 that is formed as a byproduct 
of the reaction. An alternate path was activation of the acid as a mixed anhydride in the 
presence of a proton scavenger. Compound 2.38a was treated with methyl chloroformate 
in the presence of triethyl amine to give mixed anhydride that was quenched with 
diazomethane to give the desired diazoketone 3.35a in 65 yield.24 A Wolff 
rearrangement yielded 3.36a (77%) which was subjected to a Curtius rearrangement to 
give the (R)-fi2'2 serine (3.37a) in 50% yield (70% ee). Analysis by chiral HPLC showed 
that the enantiomeric composition was retained throughout each step of the synthesis. 
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Scheme 3.5. Generation of both enantiomers of p2'2- and P3'3- amino acids from a common 
malonate half-ester intermediate. The chiral HPLC of 334a shows that the enantiomeric 
composition of 2.32a was retained throughout both the Wolff rearrangement and Curtius 
rearrangement 
Both enantiomers of the p3,3-serine analogues can be synthesized using 
intermediates from the p2'2-serine synthetic path. To synthesize the (5)-enantiomer, 
Compound 3.33a was converted to 3.38a (73% yield) by treatment with isobutylene 
(IBE) and catalytic amounts of sulfuric acid. Saponification of the ethyl ester of 3.38a led 
to a half-ester 3.39a (64% yield) that was subjected to a Curtius rearrangement to yield 
3.40a in 58 % yield. Analysis by chiral HPLC showed that the enantiomeric ratio of 
2.32a was retained throughout the entire synthesis. To generate the (i?)-enantiomer, 3.35a 
was subjected to a Wolff rearrangement in the presence of methanol which yielded 3.41a 
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(50% yield). The tert-buty\ ester of 3.35a must be cleaved to give the free acid 
functionality. Hydrolysis of the ter^-butyl ester can be accomplished by using catalytic 
amounts of H2SO4, but a tert-butyl cation scavenger (i.e. anisole) would be necessary to 
prevent ter/-butylation of the aromatic functionality of the protecting group. 3 A more 
Oft 
efficient solution is the use of KSF montmorillonite clay to cleave the tert-bvXy\ ester. 
This method is chemoselective for the tert-b\\\y\ ester. The clay also acts as a ter/-butyl 
cation scavenger and can be removed by vacuum filtration. Treatment of 3.41a with KSF 
clay in refluxing acetonitrile gave 71% yield of 3.42a. The free acid was then subjected 
to a Curtius rearrangement to give the (7?)-p3'3-serine (3.42a) in 66% yield. HPLC 
analysis of 3.43a proved that the enantiomeric composition of 2.32a (70%) ee) was 
preserved throughout the synthesis. 
a R ; 
O 3 .33 H 2 S 0 4 
'D II CHoCIo 
o 
OBn bR = 
3 .44b 
BnO 
N=N — 
© 
3.35 
0 O 
•V-
*
%
 R 
O 3.38 O 3.39 
°^ 
OBn 
a 64% \ DDPPA/E t 3 N 
I. 44% \ 2 ) PMB-OH 
C H 2 C I 2 \ 3 4 0 
H 
P M B O \ ^ N ~ 
a. 58 
b. 26% 
,0 
0/ O O ' 
3.43 
H 
o o 
a. 50% 
b. 6 1 % 
1)DPPA/Et3N 
2) PMB-OH 
3.42 
0 ' CH2CI2 
a. 7 1 % 
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Scheme 3.6. Synthesis of both enantiomers of p3,3-serine and tyrosine from intermediates 
generated in the p2'2 synthetic path. 
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The synthesis of the p2' - and (3 ' -tyrosine series was carried out using a similar 
synthetic methodology. It was decided at this point, to proceed with racemic synthesis of 
the tyrosine series. This decision was due to the large amount of time each PLE 
hydrolysis requires and the tedious workup to obtain 2.32b that is required. Once the 
synthesis of the tyrosine analogues has been optimized, each amino acid can be 
synthesized as needed using 2.32b from the PLE hydrolysis. To synthesize the (i?)-p2'2-
tyrosine , Compound 2.32b was subjected to an Ardnt-Eistert synthesis to give 
diazoketone 3.32b (73% yield). This was followed by a Wolff rearrangement in the 
presence of water to give the desired half ester (3.33b, 63 % yield) that had been 
homologated by one methylene group. Compound 3.34b (45% yield) was obtained by a 
Curtius rearrangement of 3.33b. The (S)- p2'2-tyrosine was synthesized by homologation 
of 2.38b to 3.36b (26% yield) using a Wolff rearrangement that was followed by a 
Curtius rearrangement which was quenched with PMB-OH yielded the (S)-p2'2-Tyrosine 
(3.37b, 62% yield). 
To synthesize the (,/?)-p3'3-tyrosine, 3.33b was ter/-butylated using isobutylene 
with catalytic amounts of sulfuric acid to give 3.38b in 82% yield. The ethyl ester was 
then saponified to give 3.39b (% yield). This half-ester (3.39b) was subjected to a Curtius 
rearrangement and quenched with PMB-OH to give the (i?)-(33'3-tyrosine (3.40b, 26% 
yield). The (5)-pJ'3-tyrosine was synthesized by Wolff rearrangement of 3.35b in 
methanol to give 3.41b in 61% yield. The tert-buty\ ester was then cleaved by the KSF 
clay method to give 3.42b (59% yield).26 The acid moiety of 3.42b was converted to the 
(S)- p3'3-tyrosine (3.43b, 44% yield) by means of a Curtius rearrangement with 
subsequent quenching of the isocyanate with PMB-OH. One problem encountered with 
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the synthesis of the p2'2- and p3'3-tyrosine (3.37b) was the lower yield of the Wolff 
rearrangement. This is due to the formation of a keto-alcohol intermediate that cyclizes to 
give 3.44b. Optimization of the reactions condition for the Wolff rearrangement of the 
diazoketones may lead to an increased yield of each. It is possible that these 
intermediates were also formed in earlier Wolff rearrangements using the 2.32b and 
2.35b. 
Conclusions 
It has been shown in this chapter that both enantiomers of P - and p ' - serine 
and tyrosine analogues can be synthesized from a common malonate half-ester 
intermediate. As outlined in Chapter 2, this same common intermediate can be used to 
synthesize both enantiomers of the a-methyl serine and a-methyl tyrosine series. Also 
seen in Chapter 2 is that the common malonate half-ester intermediate is generated using 
simple, cost-effective starting materials and an enzyme to catalytically provide the 
needed chirality. The synthetic methodology outlined above had proven to be efficient. 
The chemistry used in the synthesis of the P ' - and P ' -amino acids is similar (Ardnt-
Eistert synthesis, Wolff rearrangement, and the Curtius rearrangement). Clearly put, both 
enantiomers of 3 different classes of unnatural amino acids have been successfully 
synthesized from the same common intermediate. This synthetic methodology has the 
potential to generate a large number of unnatural amino acids for use in peptidomimetic 
compounds. The ability to synthesize these classes from a common intermediate and with 
common chemistry may allow this methodology to be utilized by biologists and 
biochemists that do not have access to a full scale synthetic laboratory. Additionally, the 
9 9 -j -5 
use of common synthetic methodology may allow a library of P ' - and P ' -amino acids 
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to be efficiently synthesized and incorporated into the same peptide in a combinatorial 
fashion. This will allow for the possible evaluation of an entire library of peptidomimetic 
compounds. 
Experimental 
See Chapter II (pgs 43-44) for general experimental. Diazomethane was generated 
using the Sigma-Aldrich mini-diazomethane apparatus and the procedure. Diazald was 
prepared using an Organic Syntheses preparation. Separation of the enantiomers of the 
P ' - and P ' - tyrosine analogues by chiral HPLC was not accomplished with either the 
AD-H or OJ-H chiral columns. 
(i?)-Ethvl 2-(benzvIoxvmethvl)-4-diazo-2-methvl-3-oxobutanoate (3.32a): An amount 
of 1.99 g (7.48 mmol) of 2.32a was dissolved in 10 mL of dry CH2C12 and 8.10 mL (113 
mmol) SOCI2 was added slowly to the solution. The solution was heated to reflux solvent 
and allowed to reflux overnight. The excess CH2CI2 and SOCI2 were removed by rotary 
evaporation and the acid chloride was placed under vacuum for 3 hours to remove any 
residual SOCI2. The acid chloride was dissolved in dry CH2CI2 and added dropwise to an 
ethereal solution of anhydrous diazomethane (13.6 mmol) containing 1.13 mL (7.51 
mmol) of Et3N via syringe and allowed to react without stirring overnight at 0 °C. The 
excess diazomethane was then removed by bubbling dry N2 into the solution for 15 
minutes and the triethyl ammonium salt is removed by gravity filtration. The resulting 
solution was then concentrated using a rotary evaporator and placed under vacuum in the 
dark for 3 hours to give 2.59 g of crude diazoketone 3.32a as an orange, transparent, 
viscous oil. This material was used in the next step without further purification. IR (cm"1) 
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2106, 1727. 'H-NMR (300 MHz, CDC13) 1.24 (3H , t, J = 7 Hz), 1.47 (3H, s), 3.78 (2H, 
q, J= 9 Hz), 4.18 (2H, q,J= 7 Hz), 4.54 (2H, s), 5.51 (1H, s), 7.29 (5H, m), 13C-NMR 
(75 MHz, CDC13) 14.3, 18.5, 54.6, 58.8, 61.8, 73.1, 73.7, 127.8, 127.9, 128.6, 138.1, 
171.6,192.0. 
(5V3-(4-(benzvloxv)methvl)-4-ethoxv-3-methvl-4-oxobutanoic acid (3.33a); An 
amount of 2.59 g of 3.32a (9.24 mmol) was placed in a 25 mL roundbottomed flask and 
dissolved in 10 mL of 30% H2O / 70% THF was added. Nitrogen was bubbled through 
the resulting solution for 15 minutes to deoxygenate the solution. The solution was then 
irradiated with a 500W Hanovia lamp at a distance of approximately 10 cm. The photo-
induced Wolff was monitored by the disappearance of the diazo stretch by IR (2106 cm" 
'). The reaction was complete after 48 hours, diluted with 50 mL of Et20 and extracted 
three times with 1.0 M NaOH. The basic aqueous layers were combined, acidified to pH 
= 1.0 with concentrated HC1, and extracted three times with Et20. These Et20 washes 
were combined, dried over MgSCU, filtered, concentrated by rotary evaporation, and 
placed under high vacuum for 3 hours to give 1.31 g (4.70 mmol, 62% yield, 66% ee) of 
a clear viscous oil. TLC (25% /PrOH / 75% Hexane) Rf = 0.41, [a]D220 = -3.2° (c = 
0.061, CH2CI2), IR 3350, 1707. 'H-NMR (300 MHz, CDC13): 1.22 (3H, t, J= 7 Hz), 1.32 
(3H, s), 2.62 (1H, d, J= 16 Hz), 2.90 (1H, d, J= 16 Hz), 3.52 (1H, d, J= 9 Hz), 3.65 
(1H, d, J= 9 Hz) 4.16 (2H, q, J= 7 Hz), 4.51 (2H, s), 7.30 (m, 5H) 13C-NMR (75 MHz, 
CDCI3) 14.2, 20.9, 45.4, 61.2, 73.4, 74.4, 127.6, 127.8, 128.5, 138.2, 175.0, 177.4. 
HRMS: [Ci5H2o05Na+] calcd = 303.1203, Obsd = 303.1209. The % ee was determined 
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by analytical chiral HPLC (Chiracel OJ-H, 257 nm, flow rate = 1 mL / minutes, 4% 
/PrOH / 96% Hexane) Rt(S) = 15.35, Rt(R) = 16.82 . 
(>y)-ethv}3-(benzvloxv)-2-(((4-methoxvbenzvoxv)carbonvlainino)methvl)-2-
methylpropanoate (3.34a): An amount of 0.50 g (1.80 mmol) of 3.33a was dissolved in 
lOmL of 1,2-Dichlroethane in a 50 mL roundbottomed flask with a magnetic stirbar. 415 
uL (1.98 mmol) of DPP A and 750 uL of Et3N (5.38 mmol) was added and the solution 
was brought to reflux solvent for 3 hours, at which time 335 uL (2.70 mmol) of PMB-OH 
was added and the solution was again heated to reflux solvent. The solution was diluted 
with 50 mL of CHCI3 and washed three times with 1.0 M NaOH and three times with 
10% HC1. The organic layer was dried over MgS04, filtered, and concentrated by rotary 
evaporation to give an orange, transparent, viscous oil that was purified by flash 
chromatography (35 mL of silica gel, 5% /PrOH / 95% hexane) to give 0.414 g (1.00 
mmol, 55% yield, 68% ee) of a clear, viscous oil. TLC Rf = 0.24, [a]D220 = -0.9° (c = 
0.0378, CH2CI2), IR 1726. 'H-NMR (300 MHz, CDC13) 1.15 (3H, s), 1.41 (3H, t, J= 7 
Hz), 3.41 (1H, d, J= 9 Hz), 3.49 (2H, dd, J= 6 Hz), 3.64 (1H, d, J= 9 Hz), 3.80 (3H, s), 
4.13 (2H, q, J= 2 Hz), 4.48 (2H, s), 5.01 (2H, s), 5.25 (1H, bt, J= 6 Hz), 6.88 (2H, d, J = 
9 Hz), 7.29 (m, 7H) 13C-NMR (75 MHz, CDC13) 14.3, 18.6, 45.7, 48.2, 55.5, 61.1, 66.7, 
73.5,74.5, 114.0,127.6,127.8,128.6,128.9, 130.1,138.1,157.0, 159.7, 175.1. HRMS: 
[C23H29N06Na]+ calcd = 438.1887 obsd = 438.1879. The % ee was determined by 
analytical chiral HPLC (Chiracel OJ-H, 282 nm, 5% /PrOH / 95% hexane) Rt(S) = 69.73, 
Rt(R) = 93.73. 
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(5Vfe^butvt-2-(benzvloxvmethvl)-4-diazo-2-methvl-3-oxobutanoate (3.35a) An 
amount of 1.31 g (4.50 mmol) of 2.38a and 1.42 mL of Et3N (9.50 mmol) was dissolved 
in 25 mL of dry THF under a blanket of N2 at -50 °C. Then, 360 uL (4.70 mmol) of 
methyl chloroformate was added slowly to the solution via syringe. The solution was 
allowed to stir at - 50 °C for 3 hours. An ethereal solution of anhydrous diazomethane 
(21.6 mmol) was added drop-wise to the mixed anhydride solution via a dry syringe and 
allowed to react without stirring overnight at 0 °C. The excess diazomethane was then 
removed by bubbling dry N2 into the solution for 15 minutes and the solution was filtered 
to remove the triethylammonium salt. The crude 3.35a was purified using 40% Et20 / 
60% hexane and a flash column with 200 mL of silica gel. The pure fractions were then 
concentrated using a rotary evaporator and placed under vacuum in a flask wrapped in 
foil for 3 hours to give 0.91 g (2.89 mmol, 64% yield) of an orange, transparent, viscous 
oil. TLC (40% Et20 / 60% hexane) Rf = 0.38; IR (cm4) 2106, 1725. 'H-NMR (300 MHz, 
CDCI3) 1.44 (3H, s), 1.45 (9H, s), 3.73 (1H, d, J= 9 Hz), 3.80 (1H, d, J= 9 Hz), 4.55 
(2H, s), 5.50 (1H, s), 7.33 (5H, m), 13C-NMR (75 MHz, CDC13) 18.5, 28.0, 54.1, 59.4, 
73.2, 73.7, 82.1, 127.7, 127.8, 128.5, 138.1, 170.6, 192.3 
(i?)-3-(Benzvloxymethvl)-4-fe^-butvl-3-methvl-4-oxobutanoic acid (3.36a) An 
amount of 0.20 g (0.63 mmol) of 3.35a was dissolved in 10 mL of 30% water / 70% THF 
in a 25 mL roundbottomed flask. Dry N2 was passed through the solution for 15 minutes 
to deoxygenate the solution. The solution was irradiated with a 500W Hanovia lamp at a 
distance of approximately 10 cm. The photo-induced Wolff was monitored by the 
disappearance of the diazo stretch at 2106 cm"1 by IR spectroscopy. The reaction was 
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complete after 48 hours. The solution was then diluted with 50 mL of Et20 and extracted 
three times with 1.0 M NaOH. The basic aqueous layers were combined, acidified to pH 
~ 2.0 with 10% HC1, and extracted three times with CH2CI2. These CH2CI2 washes were 
combined, dried over MgSC>4, filtered, concentrated by rotary evaporation, and placed 
under vacuum for 3 hours to give 0.15 g (0.49 mmol, 77% yield) of a clear, viscous oil. 
[a]D225 = +3.6° (c = 0.05, CH2C12) IR 1705. 'H-NMR (300 MHz, CDC13) 1.29 (3H, s), 
1.42 (9H, s,), 2.56 (1H, d, J= 16 Hz), 2.87 (1H, d, J= 16 Hz), 3.48 (1H, d, J= 9 Hz), 
3.65 (1H, d, J= 9 Hz) 4.52 (2H, s), 7.31 (7H, m) 13C-NMR (75 MHz, CDCI3) 21.1, 28.0, 
39.5, 45.9, 73.5, 74.7, 81.3, 127.6, 127.8, 128.5, 138.3, 174.2, 177.6 HRMS: 
[C17H2405Na] + calcd= 466.2200, obsd = 466.2193. 
(ig)-ferf-Butvl-3-(benzvloxv)-2-(((4-methoxybenzvloxv)carbonvlamino)methvn-2-
methvlpropanoate (3.37a): An amount of 0.15g (0.49 mmol) of 3.36a was dissolved in 
10 mL of 1,2-dichlroethane in a 25 mL round-bottomed flask with a magnetic stirbar. 
Then, 113 uL (0.54 mmol) of DPP A and 739 uL of Et3N (5.30 mmol) was added and the 
solution was brought to reflux solvent for 3 hours, at which time 91 uL (0.73 mmol) of 
PMB-OH was added and the solution was again brought to reflux solvent. The solution 
was cooled to room temperature and diluted with 50 mL of CHCI3 and washed 3 times 
with 1.0 M NaOH and two times with water. TLC showed a baseline impurity that was 
removed by filtration through silica gel. The solution was then dried over MgSO/j, 
filtered, and concentrated by rotary evaporation to give a orange, transparent, viscous oil. 
This was purified by flash chromatography (200 mL of silica gel, Rf = 0.65, 30% EtOAc / 
70% hexane) to give 0.11 g (50% yield, 0.24 mmol, 69% ee) of a clear, viscous oil. 
80 
[a]D220 =+1.5° (c = 0.03 ,CH2C12)IR 3420, 1717. 'H-NMR (300 MHz, CDC13) 1.11 (3H, 
s), 1.41 (9H, s), 3.45 (3H, m), 3.60 (1H, d, J= 9 Hz), 3.78 (3H, s), 4.48 (2H, m), 5.00 
(2H, s), 5.31 (1H, bt, J= 6 Hz), 6.87 (2H, d, J= 9 Hz), 7.28 (7H, m) l3C-NMR (75 MHz, 
CDCI3) 18.6, 28.1, 45.7, 48.5, 55.4, 66.5, 73.5, 74.8, 81.1, 114.0, 127.5, 127.7, 128.5, 
128.9, 130.1, 138.2, 156.9, 159.6, 174.2. HRMS: [C25H33N06Na]+ calcd = 466.2200 obsd 
= 466.2193. The % ee was determined by analytical chiral HPLC (Chiracel OJ-H, 282 
nm, 6% rPrOH / 94% hexane) Rt(S) = 29.24, Rt(R) = 41.78. 
(S)-4-tert-but\l 1-ethyl 2-(benzyloxvmethyl)-2-methvlsuccinate (3.38a): An amount 
of 0.540 g (1.93 mmol) of 3.33a was dissolved in 5 mL of dry CH2CI2 and placed in a 20 
mL pressure vessel at -10 °C. Then, 250 uL of H2SO4 and 15 mL of condensed 
isobutylene were added, the vial was sealed and the reaction was allowed to stir overnight 
a room temperature. The flask was then placed in an icebath at 0 °C for 15 minutes then 
opened and allowed to stir at room temp for 2 hours to allow evaporation of any 
remaining isobutylene. The solution was diluted with 25 mL of Et20 and washed three 
times with 1.0 M NaOH, dried over MgSC>4, filtered, and concentrated by rotary 
evaporation to give a clear, viscous oil. 0.51 g (4.4 mmol, 73% yield). TLC (50% Et20 / 
50% hexane) Rf = 0.34, [a]D227 = -3.8° (c = 0.02, CH2C12) IR (cm"1) 1726 'H-NMR (300 
MHz, CDCI3) 1.24 (3H, t, J - 7 Hz), 1.30 (3H, s), 1.41 (9H, s), 2.46 (1H, d, J= 16 Hz), 
2.74 (1H, d, J = 16 Hz), 3.54 (1H, d, J= 9, 1 H), 3.59 (1H, d, J= 9Hz), 4.15 (2H, q,J = 
7 Hz), 4.51 (2H, s), 7.31 (5H, m) l3C-NMR (75 MHz, CDCI3) 14.3, 20.7, 28.2, 40.9, 
45.6, 60.8, 73.4, 74.8, 80.8, 127.6, 127.7, 128.5, 138.5, 170.6, 175.1. HRMS: 
[C19H2805Na]+ calcd = 359.1829, obsd = 359.1824. 
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(,Sy2-(benzvloxvmethvl)-4-fe^butoxv-2-methvl-4-oxobutanoic acid (3.39a): An 
amount of 0.658 g (2.00 mmol) of 3.39a was dissolved in 7 mL of THF. 0.140 g (5.9 
mmol) of LiOH was dissolved in 3 mL of water and added to the reaction flask. The 
reaction mixture was allowed to stir at room temperature for 72 hours. The THF was 
removed by rotary evaporation and 30 mL of 1.0 M NaOH was added to the reaction 
mixture. The basic aqueous layer was then washed 3 times with 50 mL portions of E12O, 
acidified to pH 1.0 using cold 10% HC1, then extracted with three portions of Et20. The 
Et20 extracts were combined and concentrated by rotary evaporation then placed under 
vacuum to give 0.395 g (1.30 mmol, 64% yield) of a clear, viscous, liquid. TLC (20% 
/PrOH / 80% hexane) Rf = 0.48, [a]D213 = - 2.9° (c = 0.02 ,CHC13) IR (cm"1) 1726. 'H-
NMR (300 MHz, CDC13) 1.36 (3H, s,), 1.42 (9H, s), 2.51 (1H, d, J= 16 Hz), 2.75 (1H, d, 
./= 16 Hz), 3.59 (2H, s), 4.55 (2H, s), 4.99 (2H, s), 7.33 (5H, m) ,3C-NMR (75 MHz, 
CDCI3) 20.6, 28.1, 40.9, 45.6, 73.6, 74.4, 81.3, 127.7, 127.8, 128.6, 138.2, 170.5, 181.3 
HRMS: [Ci7H2405Na]+ calcd= 331.1516, obsd = 331.1509. 
(5r)-ferf-Butvl4-(benzvloxv)-3-((4-methoxvbenzyloxv)carbonvlamino)-3-
methvlbutanoate (3.40a): An amount of 0.395 g (1.30 mmol) of 3.39a was dissolved in 
10 mL of 1,2-dichlroethane in a 25 mL roundbottomed flask with a magnetic stirbar. 
Then, 304 uL (1.40 mmol) of DPP A and 739 uL of Et3N (5.30 mmol) was added and the 
solution was brought to reflux solvent for 3 hours, at which time 587 uL (2.00 mmol) of 
PMB-OH was added and the solution was brought to reflux solvent. The solution was 
diluted with 50 mL of CHCI3 and washed three times with 1.0 M NaOH, three times with 
10 % HC1, and one time with Brine. The crude material was then filtered through a plug 
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of silica gel to remove a baseline impurity. The solution was dried over MgSCU, filtered, 
and concentrated by rotary evaporation to give an orange, transparent, viscous oil that 
was purified by flash chromatography (200 mL of silica gel, 50% Et20 / 50% hexane, Rf 
= 0.18) to give 0.366 g (0.76 mmol, 58% yield, 69% ee) of a clear, viscous oil. [a]D218 = -
3.20° (c = 0.09, CH2C12) IR3361, 1726. 'H-NMR(300 MHZ, CDC13) 1.41 (12H, s), 2.64 
(1H, d, J= 14 Hz), 2.72 (1H, d, J= 14 Hz), 3.59 (2H, m), 3.79 (3H, s), 4.51 (2H, s), 4.99 
(2H, s), 5.57 (1H, bs), 6.87 (2H, d, J= 8.55 Hz), 7.30 (7H, m) l3C-NMR (75 MHz, 
CDCI3) 22.2, 28.2, 42.2, 54.6, 55.4, 66.1, 73.4, 74.5, 81.0, 114.0, 127.7, 127.8, 128.5, 
128.9, 130.0, 138.2, 155.2, 159.6, 170.7 HRMS: [C25H33N06Na]+ calcd = 466.2200 obsd 
= 466.2190. The % ee was determined by analytical chiral HPLC (Chiracel OJ-H, 6% 
/PrOH / 94% hexane, 286 nm, flow rate = 1 mL / minute) Rt(S) = 29.24, Rt(R) = 41.78. 
(/?M-ter^butvl-4-methvl-2-(benzyIoxvmethvO-2-methvlsuccinate (3.41a): An amount 
of 0.70 g (2.20 mmol) of 3.35a was dissolved in 10 mL of dry MeOH in a 25 mL 
roundbottomed flask. Dry N2 was passed through the solution for 15 minutes to 
deoxygenate the solution. The solution was irradiated with a 500W Hanovia lamp. The 
photo-induced Wolff was monitored by the disappearance of the diazo stretch (2106 cm" 
). The reaction was complete after 48 hours and the crude reaction mixture was 
concentrated by rotary evaporation, and placed under high vacuum for 3 hours to give a 
clear viscous oil that was purified by flash chromatography (40% Et20 / 60% hexane, Rf 
= 0.38) to give 0.35 g (1.10 mmol, 50% yield) of a clear, viscous oil. [a]D21-0 = + 5.4° (c 
= 0.08 ,CH2C12) IR 1724,. 'H-NMR (300 MHz, CDC13) 1.27 (3H, s), 1.43 (9H, s), 2.53 
(1H, d, J= 16 Hz), 2.79 (1H, d, J= 16 Hz), 3.50 (1H, d, J= 9 Hz), 3.61 (1H, d, J= 9 Hz), 
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3.63 ( 2H, s), 4.51 (2H, s), 7.31 (5H, m). 13C-NMR (75 MHz, CDC13) 21.0, 28.0, 39.3, 
46.0, 51.5, 73.4, 74.7, 80.8, 127.55, 127.64, 128.4, 128.5, 138.5, 172.1, 174.0. HRMS: 
[CsHaeOsNaf calcd = 345.1672 , obsd = 345.1669. 
(iO-2-((benzvloxv)methvl)-4-methoxv-2-methvl-4-oxobutanoic acid (3.42a): In a 50 
rnL roundbottomed flask 0.352 g (1.10 mmol) of 3.41a was dissolved in 20 mL of dry 
CH3CN and 1 mL of water was added. Then, 1.0 g of KSF Montmorillonite clay was 
added and the solution was heated to reflux solvent. The reaction was monitored by TLC 
(40% Et20 / 60% hexane) and was determined to be complete after 7 hours. The KSF 
clay was removed by vacuum filtration, and the filtrate was washed with CH3CN. The 
CH3CN was removed by rotary evaporation and placed under vacuum for 3 hours to give 
a clear viscous oil that was purified by flash chromatography (10% MeOH / 90% CHCI3, 
Rf = 0.50) to give 0.207 g (0.77 mmol, 71% yield) of a clear, viscous oil. [a]D212 = +4.8° 
(c = 0.041, CH2CI2). IR (cm"1) 1736, 1703. 'H-NMR (300 MHz, CDC13) 1.34 (3H,s), 
2.62 (1H, d, J= 16 Hz), 2.82 (1H, d, J= 16 Hz), 3.56 (1H, d, J= 9 Hz), 3.62 (3H, s) 3.65 
(1H, d, J= 9 Hz), 4.52 (2H, s), 7.31 (5H, m), 10.00 (1H, bs). 13C-NMR (75 MHz, 
CDCI3) 20.8, 28.9, 38.9, 45.5, 51.8, 73.5, 74.0, 127.7, 127.8, 128.5, 138.1, 171.9, 181.2. 
HRMS: [Ci4Hi805Na]+ calcd = 289.1046, obsd = 289.1039. 
(i?)-methvl-4-(benzvloxv)-3-(((4-methoxybenzvoxv)carbonvlamino)methvl)-3-
methvlbutanoate (3.43a): In a 25 mL roundbottomed flask 0.182 g (0.68 mmol) of 
3.42a was dissolved in 10 mL of 1,2-dichlroethane. The solution was stirred and 159 uL 
(0.75 mmol) of DPP A and 739 uL of Et3N (5.30 mmol) was added and the solution was 
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brought to reflux solvent for 3 hours, at which time 127 uL (1.00 mmol) of PMB-OH was 
added and the solution was again heated to reflux solvent. The solution was cooled and 
diluted with 50 mL of CHCI3 and washed three times with 1.0 M NaOH and two times 
with water. The organic layer was then filtered through a plug of silica gel to remove a 
baseline impurity. The solution was then dried over MgSO/j, filtered, and concentrated by 
rotary evaporation to give an orange, transparent, viscous oil that was purified by flash 
chromatography (200 mL of silica gel, 30% EtOAc / 70% hexane) to give 0.195 g (0.49 
mmol, 72% yield, 66% ee) of a clear viscous oil. TLC Rf = 0.39, [a]D143 = +1.7° (c = 
0.04 ,CH2C12) IR 3369, 1717,. 'H-NMR (300 MHz, CDCI3) 1.43 (3H, s), 2.70 (1H, d, J = 
14 Hz), 2.81 (1H, d, J= 14 Hz), 3.58 (5H, s), 3.79 (3H, s), 4.49 (2H, s), 4.99 (2H, s), 5.50 
(1H, bs), 6.87 (2H, d, J= 7 Hz), 7.30 (7H, m) (75 MHz, CDCI3) 22.4, 40.7, 51.7, 54.6, 
55.4, 66.1, 73.4, 74.6, 114.0, 127.75, 127.8, 128.1, 128.5, 128.7, 128.9, 130.0, 138.2, 
138.1, 155.3, 159.6, 171.8. HRMS: [C22H27N06Na]+ calcd = 424.1701, obsd = 424.1720. 
The % ee was determined by analytical chiral HPLC (chiracel OJ-H, 280nm, 4% z'PrOH / 
96% hexane) Rt(S) = 99.703, Rt(R) = 122.183. 
(±)-Ethvl 2-(4-(benzvloxv)benzvl)-4-diazo-2-methvl-3-oxobutanoate (3.32b): An 
amount of 2.00 g (5.84 mmol) of 2.32b was and 6.31 mL (87.6 mmol) SOCI2 was 
dissolved in 30 mL of dry CH2CI2 and the solution was heated to reflux solvent. After 
refluxing overnight, the excess CH2CI2 and SOCI2 were removed by rotary evaporation 
and the acid chloride was placed under reduced pressure with an N2 cold finger for 3 
hours. An ethereal solution of CH2N2 was generated via Aldrich's procedure for an 
alcohol free solution using the mini-Diazald apparatus and allowed to dry over KOH for 
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3 hours. The concentration of CH2N2 was determined by UV/Vis at 410 nm (s = 7.2) to 
be 20 mmol.28 The acid chloride was then dissolved in anhydrous CH2CI2 and added 
dropwise to the ethereal CH2N2 solution and allowed to react without stirring overnight at 
0 °C. The excess CH2N2 was then removed by bubbling dry N2 into the solution for 15 
minutes. The solution was washes three times with 10% HC1, dried over MgSCU, filtered, 
and concentrated using a rotary evaporator and placed under high vacuum in a flask 
wrapped in foil for 3 hours to give 2.92 g of a orange, transparent, viscous oil. 
Purification by flash chromatography (300 mL of silica gel, 50% Et20/ 50% hexane) 
gave 1.56 g (73% pure yield, 4.26 mmol) TLC (50% Et20 / 50% hexane) Rf = 0.35, IR 
(cm"1) 1716, 2102. 'H-NMR (300 MHz, CDCI3) 1.26 ( 3H, t, J= 7 Hz), 1.28 (3H, s), 3.05 
(1H, d,J= 14 Hz), 3.25 (1H, d, J= 14 Hz), 4.18 (2H, q, J= 7 Hz), 5.03 (2H, s), 5.42 
(1H, s), 6.87 (2H, d, J = 9 Hz), 7.04 (2H, d, J= 9 Hz), 7.38 (5H, m), l3C-NMR (75 MHz, 
CDCI3) 14.2, 19.5,40.7,54.2,59.0,61.7,70.1, 114.6, 127.6, 128.1, 128.6, 128.7, 131.4, 
131.7, 157.9, 172.7, 193.1 
(±)-3-(4-(benzvloxv)benzvl)-4-ethoxv-3-methvl-4-oxobutanoic acid (3.33b: An 
amount of 1.56 g (4.26 mmol) of 3.32b was placed in a 25 mL roundbottomed flask and 
dissolved in 13 mL of 23% H2O / 77%o THF. Nitrogen was bubbled through the solution 
for 15 minutes to deoxygenate the solution. The solution was then irradiated with a 500W 
Hanovia lamp at a distance of approximately 10 cm. The photo-induced Wolff was 
monitored by the disappearance of the diazo stretch at 2102 cm"1 by IR. The reaction was 
complete after 48 hours and the solution was then diluted with 30 mL of Et20 and 
extracted 3 times with 1.0 M NaOH, acidified to pH ~ 1.0 with 1.21 M HC1, and 
extracted three times with Et20. These Et20 washes were combined, dried over MgS04, 
filtered, concentrated by rotary evaporation, and placed under reduced pressure to give 
0.95 g (2.67 mmol, 63 % yield) of a clear viscous oil. TLC (50% Et20 / 50% hexane) Rf 
= 0.22. IR (cm-1) 1716.0 cm"1. 'H-NMR (300 MHz, CDC13) 1.20 (3H, t, J= 7 Hz), 1.25 
(3H, s), 2.42 (1H, d, ./= 17), 2.79 (1H, d, J = 17 Hz), 2.88 (2H, s), 4.12 (2H, q, J= 1 
Hz), 5.03 (2H, s), 6.88 (2H, d, J = 9 Hz), 7.02 (2H, d, J = 9 Hz) 7.38 (5H, m). 13C-NMR 
(75 MHz, CDCb) 14.2, 22.1, 41.6, 43.9, 45.2, 61.0, 70.1, 127.7, 128.1, 128.7, 128.9, 
131.5, 137.1, 157.9, 176.0, 177.8. HRMS: [C2iH2405Na]+calcd = 379.1516 , obsd = 
379.1507. 
(±)-ethvl 2-(4-(benzvoxv)benzvl)-3-((4-methoxvbenzvoxvl)carbonvlamino)-2-
methvlpropanoate (3.34b): An amount of 0.153 g (0.31 mmol) of 3.33b was dissolved 
in 10 mL of 1,2-dichlroethane. Then, 100 uL (0.47 mmol) of DPPA and 253 uL of Et3N 
(1.70 mmol) was added and the solution was heated to reflux solvent for 3 hours, at 
which time 80 uL (0.64 mmol) of PMB-OH was added and the solution was brought to 
reflux solvent. The solution was diluted with 30 mL of CHCI3 and washed three times 
with 10 % HC1. TLC showed a baseline impurity that was removed by filtration through 
silica gel. The material was then dried over MgSCU, filtered, and concentrated by rotary 
evaporation to give a orange, transparent, viscous oil that was purified by flash 
chromatography (200 mL of silica gel, 10% /PrOH / 90% hexane) to give 0.094 g (0.19 
mmol, 45% yield) of a clear, viscous oil. TLC Rf = 0.31, IR (cm"1) 1706. 'H-NMR (300 
MHz, CDCI3) 1.16 (3H, s), 1.22 (3H, t, J = 7 Hz), 2.82 (2H, s), 3.33 (2H, m), 3.80 (3H,s), 
4.11 (2H, q, J =7 Hz), 5.02 (4H, s), 5.12 (1H, bt, J = 7 Hz), 6.87 (4H, m), (2H, d, J = 9 
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Hz) 7.34 (7H, m). 13C-NMR (75 Hz, CDC13) 14.4, 20.6, 42.5, 47.4, 55.5, 61.0, 66.8, 70.2, 
114.1,114.7,127.7,128.7, 130.2, 137.2, 156.9,157.9,159.8, 176.2. HRMS: 
[C29H33N05Na]+ calcd = 514.2200, obsd = 514.2188. 
(±)-tert-butyl 2-(4-(benzvloxv)benzvl)-4-diazo-2-methvl-3-oxobutanoate (3.35b) An 
amount of 2.12 g (3.34 mmol) of 2.38b and 1.81 mL of Et3N (12.0 mmol) was dissolved 
in 30 mL of anhydrous THF under a blanket of N2 at 0 °C. Then, 606 uL (8.58 mmol,) of 
MC was added slowly to the solution via syringe. The solution was allowed to stir at 0 °C 
for 3 hours. An ethereal solution of anhydrous diazomethane (21 mmol) was added drop-
wise to the mixed anhydride solution via a syringe and allowed to react without stirring 
overnight at 0 °C. The excess diazomethane was then removed by bubbling dry N2 into 
the solution for 15 minutes and washed 3 times with 10% HC1, dried over MgS04, 
filtered, concentrated by rotary evaporation, and purified by flash chromatography using 
50% Et20 / hexane and 200 mL of silica gel to give 1.07 g (2.71 mmol, 47% yield) of an 
orange, transparent, viscous oil. TLC (50 % Et20 / 50%) hexane) Rf = 0.39. IR (cm"1) 
2104, 1703. 'H-NMR (300 MHz, CDCI3) 1.24 (3H,s), 1.45 (9H, s), 3.02 (1H, d, J= 14 
Hz), 3.19 (1H, d, J= 14 Hz), 5.03 (2H, s), 5.41 (1H, s), 6.87 (2H, d, J= 9 Hz), 7.08 (2H, 
d, J= 9 Hz) 7.33 (5H, m), l3C-NMR (75 MHz, CDC13) 19.7, 28.0, 40.5, 53.9, 59.6, 70.1, 
82.2, 127.7, 128.1, 128.8, 129.0, 131.6, 137.2, 157.9, 171.8, 193.6 
(±)-3-(4-(Benzvloxv)benzyl)-4-fe^-butoxv-3-methyi-4-oxobutanoic acid (3.36b) An 
amount of 0.60 g (1.54 mmol) of 3.36b was dissolved in 13 mL of 23% H20 / 77% THF. 
Anhydrous N2 was passed through the solution for 15 minutes to deoxygenate the 
solution. The solution was then irradiated with a 500 W Hanovia lamp at a distance of 
approximately 10 cm. The photo-induced Wolff was monitored by the disappearance of 
the diazo stretch at 2104 cm" by IR spectroscopy. The reaction was complete after 48 
hours. The solution was diluted with 20 mL of Et20 and extracted three times with 1.0 M 
NaOH. The basic aqueous layers were combined, acidified to pH ~ 2.0 with 10 % HC1, 
and extracted three times with CH2CI2. The CH2CI2 washes were combined, dried over 
MgSC>4, filtered, concentrated by rotary evaporation, and placed under reduced pressure 
to give 0.154 g (0.40 mmol, 26% yield) of a clear, viscous oil. IR (cm"1) 1707. 'H-NMR 
(300 MHz, CDCI3) 1.20 (3H, s), 1.41 (9H, s), 2.36 (1H, d, J= 17 Hz), 2.71 (1H, d, 7=17 
Hz), 2.86 (2H, s), 5.03 (2H, s), 6.88 (2H, d, J= 9 Hz), 7.05 (2H, d, J= 9 Hz) 7.38 (5H, 
m) 13C-NMR (75 MHz, CDCI3) 22.4,28.0,41.8,43.7,45.6,70.1,81.2, 114.6, 127.7, 
128.1, 128.8, 129.2, 131.7, 137.2, 157.8, 175.3, 178.1. HRMS: [C23H2g05Na]+calcd = 
407.1829, obsd= 407.1823. 
(±)-fert-Butyl 2-(4-(benzvloxvbenzvl)-3-((4-methoxvbenzvIoxv)carbonylamino)-2-
methvlpropanoate (3.37b): An amount of 0.15g (0.40 mmol) of 3.36b was dissolved in 
10 mL of 1,2-dichlroethane. Then, 94 uL (0.43 mmol) of DPP A and 796 uL of Et3N 
(1.20 mmol) was added and the solution was heated to reflux solvent for 3 hours, at 
which time 49 uL (0.40 mmol) of PMB-OH was added and the solution was heated to 
reflux solvent. The solution was cooled to room temperature and diluted with 15 mL of 
CH2CI2, washed three times with 10% HC1, and filtered through silica gel. The solution 
was concentrated by rotary evaporation to give a orange, transparent, viscous oil. This 
was purified by flash chromatography using 50 % Et20 / 50% hexane and 70 mL of silica 
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gel to give 0.128 g (0.25 mmol, 62 % yield) of a clear, viscous oil. TLC (50% Et20 / 50% 
hexane) Rf = 0.24, IR 3356, 1712. "H-NMR (300 MHz, CDC13) 1.12 (3H, s), 1.43 (9H, s), 
2.81 (2H, s), 3.31 (2H, m), 3.80 (3H, s), 5.40 (4H, m), 5.16 (1H, bt, J = 7 Hz), 6.89 (4H, 
m), 7.07 (2H, d, J= 9 Hz), 7.28 (5H, m) 13C-NMR (75 MHz, CDC13) 20.8, 28.2, 42.2, 
47.5,48.6,55.4,66.7,70.1,81.4, 114.1,114.6, 127.7, 128.1, 128.7, 129.2, 130.2, 131.4, 
137.2, 156.9, 157.8, 159.7, 175.4. HRMS: [C3iH37N06Na]+ calcd = 542.2513, obsd = 
542.2506. 
(±)-4-tert-but\l 1-ethyl 2-(4-(benzyloxv)benzvl)-2-methylsuccinate (3.38b): An 
amount of 0.95 g (2.67 mmol) of 3.33b was dissolved in 5 mL of anhydrous CH2CI2 and 
placed in a 20 mL pressure vessel at 0 °C. Then, 100 uL of H2SO4 and 2.00 mL of 
condensed isobutylene (IBE) were added, the vial was sealed and the reaction was 
allowed to stir overnight a room temperature. The flask was placed in an icebath at 0 °C 
for 15 minutes and then opened and allowed to stir at room temp for 15 minutes. The 
solution was diluted with 40 mL of Et20 and washed three times with 1.0 M NaOH, dried 
over MgS04, filtered, and concentrated by rotary evaporation to give a clear, orange, 
viscous oil. 0.91 g (2.21 mmol, 83% yield). TLC (50 % Et20/Hexane) Rf = 0.53, IR (cm" 
') 1724 ' H-NMR (300MHz, CDCI3) 1.20 (3H, s), 1.22 (3H, t, J= 7 Hz), 1.43 (9H, s), 
2.31 (1H, d, J= 16 Hz), 2.67 (1H, d,J = 16 Hz), 2.80 (1H, d, J= 13 Hz), 2.90 (1H, d, J = 
13 Hz), 4.12 (2H, m), 5.03 (2H, s), 6.88 (1H, d, J= 9 Hz), 7.02 (1H, d, J= 9 Hz), 7.39 
(5H, m) 13C-NMR(75MHz, CDCI3) 14.3, 21.9, 28.2, 43.4, 43.9, 45.4, 60.7, 70.1, 80.8, 
114.6, 127.7, 128.1, 128.8, 129.3, 131.6, 137.2, 157.8, 170.8, 176.1. HRMS: 
[C25H3205Na]+ calcd = 435.2141, Obsd = 435.2139. 
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(±)-2-(4-(benzvloxv)benzvl)-4-te^butoxv-2-methvl-4-oxobutanoic acid (3.39b): An 
amount of 0.35 g (0.85 mmol) of 3.38b was dissolved in 5 mL of EtOH and 582 uL 
(7.27 mmol) of a 12.5 M NaOH solution was added to the reaction flask. The reaction 
mixture was allowed to stir at room temperature for 72 hours. The solution was diluted 
with 10 mL 1.0 M NaOH, washed three times with Et20, acidified with cold 10% HCl 
and, extracted into Et20. The resulting solution was dried over MgS04, filtered, and 
concentrated by rotary evaporation to give 0.14 g (0.38 mmol, 44% yield) of a clear, 
viscous, liquid. TLC (50% Et20 / 50% hexane) Rf = 0.07, IR (cm"1) 1724, 1698. 'H-NMR 
(300 MHz, CDC13) 1.22 (3H, s,), 1.44 (9H, s), 2.33 (1H, d, J= 16 Hz), 2.66 (1H, d, J = 
16 Hz), 2.90 (2H, m), 5.02 (2H, s), 6.90 (2H, d, J= 9 Hz), 7.07 (2H, d, J= 9 Hz), 7.33 
(5H, m) l3C-NMR (75 MHz, CDCI3) 21.7, 28.2, 43.3, 43.5, 45.4, 70.2, 81.3, 114.7, 127.7, 
128.1, 128.8, 137.2, 157.9, 170.6, 183.0. HRMS: [C23H2805Na]+calcd = 407.1829, obsd 
= 407.1824. 
(±)-fg^-Butvl4-(4-(benzvloxv)phenvl)-3-((4-methoxvbenzvloxv)carbonylamino)-3-
methylbutanoate (3.40b): In a 25 mL roundbottomed flask 0.143 g (0.37 mmol) of 
3.39b was dissolved in 10 mL of 1,2-dichlroethane. Then, 88 uL (0.41 mmol) of DPP A 
and 168 uL of Et3N (1.16 mmol) was added and the solution was allowed to stir for 30 
minutes and brought to reflux solvent for 2 hours, at which time 69 uL (0.56 mmol) of 
PMB-OH was added and the solution was again heated to reflux solvent for 72 hours. 
The solution was cooled and diluted with 20 mL of CHCI3 and washed two times with 
10% HCl, filtered throught silica gel, and concentrated by rotary evaporation to give a 
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transparent, viscous oil. This was purified by preperative TLC using 50% Et20 / 50% 
hexane) to give 0.05 g (0.10 mmol, 26% yield) of a clear viscous oil. TLC Rf = 0.38, IR 
3389, 1717. 'H-NMR (300 MHz, CDC13) 1.33 (3H, s), 1.44 (9H, s), 2.38 (1H, d,J= 14 
Hz), 2.64 (1H, d,J= 14 Hz), 3.02 (2H, s), 3.81 (3H, s), 5.02 (2H, s), 5.04 (2H, s), 5.17 
(1H, bs), 6.83 (2H, d, J= 9 Hz), 6.90 (2H, d, J= 9 Hz), 7.37 (7H, m) 13C-NMR (75 MHz, 
CDCI3) 24.6, 28.3, 43.3, 44.2, 54.8, 55.5, 66.1, 70.1, 81.2, 114.0, 114.5, 127.7, 128.8, 
130.2, 137.3, 157.8, 159.7, 170.9. HRMS: [C3|H37N06Na]+ calcd = 542.2513 Obsd = 
542.2511. 
(±)-l-ferf-butvI-4-methvl-2-(4-(benzvloxv)benzvl)-2-methyIsuccinate (3.41b): An 
amount of 1.07 g (2.71 mmol) of 3.35b was dissolved in 10 mL of HPLC MeOH in a 25 
mL round-bottomed flask. The solution was degassed for 15 minutes with dry N2. The 
solution was irradiated with a 500W Hanovia lamp. The photo-induced Wolff was 
monitored by the disappearance of the diazo stretch (2104 cm"1). The reaction was 
complete after 48 hours and the crude reaction mixture was concentrated by rotary 
evaporation, and placed under high vacuum for 3 hours to give a clear viscous oil that 
was purified by flash chromatography using 50% Et20 / 50% hexane and 200 mL of 
silica gel. TLC (50% Et20 / 50% hexane, Rf = 0.44) to give 0.66 g (1.63 mmol, 61% 
yield) of a clear, viscous oil. IR (cm"1) 1720. 'H-NMR (300 MHz, CDC13) 1.18 (3H, s), 
1.42 (9H, s), 2.34 (1H, d, J= 16 Hz), 2.67 (1H, d, J= 16 Hz), 3.65 ( 2H, s), 5.03 (2H, s), 
6.88 (2H, d, J= 9 Hz), 7.05 (2H, d, J= 9 Hz) 7.38 (5H, m). 13C-NMR (75 MHz, CDCI3) 
20.1, 33.3, 41.8, 43.8, 45.7, 51.6, 70.1, 80.8, 114.5, 127.7, 128.1, 128.8, 129.4, 131.7, 
137.2, 157.8,172.2, 175.1. HRMS: [C24H3o05Na]+calcd = 421.1985 , obsd = 421.1984 
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(±)-2-(4-(benzvloxv)benzvl)-4-methoxv-2-methyl-4-oxobutanoic acid (3.42b): In a 25 
mL roundbottomed flask 0.66 g (1.66 mmol) of 3.41b was dissolved in 10 mL of dry 
CH3CN and 1 mL of water was added followed by addition of 1.0 g of KSF 
Montmorillonite Clay. The resulting solution was heated to reflux solvent. The reaction 
was monitored by TLC (50% Et20 / 50% hexane) and was determined to be complete 
after 4 days. The KSF clay was removed by vacuum filtration, and the filtrate was 
washed with CH3CN. The CH3CN was concentrated by rotary evaporation to give a clear 
viscous oil that was purified by flash chromatography (5% MeOH / 95% CHCI3, Rf = 
0.55) to give 0.34 g (0.98 mmol, 59 % yield) a white amorphous solid. Mp = 99 - 103 °C 
IR (cm"1) 2935, 1735, 1697. 'H-NMR (300 MHz, CDC13) 1.26 (3H, s), 2.43 (1H, d, J = 
16 Hz), 2.74 (1H, d, J= 16 Hz), 3.68 (3H, s), 5.03 (2H, s), 6.90 (2H, d, J = 9 Hz), 7.07 
(2H, d, J = 9 Hz), 7.38 (5H, m), 13C-NMR (75 MHz, CDC13) 21.9, 41.4, 43.6, 45.3, 51.9, 
70.2, 114.7, 127.7, 128.2, 128.7, 128.8, 131.6, 137.2, 138.0, 172.0, 181.5, HRMS: 
[C2oH2205Na]+ calcd = 365.1359, obsd = 365.1360. 
(±)-methvl-4-(4-(benzvioxv)phenvl)-3-((4-methoxvbenzvoxv)carbonylamino)-3-
methvlbutanoate (3.43b): In a 50 mL roundbottomed flask 0.34 g (0.99 mmol) of 3.42 
was dissolved in 20 mL of 1,2-dichlroethane. Then, 245 uL (1.14 mmol) of DPPA and 
467 uL of Et3N (3.11 mmol) was added and the solution was allowed to stir for 30 
minutes, then brought to reflux solvent for 2 hours, at which time 193 uL (1.55 mmol) of 
PMB-OH was added and the solution was again heated to reflux solvent for 72 hours. 
The solution was cooled and diluted with 20 mL of CHCI3 and washed two times with 
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10% HC1, filtered through silica gel, and concentrated by rotary evaporation to give a 
transparent, viscous oil. This was purified by flash chromatography using 30% EtOAc / 
70% hexane) to give 0.21 g (0.44 mmol, 44% yield) of a clear viscous oil. TLC Rf = 0.29, 
IR (cm"1) 3459, 3378, 1723, 1711. 'H-NMR (300 MHz, CDC13) 1.33 (3H, s), 2.56 (1H, d, 
J= 14 Hz), 2.86 (1H, d, J= 14 Hz), 2.98 (1H, d, J= 14 Hz), 3.10 (1H, d, J= 14 Hz), 3.65 
(3H, s), 3.81 (3H, s), 5.03 (2H, s), 5.06 (2H, s), 6.85 (2H, d, J= 9 Hz), 6.92 (2H, d, J= 9 
Hz),7.00 (2H, d, J= 9 Hz), 7.30 (7H, m) (75 MHz, CDC13) 24.7, 42.6, 43.2, 51.7, 54.6, 
55.4, 66.1, 70.0, 114.0, 114.5, 127.6, 128.1, 128.7, 129.0, 129.1, 130.2, 131.8, 137.2, 
155.1, 157.7, 159.6, 172.8. HRMS: [C28H3iN06Na]+ calcd = 500.2044, obsd = 500.2041. 
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CHAPTER IV 
y2'2- and y4'4- AMINO ACIDS 
Literature Review 
Introduction 
The y-amino acid class of unnatural amino acids has received a large amount of 
interest from scientists in the academic and industrial communities. This class of 
unnatural amino acids is similar to (3-amino acids in that they have increased 
conformation ability and have been shown to add secondary structure to peptides with as 
few as four residues.1 This is due to the presence of two additional methylene carbons 
between the amine and carboxylic acid substituents of the y-amino acids. Part C of 
Hypothesis 1 states that a series of homochirally similar y-amino acids may be 
o r 2 
H 0 A r ^ , N H 2 
R 4.1 
2"> 0 Y ' 
HO X ^ ^ 2 K R 4_4 
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0 R' 
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3 4 4.6 
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HO^-V^ 2 
R' 4.9 
synthesized 
from a 
common 
intermediate. 
There are too 
many different 
classes of y-
amino acids to 
be covered in 
Figure 4.1. Different classes of mono and di-substituted y-amino acids 
this 
dissertation (Figure 4.1). For this reason, this chapter will focus on the synthesis of the 
y2'2- (4.4) and y4'4- (4.6)class of unnatural amino acids, in a straight-forward manner. 
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Like the a-methyl (Chapter 2), p2'2-, and p3'3- (Chapter 3), It is proposed here in that both 
enantiomers of y2,2- and y4'4- amino acids can be synthesized from a common malonate 
half ester intermediate by means of straight-forward chemical transformations. As 
outlined in the previous chapters, we intend to incorporate these y-amino acids into 
peptidomimetic neurotensin analogues for the purpose of testing the biological properties 
of such peptidomimetic compounds. 
Properties ofy-Amino Acids and y-Peptides 
Several pharmaceutical compounds that are currently marketed contain y-amino 
acids. To date, the a-
hydroxy and p-hydroxy 
y-amino acids are the 
most synthesized class 
of y-amino acids due to 
their pharmacological 
activity.3"6 One 
example is a statine-
based peptidomimetic 
inhibitor of Human p-
secretase (4.10), which 
has an IC50 = 0.3 uM. 
4.10 
OH O 
O I O 
I H J : H 
OH 
4.11 (IC9564) 
OH O 
4.12 (GABA) 
H,N OH 
4.13 (Gabapentin) 
NH2 C02H 
o 
4.14 Lyrica 
H.NyY0 
Figure 4.2. y-Amino acids pharmaceuticals 
This compound contains a 3-hydroxy y4-Leu at its core.5 Another example is a 
compound believed to function as an HIV fusion inhibitor known as IC9564 (4.11), 
which also contains a 3-hydroxy y4-Leu, but at its C-terminus. Interest in y-amino acids 
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is not limited to compounds that contain a y-amino acid residue. There has been a great 
deal of interest in the synthesis of analogues of y-amino butyric acid (GABA, 4.12) 
analogues. GABA is an achiral y-amino acid that functions in the central nervous 
system.3 One GABA analog, Gabapentin (a y3,3-amino acid, 4.13), is currently used as an 
anticonvulsant. Another GABA analogue is marketed under the Lyrica® trade name. 
Lyrica is a y3-amino acid (4.14) that has found use as a treatment for neuropathic pain.7 
This is an encouraging example of the development of a pharmaceutical compound that 
was developed in an academic laboratory and then marketed by a major pharmaceutical 
company. 
Peptides containing or composed of y-amino acids have been investigated for 
their ability to form stable secondary structures. Hanessian et al. performed solution 
4#j5 NMR studies of y-tetra-, hexa-, and 
octapeptides as well as variants of 
Bocl V T N v Y fBz 
^
 2 theses peptides containing ex-
Figure 4.3. y-Amino acid tetramer capable of . . ^ , . . . / „,
 c . 
forming ana-helix methylated y-amino acids. They found 
that y-peptides with as few as four residues can form stable helical structures. They also 
found that substitution of (5)-a-methyl y-amino acids into the y-peptides had no 
detrimental effect on the helical structures, but (7?)-a-methyl y-amino acid containing 
peptides did not exhibit helical structures. These characteristics may allow for the control 
of the secondary structure of peptides that contain a-mefhyl y-amino acids by 
manipulation of the stereochemistry of the y-amino acids. To further explore the ability of 
the y-amino acids to form secondary structure, Hinterman et al. performed solution NMR 
studies of a y-hexapeptide, and compared their findings to data for similar a- and 0-
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peptides containing analogous residues (Figure 4.4). They found that the y-hexapeptide 
formed a right-handed helical structure with a 5-A pitch and 14-membered hydrogen 
bonded ring (Figure 4.5). The P-peptide gave a left-handed helical secondary structure 
with 5-A pitch and 14-membered hydrogen bonded ring (Figure 4.5). The a-peptide has 
the typical right-handed helix (a-helix) with a 5-A pitch and 14-membered hydrogen 
bonded ring (Figure 4.5). Interestingly, it was found that the stability of the helix 
increased with the homolongation of the amino acids. 
4.16 
4.17 
H,N-
C02H 
-H 
R 
C02H 
CH, 
H,N" 
R 
4.18 C02H 
CH, 
CH, 
H,N- -H 
R 
H XXXJ 
Figure 4.4 Analogous a-,P-, and y-Peptides 
studied by Hinterman, et al. 
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Figure 4.5. Secondary structure representations for analogous a-, p \ and y- peptides. 
Reproduced with permission John Wiley and Sons Inc. 
Seebach et al. also synthesized and evaluated the biological stability of y-peptides 
(Figure 4.6, 4.19) 
by the subjecting 
the y-peptides to 
mixtures of 
o • H o ^K^ H o K^ 
4.19 Y2-DeDtide 
Figure 4.6. y -Peptide synthesized and investigated for stability 
by Seebach et al.9 
peptidases that 
quickly degrade 
natural peptides. The y-peptides were shown to be intact for 48 hours under enzymatic 
conditions that would degrade the natural (a-peptides) completely within one hour. This 
stability led to the synthesis and evaluation of cyclic somatostatin analogues that were 
composed of 2 y-amino acids.10 These analogues were capable of binding to the 
somatostatin receptor by mimicking the P-turn structure of somatostatin. These 
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experiments demonstrated that peptidomimetic compounds containing y-amino acids 
were capable of mimicking the conformations of natural peptides which allow the 
peptidomimetics to bind to natural receptors. This is a significant find due to the 
pharmacological properties of somatostatin analogues (see Chapter I). " The stability of 
y-peptides combined with the ability to bind to natural receptors, make theses compounds 
promising peptidomimetic compounds. 
Synthesis ofy-Amino Acids 
There are fewer synthetic methodologies in the literature for y-amino acids than 
for a-methyl and (3-amino acids. These methods include but are not limited to 
chemoenzymatic routes, ' 5' transition metal catalytic routes, 7'' and multiple synthetic 
"2 1 Q 
routes that make use of compounds from the chiral pool to generate y-amino acids. ' 
One method that has influenced the work of our group involves homolongation of N-Boc 
protected a-amino acids using double Ardnt-Eistert syntheses and Wolff rearrangements 
to produce a y-amino acid (Scheme 4.1 A). While this homolongation method worked 
well for the synthesis of P-amino acids (Chapter III),21 use of a second Ardnt-Eistert / 
Wolff rearrangement resulted in low yields of the y-amino acids (25%). This was 
primarily due to the formation of a cyclic imino anhydride which is less reactive toward 
nucleophiles than the mixed anhydride. As a more productive alternative, the same group 
was able to get reasonable yield through the conversion of Boc-protected a-amino acids 
into Weinreb amides. The Weinreb amides were reduced to a-amino aldehydes and 
converted into a,(3-unsaturated y-amino methyl esters via a Witting type reaction, which 
results in an a,(3-unsaturated diester (4.26). The olefin functionality was reduced with 
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Pd/C and the methyl ester was saponified, which yielded the N-Boc y-amino acid in good 
yields (Scheme 4.1, 55-72% yield) 20 
^ X 
4.25 
4.20 
1. Et3N 
0 f ^ - 2. CIC02Et x 
O N , N CO,H 3CH2N2 H 
4.21 
O 
. A . . 
O N COCHN, 
H 
CF3C02Ag/Et3N 
H,0 
4.24 
A) Double Ardnt-Eistert / Wolff Synthesis of y-Phenylalanine 
4.26 
j 1)DCC, HOBt, Et3N 
a
 L _ MeONHMe . HCI 
O f 2) LiAIH4 
>^ A JL,o 
° M Y OH " H " 3) (PhO)2P(0)CH2C02Me, 
° NaH 
4.27 
O ft f D H2, Pd/C - J tf 
0 N C=CHC02Me ' ^ 0 N 
H H 2)NaOH H 
B). Witting reaction to synthesize N-Boc y-leucine 
Scheme 4.1. Two syntheses of y-amino acids from a-amino acids 
Another popular route to the synthesis of y-amino acids by elongation of a N-Boc 
a-amino acids was developed by Smrcina et al. (Scheme 4.2). This method uses an a-
amino acyl Meldrum's acid derivative (4.29), which can be heated to accomplish the 
decarboxylative ring closure to the N-Boc lactam (4.31). The lactam can then be 
hydrolyzed to give the N-Boc y-amino acid (4.32). By altering the sequence of reduction 
and decarboxylative ring closure, a 3-hydroxy N-Boc y-amino acid can be synthesized 
(4.35). The biological activity, stability to proteolytic degradation, and unique structural 
characteristics stability of y-peptides denote the need for efficient syntheses of y-amino 
acids. 
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Scheme 4.2 . Homolongation of an a-amino acid to a 
y-amino acid using Meldrum's acid 
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It is clear from the literature review above that there are many different methods 
currently used to synthesize y-amino acids. However there are no methods currently 
available to synthesize the y2'2- and y4'4- class of unnatural amino acids. It is the intention 
of this work to contribute 
O O to the current synthetic 
HO 
r 
2,2 H,N 
4.36 
»
,%
 R methodology by providing 
4.37 
an efficient method to 
synthesis both 
enantiomers of y ' - and 
y ' -tyrosine analogues. 
The same common 
malonate half-ester 
intermediate that was used 
Scheme 4.3 . Generation of both enantiomers of y2'2-and in the Chapters 2 and 3 
y^-amino acids from a common malonate half ester 
intermediate was used to synthesize the 
desired y-amino acids. It is demonstrated that the use of the Wittig reaction to 
homologate the malonate half esters (2.32b and 2.38b) yields intermediates that can be 
converted into both enantiomers of the desired amino acids. The synthetic 
methodology developed in this chapter will eventually be used to synthesize amino acid 
analogues that will be incorporated into neurotensin analogues. 
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Results and Discussion 
Like the previous chapters, our synthetic plan was to synthesize both enantiomers 
of the y2'2- and y4,4-amino acids using the same common intermediate (2.32b) that was 
used to synthesize both enantiomers of the a-methyl, p ' -, and (3 ' -amino acids 
(Chapters II and III). The y-amino acids discussed in this section will be synthesized 
using familiar chemistry that was also used for the synthesis of the a-methyl, p2'2-, and 
p ' -amino acids (protecting group chemistry and the Curtius rearrangement). It is 
important to note that the compounds in this chapter are synthesized using racemic half-
esters. As explained in Chapter III, the use of+/-2.32b is due to the difficulty in obtaining 
large enough quantities of 2.32b for parallel synthesis. For the purpose of clearly 
illustrating my synthetic strategy, the major enantiomer of 2.32b obtained from the PLE 
hydrolysis has been used to demonstrate the products that should be obtained in the 
following synthesis. The synthesis of the y-tyrosine series was accomplished by 
conversion of 2.32b was to a mixed anhydride by treatment with methyl chloroformate 
4.40 4.41 4.42 
o ^ Q K?> Q 
O j • Br^0R — - f>X>oR — - fy,^ 
\ = / 1 ° Et20 \ = / 1 Br \ = / 
a R = tBu 
b R = Me 
Scheme 4.4 . Synthesis of the needed Wittig reagents 
(MC). This 
mixed anhydride was reduced to 4.43 using NaBFL; with slow addition of methanol. 
The alcohol ester (4.43) was oxidized to 4.44 (66% yield) using a standard PCC 
oxidation. The pyridinium chlorochromate (PCC) was removed by filtration through 
silica and 4.44b was used without further purification due to the instability of the 
aldehyde.8'24 To facilitate the Wittig reaction, 4.40A (synthesized in house, Scheme 4.4) 
was added to 4.44 and allowed to reflux for 5 days to give 78% yield.23'23'26 The reaction 
was fairly slow and sterics are thought to be the largest factor in the slow rate of the 
reaction. The resulting ot,p-unsaturated diester (4.45) was reduced using palladium that 
was absorbed onto amorphous carbon, under a hydrogen atmosphere to give 4.46 in 94% 
yield. The free phenol functional group of 4.46 was converted to a methyl-phenyl ether 
by treatment with methyliodide to give 4.47 (85% yield). To synthesize the (R)- y2'2-
tyrosine, 4.47 was treated with KSF montmorillonite clay in refluxing acetonitrile to give 
4.48 in 45% yield.27 A subsequent Curtius rearrangement generated an isocyanate that 
was quenched with PMB-OH to give 4.49 (80% yield). In an attempt to synthesize the 
(5)-y4'4-tyrosine, 4.32 was treated with NaOH to saponify the ethyl ester. Unfortunately, 
the product of the saponification was 4.48 instead of 4.50. The tert-buty\ ester seems to 
be of sufficient distance from the neopentyl backbone of 4.47 to allow the tert-butyl ester 
to be saponified at a faster rate than the ethyl ester. This was confirmed by repetition of 
the experiment which resulted in the same outcome. Another route will have to be 
developed to obtain the (5)-y4'4-tyrosine (4.51). This alternate route is discussed in 
Chapter VI of this dissertation. 
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Scheme 4.5 . Generation of one enantiomer of y2'2 -tyrosine (4.49) and the attempted synthesis 
of one enantiomer of y4'4-tyrosine (4.51) from a common malonate half ester intermediate. 
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The (5)-y2,2-tyrosine and (i?)-y4'4-tyrosine were synthesized in a similar 
methodology to the synthesis in the previous paragraph. To synthesize the necessary ester 
alcohol we first attempted a 
4.52 o 2.32b o 0 
\(R) BH3«DMS 
THF 
OBn OBn 
Scheme 4.6. Reduction of half ester 2.32b to an 
acid alchohol 4.52 was successful, but as a 
mixture of 5 products 
borane reduction of the ester 
OH functionality of 2.32b (Scheme 
4.6).24 The free ester can then 
be esterified with methyl 
iodide to give the needed ester-
alcohol. Although our group 
has successfully reduced half-ester via this method before, a mixture of five products was 
obtained from this reaction with 2.32b. Rather than pursue a method that required a 
tedious purification, another route to the needed ester alcohol was taken. Compound 
2.38b was reduced to 4.53 in 66% yield by conversion to a mixed anhydride with 
subsequent reduction using NaBH4. Compound 4.53 was oxidized to the ester-aldehyde 
(4.54) by mean of a PCC oxidation. Treatment with Wittig reagent (4.42b) yielded 4.55 
(84% yield). Compound 4.55 was reduced to 4.56. Saponification of 4.60 with NaOH 
produces 4.60 (91% yield). When 4.60 is subjected to a Curtius rearrangement, the result 
is 4.61 (61% yield). When the ter^-butyl ester is hydrolyzed with KSF clay, the result is 
4.58. This compound is converted to 4.62 in by means of a Curtius rearrangement that 
was quenched with PMB-OH. 
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Scheme 4.7 . Generation of the other enantiomer of y2'2 -tyrosine (4.61) and one enantiomer 
of y4'4-tyrosine (4.59) from a common malonate half ester intermediate. 
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Conclusions 
The biological activity and proteolytic stability of y-amino acids and of 
compounds composed of or containing y-amino acids makes this class of amino acids 
interesting pharmacores. The desire to study the properties of y-amino acids has led to the 
development of several unique syntheses. However, each class of y-amino acid requires a 
different synthetic strategy. The synthesis detailed in this chapter clearly demonstrates 
that a combination of the Wittig reaction, the Curtius rearrangement, and protecting 
group chemistry can be used to synthesize the y ' - and y4'4-tyrosine analogues from a 
common synthetic intermediate in good yields. Although the amino acids synthesized in 
this chapter were synthesized racemically, one can clearly see that the methodology can 
be applied to the synthesis of enantiomerically enriched y-amino acids. Furthermore, the 
Wittig reaction is known to proceed without scrambling of the stereochemistry of a-
amino aldehydes and we hypothesize that the same result will be seen when applied to 
our substrates.20 The conclusion for this chapter illustrates the synthetic potential of the 
malonate half-esters. In previous chapters (Chapters 2 and 3), it has been shown that the 
malonate half-ester intermediate (2.32b) can be transformed to both enantiomers of a-
methyl, (32'2-,(33'3-tyrosine analogues using a common intermediate. In this chapter, It has 
•y -y 
been demonstrated that the same intermediate (2.32b) and both enantiomers of the y ' -
and one enantiomer of the y ' -tyrosine analogues using known protecting group 
chemistry and functional group transformations (Ardnt-Estert, Wolff Reaction, and 
Wittig Reaction). The future directions section of this dissertation (Chapter 6) will 
discuss a potential method that may the used to synthesize the (5)-y4'4-tyrosine analogue. 
I l l 
It is our hope that peptidomimetic compounds containing these unnatural amino acids can 
be synthesized and will display unique biological properties. 
Experimental 
See Chapter II (pgs 43 to 44) for general experimental. The Wittig salts were 
prepared in house via a literature procedure using triphenyl phosphine and the appropriate 
a-bromoester.26 Treatment of the Wittig salt with aqueous NaOH yielded the desired 
Wittig reagents. Chiral HPLC separation of the y-amino acids was not successful with the 
available OJ-H or AD-H chiral columns. 
(±)-Ethvl 2-(4-(benzvloxv)benzvl)-3-hvdroxv-2-methvlpropanoate (4.43): An amount 
of 5.53 g (16.2 mmol) of 2.32b was dissolved in 100 mL of anhydrous THF and 1.30 mL 
(17.01 mmol) of methyl chloroformate was added at 0 °C. The reaction stirred for 60 
minutes followed by addition of 1.84 mL (24.30 mmol) of Et3N and stirring for an 
additional 40 minutes. Then, 1.84 g of NaBfL; was added and the solution was allowed to 
stir for an additional 20 minutes at 0 °C. Addition of 10 mL of MeOH took place over 30 
minutes and the reaction was allowed to slowly warm to room temperature overnight. 
Cold 10% HC1 was added at 0 °C to quench the excess NaBLL;. The reaction was diluted 
with 100 mL of Et20, washed three times with 10% HC1, dried over MgSC«4, filtered, and 
concentrated by rotary evaporation to give a clear, viscous liquid that was purified by 
flash chromatography with 50% EtiO / 50% hexane and 400 mL of silica gel to give 3.50 
g (10.7 mmol, 66% yield) of a clear, viscous liquid. TLC (50% Et20 / 50% hexane) Rf = 
0.18, IR (cm-1) 3885, 1716. 'H-NMR (300 MHz, CDC13) 1.10 (3H, s), 1.24 (3H, t, J= 1 
Hz), 2.50 (1H, bs), 2.82 (1H, d, J= 14 Hz), 2.91 (1H, d, J= 14 Hz), 3.52 (1H, d, J= 11 
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Hz), 3.57 (1H, d, J= 11 Hz), 4.15 (2H, q, J= 7 Hz), 5.03 (2H, s), 6.88 (2H, d, J= 9 Hz), 
7.08 (2H, d,J= 9 Hz), 7.38 (5H, m). (75 MHz, CDC13) 14.3, 19.5, 41.3, 48.8, 61.0, 
70.13, 114.58, 127.7, 128.1, 128.8, 129.1, 131.5, 157.7, 177.1. HRMS: [ C ^ ^ N a f 
calcd = 351.1567, obsd = 351.1562. 
(±)-l-tert-But\l 5-ethyl 4-(4-benzvloxv)benzvD-4-methylpent-2-enedioate (4.45): An 
amount of 3.37 g (10.2 mmol) of 4.33 and 2.65 g (12.31 mmol) of PCC were dissolved in 
50 mL of dry CH2CI2 at room temperature. Conversion of the alcohol functionality to an 
aldehyde was complete after 48 hours by TLC. The reaction was filtered through a silica 
plug. Then, 4.63 g (12.31 mmol) of tert-buty\ triphenyl phosphonate was added to the 
resulting solution. The solution was heated to reflux solvent for 72 hours, then filtered 
through a silica plug and purified by flash chromatography to give 3.39 g (7.99 mmol, 
78% yield) of a clear, viscous oil. TLC (15% Et20 / 85% hexane) Rf = 0.15, IR (cm'1) 
1710. 'H-NMR (300 MHz, CDCI3) 1.23 (3H, t, J= 7 Hz), 1.26 (3H,s,), 1.49 (9H, s), 2.83 
(1H, d, J= 13 Hz), 3.05 (1H, d,J= 13 Hz), 4.14 (2H, m), 5.02 (2H, s), 5.72 (1H, d, J = 
16 Hz), 6.86 (2H, d, J= 9 Hz), 7.01 (2H, d, J= 9 Hz), 7.08 (1H, d, J= 16 Hz), 7.38 (5H, 
m) l3C-NMR (75 MHz, CDC13) 14.4, 20.4, 28.3, 44.6, 49.8, 61.4, 70.1, 80.7, 114.6, 
122.4, 127.7, 128.1, 128.7, 128.8, 131.5, 137.2, 149.7, 157.9, 165.9, 174.1.[C26H3205Na]+ 
calcd = 447.2142, obsd = 447.2138. 
(±)-5-fert-Butyl-l-ethvl 2-(4-hvdroxvbenzvI)-2-methvlpentanedioate (4.46): An 
amount of 3.39 g (7.99 mmol) of 4.46 was dissolved in 40 mL of distilled THF and 0.50 
g of Pd/C was added as a THF slurry. The solution was degassed with H2 and allowed to 
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stir over an H2 atmosphere. The reaction was monitored by TLC and was complete after 
48 hours. The Pd/C was removed by filtration through a Celite plug and the solvent was 
removed by rotary evaporation to give 2.52 g (7.49 mmol, 94% yield) a clear viscous 
liquid. Rf = 0.09 (50% Et20 / 50% hexane), IR (cm"1) 3406, 1724, 1698. 'H-NMR 
(300MHz, CDCI3) 1.08 (3H, s,), 1.25 (3H, t, J= 7 Hz), (9H, s),1.71 (1H, m), 2.06 (1H, 
m), 2.24 (2H,m), 2.67 ( l H , d , J = 13 Hz), 2.91 (1H, d,J= 13 Hz), 4.12 (2H,m), 6.08 
(1H, bd, J= 62 Hz), 6.66 (2H, d, J= 9 Hz), 6.94 (2H, d, J= 9 Hz). I3C-NMR (75MHz, 
CDCI3) 14.3,20.8,28.3,31.4,33.8,45.0,47.0,60.8,80.9, 115.1, 128.9, 131.4, 155.0, 
173.5, 176.8. HRMS: [dgHzgOsNaf calcd = 359.1829, obsd = 359.1827. 
(±)-5-tert-But\i 1-ethyl 2-(4-methoxvbenzvD-2-methvlpentanedioate (4.47): An 
amount of 2.52 g (7.49 mmol) of 4.46 was dissolved in 20 mL of anhydrous DMF 
followed by addition of 1.55 g (11.23 mmol) of anhydrous K2CO3 and dropwise addition 
of 701 uL (11.2 mmol) of CH3I. The reaction was allowed to stir for 48 hours, was 
diluted with Et20, washed with ddH20, dried over MgSC^, and concentrated by rotary 
evaporation to give 2.24 g (6.93 mmol, 85 % yield) of a clear viscous oil. Rf = 0.37 (1:1 
Et20 : hexane), IR (cm-1) 1723. 'H-NMR (300MHz, CDCI3) 1.07(3H, s,), 1.23 (3H, t, J 
= 7 Hz), 1.42 (9H, s), 1.71 (1H, m), 2.03 (1H, m), 2.31 (2H, m), 2.65 (1H, d, J= 13 Hz), 
2.75 (1H, d, J= 13 Hz), 3.76 (3H, s), 6.78 (2H, d, J= 9 Hz), 7.01 (2H, d, J= 9 Hz). 13C-
NMR (75MHz, CDCI3) 14.4, 20.8, 28.2, 31.3, 34.0, 44.8, 46.9, 55.3, 60.6, 80.4, 113.6, 
129.5, 131.3, 158.4, 172.9, 176.3. HRMS: [C2oH3o05Na]+ calcd = 373.1985, obsd = 
373.1984. 
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(±)-5-ethoxv-4-(4-methoxvbenzvr)-4-methvl-5-oxopentanoic acid (4.48): In a 25 mL 
roundbottomed flask 0.50 g (1.43 mmol) of 4.47 was dissolved in 15 mL of dry CH3CN 
and 1 mL of water was added followed by addition of 1.0 g of KSF Montmorillonite clay. 
The resulting solution was heated to reflux solvent and the reaction was determined to be 
complete after 4 days by TLC. The KSF clay was removed by vacuum filtration and the 
solution was concentrated by rotary evaporation to give a clear viscous oil that was 
purified by flash chromatography to give 0.24 g (0.65 mmol, 45% yield) a clear viscous 
liquid. TLC (5% MeOH / 95% CHC13, Rf = 0.58), IR (cm"1) 1706. 'H-NMR (300 MHz, 
CDC13) 1.09 (3H, s), 1.22 (3H, t, J= 7 Hz), 1.73 (1H, m), 2.09 (1H, m), 2.36 (2H, m), 
2.67 (1H, d,J= 14 Hz), 2.94 (1H, d,J= 14 Hz), 3.67 (3H, s) 4.11 (2H, q, J= 7 Hz), 6.79 
(2H, d, J= 9 Hz), 7.00 (2H, d, J= 9 Hz), 9.14 (1H, bs). 13C-NMR (75MHz, CDCI3) 14.3, 
20.8,30.0,33.5,44.7,46.8,55.3,60.8, 113.6,129.2, 131.2, 158.4, 176.2, 179.5. HRMS: 
[Cl6H2205Na]+ calcd = 317.1359, obsd = 317.1355. 
(±)-Ethvl 2-(4-methoxvbenzvD-4-((4-methoxvbenzvloxv)carbonvlamino)-2-
methvlbutanoate (4.49): An amount of 0.24 g (0.82 mmol) of 4.48 was dissolved in 
20.00 mL of CH2CI2 in a 50 mL RBF with a magnetic stirbar. 193 uL (0.90 mmol) of 
DPPA and 368 uL of Et3N (2.45 mmol) was added and the reaction was allowed to stir 
for 30 minutes. The solution was brought to reflux solvent for 3hours, at which time 152 
uL (1.22 mmol) of PMB-OH was added and the solution was heated to reflux solvent. 
The solution was concentrated by rotary evaporation and the resulting mixture was 
purified by flash chromatography (200 mL of silica gel) to give 0.28 g (0.65 mmol, 80% 
yield) of a clear, viscous oil. TLC (50% EtOAc / 50% hexane) Rf = 0.40. IR (cm"1) 3366, 
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1712. 'H-NMR (CDCb) 1.13 (3H, s), 1.21 (3H, t, J= 7.2 Hz), 1.58 (2H,s), 1.97 (2H, s), 
2.68 (1H, d, J= 13 Hz), 2.90 (1H, d, J= 13 Hz), 3.21 (2H, m), 3.77 (3H,s), 3.80 (3H, s), 
4.08 (2H, q, J =7.1 Hz), 4.75 (1H, bs), 5.01 (2H, s), 6.79 (2H, d, J = 9 Hz), 6.88 (2H, d, J 
= 9 Hz), 7.00 (2H, d, J = 9 Hz), 7.28 (2H, d, J = 9 Hz). 13C-NMR (75MHz, CDCI3) 14.4, 
21.0,37.6,38.7,45.2,46.1,55.4,60.8, 113.6, 114.0, 128.8, 129.2, 130.2, 131.3, 156.45, 
158.5, 159.7, 176.7. HRMS: [C24H3,N05Na]+ calcd = 452.2044, obsd = 452.2042. 
(±)-tert-Butyl 2-(4-(benzvloxv)benzvD-3-hvdroxv-2-methylpropanoate (4.53): An 
amount of 2.16 g (5.83 mmol) of 2.38b was dissolved in 20 mL of anhydrous THF and 
471 uL (6.12 mmol) of methyl chloroformate and 1.32 mL (8.75 mmol) of Et3N was 
added at 0 °C. The reaction stirred for 2 hours followed by addition of 0.61 g of NaBH4. 
The reaction was then allowed to stir for 41 hours at room temperature. However, the 
reaction had not proceeded. Then, 5 mL of EtOH was added over 1 hour. The reaction 
was complete after 24 hours by TLC. Cold 10% HC1 was added at 0 °C to quench the 
excess NaBH/t. The reaction was diluted with 30 mL of Et20, washed three times with 
10% HC1, dried over MgS04, filtered, and concentrated by rotary evaporation to give a 
clear, viscous liquid that was purified by flash chromatography with 50% Et20 / 50% 
hexane and 400 mL of silica gel to give 3.50 g (10.7 mmol, 66% yield) of a white 
amorphous solid. Mp = 71 - 74 °C. TLC (30% EtOAc / 70% hexane) Rf = 0.36, IR (cm"1) 
3459, 3378, 1723, 1711. *H-NMR (300 MHz, CDCI3) 1.05 (3H, s), 1.45 (3H, s), 2.60 
(1H, t, J= 7 Hz), 2.77 (1H, d, J= 14 Hz), 2.91 (1H, d, J= 14 Hz), 3.49 (2H, d, J= 7 Hz), 
5.03 (2H, s), 6.88 (2H, d, J= 9 Hz), 7.11 (2H, d, J= 9 Hz), 7.39 (5H, m). (75 MHz, 
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CDC13) 19.7,28.2,40.2,49.0,67.2,70.1,81.4, 114.5, 127.7, 128.1,131.7, 137.2, 157.7, 
176.7. HRMS: [ C ^ g C ^ N a f calcd = 379.1880, obsd = 379.1878. 
(±)-5-tert-Buty\ 1-methyl 4-(4-(benzvIoxv)benzvl)-4-methylpent-2-enedioate (4.55): 
An amount of 0.95 g (2.67 mmol) of 4.53 and 0.69 g (3.20 mmol) of PCC were dissolved 
in 25 mL of dry CH2CI2 at room temperature. Conversion of the alcohol functionality to 
an aldehyde was complete after 48 hours by TLC. The reaction was filtered through a 
silica plug and 0.89 g (3.20 mmol) of methyl triphenyl phosphonate was added to the 
resulting solution. The solution was heated to reflux solvent for 72 hours, then an 
additional 0.89 g of methyl triphenyl phosphonate and 840 uL of diisopropyl ethylamine 
were added and the reaction was allowed to reflux for an additional 48 hours. The 
reaction solution was filtered through a silica plug and purified by flash chromatography 
to give 0.92 g (2.24 mmol, 84% yield) a clear, viscous oil. TLC (10% Et20 / 90% 
hexane) Rf = 0.17, IR (cm"1) 1720. 'H-NMR (300 MHz, CDC13) 1.23 (3H, s,), 1.43 (9H, 
s), 2.87 (1H, d, J= 13 Hz), 3.00 (1H, d, J= 13 Hz), 3.75 (3H, s), 5.03 (2H, s), 5.78 (1H, 
d, J= 16 Hz), 6.87 (1H, d, J = 9 Hz), 7.04 (1H, d, J= 9 Hz), 7.18 (1H, d, J= 16 Hz), 7.39 
(5H, m) 13C-NMR (75 MHz, CDCI3) 20.5, 28.1, 44.4, 50.4, 51.8, 70.1, 81.8, 114.5, 120.0, 
127.8, 128.1, 128.7, 128.9, 131.6, 137.2, 151.7, 157.8, 167.1, 173.2. [C25H3o05Na]+ 
calcd = 433.1985, obsd = 433.1982. 
(±)-5-tert-But\l 1-methyl 2-(4-hydroxvbeiizvD-2-methvlpentanedioate (4.56): An 
amount of 0.92 g (2.24 mmol) of 4.55 was dissolved in 30 mL of distilled THF and 0.50 
g of Pd/C was added as a THF slurry. The solution was degassed with H2 and allowed to 
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stir over an H2 atmosphere. The reaction was monitored by TLC and was complete after 
48 hours. The Pd/C was removed by filtration through a Celite plug and the solvent was 
removed by rotary evaporation to give 0.75 g (quantitative) of a clear viscous liquid. Rf = 
0.18 (50% Et20 / 50% hexane), IR (cm"1) 3411, 1712. 'H-NMR (300 MHz, CDC13) 1.04 
(3H, s), 1.44 (9H,s), 1.71 (1H, m), 2.06 (1H, m), 2.31 (2H, m), 2.64 (1H, d, J= 14 Hz), 
2.89 (1H, d, J= 14 Hz), 3.68 (3H, s), 6.69 (1H, d, J= 9 Hz), 6.99 (1H, d, J= 9 Hz) 13C-
NMR (75MHz, CDC13) 20.9, 28.2, 30.3, 34.0, 44.8, 47.3, 52.0, 81.1, 115.0, 129.1, 131.6, 
154.9, 174.6, 175.9. [Cl8H2605Na]+ calcd = 345.1672, obsd = 345.1671. 
(±)-l-tert-Butvl 5-methvl 2-(4-methoxvbenzvD-2-methvlpentanedioate (4.57): An 
amount of 0.72 g (2.24 mmol) of 4.56 was dissolved in 15 mL of acetone followed by 
addition of 0.31 g (2.24 mmol) of anhydrous K2CO3 and dropwise addition of 210 uL of 
CH3I. The reaction was allowed to stir at reflux solvent for 48 hours, filtered to remove 
the K2CO3, and concentrated by rotary evaporation to give 0.66 g (1.96 mmol, 88% yield) 
of a clear viscous oil. TLC (50% Et20 / 50% hexane) Rf = 0.32, IR (cm"1) 1717, 1737. 
'H-NMR (300 MHz, CDCI3) 1.03 (3H, s,), 1.44 (9H, s), 1.70 (1H, m), 2.04 (1H, m), 2.64 
(2H, m), 2.64 (1H, d, J= 14 Hz), 2.93 (1H, d, J= 14 Hz), 3.67 (3H, s), 3.78 (3H, s), 
6.80 (2H, d, J= 9 Hz), 7.06 (2H, d, J= 9 Hz). I3C-NMR (75 MHz, CDCI3) 20.9, 28.2, 
30.0, 44.6, 47.4, 51.9, 55.3, 80.8, 113.5, 129.6, 131.5, 158.4, 174.1, 175.5. HRMS: 
[Ci9H2805Na]+ calcd = 359.1829, obsd = 359.1826. 
(±)-5-Methoxv-2-(4-(methoxvbenzvl)-2-methvl-5-oxopentanoic acid (4.58); In a 25 
mL round-bottomed flask 0.66 g (1.66 mmol) of 4.57 was dissolved in 10 mL of dry 
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CH3CN and 1 mL of water was added followed by addition of 1.0 g of KSF 
Montmorillonite Clay. The resulting solution was heated to reflux solvent. The reaction 
was monitored by TLC (50% Et20 / 50% hexane) and was determined to be complete 
after 4 days. The KSF clay was removed by vacuum filtration, and the filtrate was 
washed with CH3CN. The CH3CN was concentrated by rotary evaporation to give a clear 
viscous oil that was purified by flash chromatography (5% MeOH / 95% CHCI3, Rf = 
0.55) to give 0.34 g (0.98 mmol, 59% yield) a white amorphous solid. IR (cm"1) 1732, 
1697. 'H-NMR (300 MHz, CDC13) 1.11 (3H, s), 1.77 (1H, m), 2.09 (1H, m), 2.39 (2H, 
m), 2.72 (1H, d, J= 14 Hz), 2.98 (1H, d, J= 14 Hz), 3.67 (3H, s), 3.78 (3H, s), 6.81 (2H, 
d, J= 9 Hz), 7.08 (2H, d, J= 9 Hz). 13C-NMR (75MHz, CDC13) 20.7, 28.9, 33.7, 44.6, 
46.9,51.9,55.4, 113.7, 129.0, 131.4, 158.6, 174.0, 182.4 HRMS: [Ci5H2o05Na]+calcd = 
303.1203, obsd = 303.1200. 
(±)-ferf-Butvl4-((4-methoxvbenzvloxv)carbonvlamino)-5-(4-methoxvphenyl)-4-
methvlpentanoate (4.59): An amount of 0.11 g (0.39 mmol) of 4.58 was dissolved in 10 
mL of methylene chloride. Then, 93 uL (0.47 mmol) of DPP A and 177 uL of Et3N (1.18 
mmol) was added and the solution was brought to reflux solvent for 1.5 hours, at which 
time 79.9 uL (1.5 eq, 0.64 mmol) of PMB-OH was added and the solution was heated to 
reflux solvent for 17 hours. The excess solvent was removed by rotorary evaporation 
followed by purification via flash chromatography (200 mL of silica gel, 50%> Et20 / 50%) 
hexane) to give 0.088 g of a clear, viscous oil. TLC Rf = 0.42, Presence of 4.59 was 
detected by 'H-NMR and ESI-MS ([M + Na]+ m/z = 438). However, the oil was found to 
be composed primarily of the isocyanate formed from the Curtius rearrangement of 4.58 
119 
([M + Na]+ m/z = 300). This is evidence that the reaction was preceding, but longer times 
or a higher boiling point solvent may be required. 
(±)-5-fer^Butoxv-4-(4-methoxvbenzvl)-4-methvl-5-oxopentanoic acid (4.60): An 
amount of 0.37 g (1.09 mmol) of 4.57 was dissolved in 10 mL of EtOH and 0.13g (3.26 
mmol) of NaOH was dissolved in 1 mL of water and added to the reaction solution. The 
reaction mixture was allowed to stir at room temperature for 48 hours. The solution was 
diluted with 15 mL water, washed three times with Et20, acidified with cold 10% HC1 
and, extracted into Et20. The resulting solution was dried over MgSCU, filtered, and 
concentrated by rotary evaporation to give 0.32 g (0.99 mmol, 91% yield) of a clear, 
viscous, liquid. TLC (50% Et20 / 50% hexane) Rf = 0.25. IR (cm"1) 1707. 'H-NMR 
(300MHz, CDC13) 1.05 (3H, s,), 1.44 (9H, s), 1.70 (1H, m), 2.05 (1H, m), 2.35 (2H, m) 
2.65 (1H, d, J= 14 Hz), 2.92 (1H, d, J= 14 Hz), 3.78 (3H, s), 6.80 (2H, d, J= 9 Hz), 
7.06 (2H, d, J= 9 Hz). 13C-NMR (75MHz, CDC13) 21.0, 28.2, 30.1, 33.8, 44.6, 47.2, 
55.4, 81.0, 113.5, 129.5, 131.5, 158.4, 175.5, 180.0. HRMS: [Ci8H2605Na]+ calcd = 
345.1672, obsd = 345.1672. 
(±)-tert-Butvl 2-(4-methoxvbenzvl)-4-((4-methoxvbenzvloxv)carbonvlamino)-2-
methvlbutanoate (4.61): An amount of 0.32 g (0.96 mmol) of 4.60 was dissolved in 10 
mL of CH2CI2 in a 50 mL RBF with a magnetic stirbar. Then, 228 uL (1.06 mmol) of 
DPPA and 435 uL of Et3N (2.89 mmol) was added and the solution was stirred for 30 
minutes at room temperature. The solution was heated to reflux solvent for 3 hours, at 
which time 179 uL (1.44 mmol) of PMB-OH was added and the solution was brought to 
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reflux solvent. The solution was diluted with 20 mL of CH2CI2, filtered through a plug of 
silica gel, and concentrated by rotary evaporation to give a orange, transparent, viscous 
oil that was purified by flash chromatography (200 mL of silica gel) to give 0.27 g (0.59 
mmol, 61% yield) of a clear, viscous oil. TLC (30% EtOAc / 70% hexane) Rf = 0.27. IR 
(cm"1) 3358, 1709. 'H-NMR (300 MHz, CDC13) 1.08 (3H, s), 1.42 (9H, s), 1.54 (1H, m), 
1.89 (1H, m), 2.65 (1H, d,J= 13 Hz), 2.87 (1H, d, J= 13 Hz), 3.20 (2H, m), 3.78 (3H, s), 
3.80 (3H, s), 4.75 (1H, bs), 5.01 (2H, s), 6.79 (2H, d, J= 9 Hz), 6.87 (2H, d, J= 9 Hz), 
7.04 (2H, d, J= 9 Hz), 7.28 (2H, d, J= 9 Hz). 13C-NMR (75MHz, CDCI3) 21.3, 28.2, 
37.7,38.9,45.0,46.5,55.4,55.5,66.6,81.0, 113.5, 114.1, 128.9, 129.4, 130.2, 131.5, 
156.5, 158.5, 159.7, 175.9. HRMS: jX^HssNOeNaf calcd = 480.2357, obsd = 480.2355. 
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CHAPTER V 
MASS SPECTROMETRY BASED ENANTIOSELECTIVITY ASSAY FOR 
MALONATE DIESTERS 
Literature Review 
Introduction 
Enzymes display great utility for use as synthetic tools. This was exemplified by 
the cover story of a 2006 issue of Chemical and Engineering News titled: "Enzymes at 
Work".1 This article highlights the advantages of the few enzymes that are currently used 
in industry. Enzymes catalyze a variety of stereo-selective reactions such as C-C, C-O, 
and C-N bond cleavage. This article points out that, with the evolution of rapid screening, 
optimization, commercial availability, and ease of use, enzymes will become a necessity 
in future drug discovery. It was demonstrated in the Chapter II that enzymes can be used 
in the synthesis of chiral malonate half esters. Chapters II, III, and IV describe how these 
chiral half esters can be transformed into a series of homochirally similar disubstituted 
unnatural amino acids.2 A crucial part of our synthetic methodology is to generate the 
malonate half esters in as close to optically pure form as possible. The enantiomeric 
composition of the amino acids is dependent on the enantioselectivity of PLE for the 
malonate diester substrate. In Chapter I, it was noted that PLE hydrolysis of 2.31a gave 
2.32a in 70% ee, where as the PLE hydrolysis of 2.31b to 2.32b showed 50% ee. The 
selectivity of PLE for these two substrates was sufficient to prove our synthetic 
methodology, but greater enantioselectivity is needed in order to achieve our goal of 
providing an efficient synthesis for these unnatural amino acid classes in optically pure 
form. There are several possible solutions to this problem which include using different 
desymmetrization enzymes, altering the protecting groups of our diesters, or modification 
of the medium in which the enzymatic hydrolysis is performed. While each of these is a 
possible solution, determining the outcome of each variable, or a combination of 
variables, is a very time consuming process. This process is made even more difficult by 
the amount of time that is required for each hydrolysis (1 day to 2 weeks). For these 
reasons, an efficient high-throughput screening process is needed. As is often stated, 
necessity is the mother of invention and this was the case with the evolution of 
hypothesis 2 of this dissertation. Hypothesis 2 states that a high-throughput mass 
spectrometry (MS) based assay for malonate diesters may be performed by monitoring 
the ratio of the mixture of labeled and non-labeled half esters that results from the 
enzymatic hydrolysis of a deuterium labeled, enantiomerically enriched D5 / Hj-diester 
(Scheme 5.1). This chapter will focus on 1) the development of a high throughput assay, 
2) determination of conditions that improve the enantioselectivity of PLE for 2.32a and 
2.32b using this MS assay, and 3) validation of the methodology by scale-up of each 
successful for comparison by chiral HPLC. 
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Scheme 5.1. General scheme for a mass spectromety based assay to monitor the 
enantioselectiviy of enzymes for malonate diesters 
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Modifying the Enantioselectivity of Pig Liver Esterase 
Multitudes of papers and several books have been published on the use of 
enzymes in organic synthesis. One example of such enzymes is PLE, which is a serine 
protease that consists of three subunits. This esterase is commercially available as a 
mixture of isozymes that is isolated by homogenation of pig livers. One kg of the esterase 
mixture can be isolated from 4 kg of pig liver. There were 64 million pigs slaughtered in 
the U.S. from 
January to July, 
2009.3 This 
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A^COOMe PLE 
5.5 COOH 
^A^COOMe 
COOMe 
COOMe PLE 
99% ee, 99% yield 
COOH 
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H3CO 
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exemplifies the 
availability of this 
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PLE has proven to 
be promiscuous for 
many different 
chiral resolutions 
96% ee, 78% yield 
Scheme 5.2. Different esters hydrolyzed by PLE 
and prochiral desymmetrizations, giving both excellent enantioselectivity and excellent 
chemical yields (Scheme 5.2). These hydrolyses are typically performed in aqueous 
buffer. This makes the chemistry environmentally friendly, whereas most chiral ligand 
asymmetrization catalysts use organic solvents that must be disposed. The crystal 
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structure of PLE has not been determined which means that the mechanism for PLE 
selectivity is unknown. However, Jones et al. were able to create a model of the active 
site of PLE (Figure 5.1).5 1.6A \ & J 
1 3"\ 
4.6A 
2.3A 
P B V Ser! 
H, 
H< 
5.4 A 
1.6A 
1.6A 
1.6A 
This model was based on 
over 100 symmetrical 
diester substrates that had 
been previously hydrolyzed 
by PLE. The model 
Figure 5.1. PLE active site model proposed by Jones, et al. . . , , , 
• ^
 r J
 contains two polar pockets 
(PF and PB) and two hydrophobic pockets (Hs and HL) with the active serine residue 
within close vicinity of the PB pocket. The model predicts that the ester to be hydrolyzed 
must be within the 1 A serine sphere, with the remaining groups best fit into the 
remaining H and P pockets. The substrate will be hydrolyzed based on the fit of the 
remaining groups in these pockets. The unhydrolyzed ester will fit into the PF pocket and 
the largest non-polar side chain should fit into the HL pocket. Since the model was 
proposed, rabbit and human carboxypeptidase, which are closely related to PLE (75% 
and 76% conserved, respectively), has verified the model. 
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Scheme 5.3. Effect of cosolvent on PLE 
enantioselectivity 
The synthetic utility of enzymes for 
asymmetric synthesis is undisputable.1'4 
However, the case often arises when PLE does 
not provide a high enantioselectivity for a 
particular hydrolysis. In such cases several 
strategies have been developed to increase the 
enantioselectivity of the enzyme. Given the 
model in Figure 5.1, the enantiomeric composition of the products is highly dependant on 
fit of the substrate into the active site of PLE. Modification of protecting groups or 
addition of a cleavable auxiliary can result in increased enantioselectivity. For example, it 
has been shown that PLE exhibits higher selectivity for malonic methyl esters over ethyl 
esters.2'7"9 While covalent modifications of a substrate molecule have proven successful 
in increasing enantioselectivity, they require a large amount of synthesis (racemic 
standards are required) and workup before analysis can be performed. Another method 
involves the direct modification of the biocatalyst by modification of the proteins primary 
structure through biochemical exchange of single or multiple amino acid residues. Many 
groups have made extensive use of directed evolution of enzymes. " This approach 
utilizes random mutations to generate mutants that are then screened for the desired 
properties. The best candidates are then subjected to directed evolution to create a more 
efficient enzyme for the desired task.10'1' While directed evolution has been successful, it 
requires thorough knowledge of biochemical techniques and requires a great deal of time 
to generate successful mutants. For the synthetic chemist, one of the more promising 
methods of increasing enantioselectivity has been termed reaction media engineering 
which utilizes the addition of organic solvents that can modify the rate of hydrolysis, the 
chemical yield and/or the enantioselectivity of the enzyme (Scheme 5.3).19 Although the 
effect seen with cosolvents is well documented, the cause remains unknown. Alcohols 
have by far been the most successful cosolvents. " The largest improvements in 
enantioselectivity is typically seen when a sterically hindered alcohol, such as 
isopropanol, is used. However, polar aprotic cosolvents have also seen extensive use. The 
disadvantage of using cosolvents is that the rate of the hydrolysis can be dramatically 
decreased. " One possible solution to the decrease in rate of hydrolysis is the use of 
small amount of ionic liquids as additives. Wallert et al. have shown that addition of 
0.1% to 5% of an ionic liquid to alcohol cosolvent systems results in increased the 
enantioselectivity and rate of hydrolysis for PLE using malonate diester substrates. It is 
clear from the literature review above that a method to evaluate the enantioselectivity of 
enzymatic hydrolyses under a variety of conditions is necessary. 
High Throughput Assays for Enantioselectivity 
Many approaches have been developed that screen catalysts for activity. The 
development of a combinatorial approach by Menger et al. has lead to a tremendous 
surge in screening of catalyst.23 The analysis of chiral mixtures using high throughput 
screening should be simple, quick, efficient, and use very little consumable material (i.e. 
solvents). This approach has been termed combinatorial asymmetric catalysis. This 
section will outline the methods that show the most potential for high throughput 
screening of enantioselectivity. 
A popular method for the high throughput quantitation and kinetics is UV/Vis 
because of the fast scan rates and the technology (i.e. plate readers) that have been 
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developed to increase the throughput of this type of assay.24'25 However, obtaining 
information about the enantiomeric composition produced is difficult.26 Berkowitz et al. 
have develop an In Situ Enzyme Screening (ISES) assay that uses a biphasic, dual cuvette 
UV/Vis assay to screen Co(III) transition metal catalysts for rate and ability to kinetically 
resolve a chiral diol. In this assay, the chiral catalyst hydrolyzes (±)-propylene oxide 
(5.12) to a chiral diol in the organic phase. The diol can then diffuse into the aqueous 
phase which contains a non-selective alcohol dehydrogenase enzyme that uses NADP as 
a coenzyme to convert 5.12 into 5.14. The conversion of NADP to NADPH during 
oxidation of the alcohol is monitored by UV/Vis (at 340 nm) to determine the rate of the 
reaction. The second cuvette contains a stereoselective alcohol dehydrogenase that 
catalyzes the conversion of S.lSSto 5.15 and monitors conversion of NAD+ to NADH. 
An estimation of resolving ability of the chiral catalyst can be made by comparing the 
rates of hydrolyses from the two cuvettes. The assay has been successful in ligand tuning 
for several Co (III) catalyst.27'28 The main drawbacks of the ISES method are: 1) the 
catalyst must be water stable and 2) finding an enzyme that is selective for the product 
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diols can be difficult and time consuming. 
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Infrared spectrometry has also 
seen use in the screening of chiral 
catalyst for the kinetic resolution of 
phenylethylacetate (5.16) and 
phenylethylacetamide.29 This method 
makes use of isotopic labeling of the 1760 1710 1660 
7 (cm"') 
Figure 5.2. FTIR spectra of (R)-1-Phenylethylacetate carbonyl with U C. These carbonyl 
at 1751 cm"1 and (5)-l-Phenylethyl-l-13C-acetate at 16 
13/ 
cm compounds have a unique and strong 
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absorbance at 1600 to 1800 cm"1. The large shift in cm"1 exhibited by the 13C-labeled 
carbonyl (40 to 50 cm" ) as compared to the unlabeled carbonyl, makes this method 
useful for the analysis of samples with multiple components. Once the spectrum has been 
taken, application of the Beer-Lambert law allows for quantitation of each enantiomer 
produced from the catalysis. This method is capable of determining the enantiomeric 
composition of 10,000 samples per day with < 7% error as compared to chiral GC. The 
assays can be performed directly from biological supernant. The major disadvantage of 
this method is that the molar absorptivity coefficient (s) must be determined prior to 
application of the assay. However, this method has shown utility as a cost-effective assay 
for enantioselectivity. Another derivation of this method is IR thermography which has 
allowed for the visualization of kinetic and enantioselectivity of catalysts through use of 
an IR camera to monitor the heat of reaction.30"32 
Microarrays have also found use in the determination of % ee. This method 
makes use of probes that fluoresce at different wavelengths depending on the 
enantiomeric composition. To use this methodology, amine functionalized glass slides are 
derivatized with D or L N-Boc-protected amino acids (the samples to be analyzed). This 
is followed by acetylation of any remaining free amines and deprotection of the amino 
acids. The amino acids on the slide are then subjected to a coupling reaction with a 
mixture of D and L proline which had been attached to a fluorescent reporter at the N-
terminus. Each enantiomer of the reporter reacts with a specific enantiomer of the amino 
acids. When these samples are scanned with a laser, the samples fluoresce at wavelengths 
that vary between red and green which is related to the enantiomeric composition of the 
amino acids. The fluorescent wavelength of each sample can be used to directly 
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determine the enantiomeric composition. This method allowed for the determination of 
enantiomeric composition of 15,500 samples on a single glass slide with an average error 
of<8%ee. 
An NMR spectroscopy based assay has been developed to observe the resolution 
of ±- 1-phenylethyl acetate by a lipase. This technology is based on NMR flow cell 
technology and has been able to obtain 1400 % ee determinations per day.34 Later 
application of chemical shift imaging allowed for an increase of up to 5600 ee-
determinations per day. One form of this assay is based on the observance of the H-
NMR of observance of acetic acid that is generated from the enzymatic resolution of 
pseudo-racemic mixtures of S-13C- 1-phenylethyl acetate and the unlabeled R-l-
phenylethyl acetate. The protons from the methyl group of the labeled acetic acid are 
observed as a doublet and can be distinguished from the singlet observed from the non-
labeled acetic acid. Integration of these peaks allows for determination of the 
enantiomeric composition of the chiral alcohols with approximately five percent error. 
Mass Spectrometry has the potential to be the highest throughput method of all of 
the analytical methods discussed in this dissertation. Multiple approaches have been 
evaluated for the determination of enantiomeric composition by mass spectrometry. The 
sensitivity of modern mass spectrometry instrumentation allows for use of very small 
quantities of analyte. Methods have been developed that make use of the formation of 
complexes with chiral selectors in the gas phase ' , supramolecular complexes ' , and 
transition metal complexes of pseudo-enantiomers.40"42 Although these methods have 
been successful, some require complex mathematical corrections and require extensive 
work to expand to new analytes. An attractive method for high-throughput screening of 
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enzyme selectivity was developed by Reetz et al. that makes use of pseudo-enantiomer 
mixtures or pseudo-meso esters in which strategic parts of the molecule of interest were 
deuterium labeled to give mass spectrometry probes (5.18, 5.19, and 5.21, Scheme 
5.5). ' The probes were subjected to enzymatic reactions and the resulting products 
(5.20 and 5.21) from the reaction were analyzed by mass spectrometry. Direct 
comparison of the sodium adducts of 5.20 and 5.21 analyte allow for direct determination 
of the enantiomeric composition. The % ee values obtained from the MS analysis of 
various compositions of 5.20 and 5.21 were compared to values found by chiral GC to 
determine the validity of the method (Scheme 5.5). It was found that the two methods 
correlated extremely well for an enantiomeric excess of either enantiomer. The most 
impressive aspect of this methodology was that it allows for the analysis of 10,000 
samples per day with less than three precent error. 
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for enzyme enantioselectivity composition developed Reetz B) The correlation plot 
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hydrolase hydrolysis of 5.18 and 5.19 
To our knowledge, no assay has been developed to screen for the 
enantioselectivity in the enzymatic hydrolysis of malonate diesters. In the previous 
Chapters, the synthetic utility of malonate half-esters for the synthesis of multiple classes 
of disubstituted unnatural amino acids was demonstrated. The incorporation of both 
enantiomers of these unnatural amino acids into neurotensin peptidomimetics requires 
that the selectivity of the PLE hydrolysis of the malonate diesters be improved. In this 
Chapter, several possible methods were outlined that can be used to monitor the increase 
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in enantioselectivity of enzymes. Reaction media engineering seems to be the simplest 
approach to modifying the enantioselectivity of enzymes. However, the cause of the 
change in enantioselectivity seen with cosolvents is not well understood. This means that 
there is no defined approach to determine which solvent will give the best result. In order 
to effectively evaluate the numerous possible combinations of solvents, enzymes, and 
buffers, a high throughput assay for the enzymatic enantioselectivity of malonate diesters 
must be developed. The analytical capacity of the mass spectrometry assay similar to the 
one developed by Reetz should allow us to obtain the highest throughput without custom 
equipment.13'16 The following section will address the development of a mass 
spectrometry based assay for the enzymatic hydrolysis of malonate diesters. This work 
will use deuterium labeling to create pseudo-pwchiral malonate diesters (5.25) that can 
be subjected to enzymatic hydrolysis and monitored by mass spectrometry (Scheme 5.6). 
The results of the assay will also be monitored by chiral HPLC to validate our assay. 
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Discussion and Results 
The first step in the development of an MS-based assay is the synthesis of 
deuterium labeled probe molecules (5.31a and 5.31b). Initially, we sought to create 
enantiomerically pure half esters (2.32a and 2.32b) in order to design an MS based assay 
similar to the one developed by Reetz.13 To accomplish this we attempted to resolve 
2.32a as a diastereomeric a-methylbenzyl ammonium salt in diisopropyl ether by a 
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literature procedure (Scheme 5.7).43 We were able to obtain the desired ammonium salt, 
but when the resulting half ester was analyzed by chiral HPLC we observed no change in 
enantiomeric excess. In an attempt to resolve 2.38b, we followed the same literature 
procedure and modified our solvent composition to include a variety of solvents and 
combination of solvents. Unfortunately, we were unable to obtain the a-methylbenzyl 
ammonium salt of 2.32b. We also attempted to purify the (7?)-enantiomers of 2.38a and 
2.38b by semi-preparative chiral HPLC. Unfortunately, we were only able to purify 
milligram quantities after several days of continual injections. The breakthrough in the 
probe synthesis came when we realized that we should be able to use a probe that was not 
enantiomerically pure. Cawley et al. were able to prove this concept mathematically and 
provide a simple formula to correct 
Observed Enantiomeric Excess 
for enantiomerically impure probes Starting % ee of Probe = 
(Figure 5.3). Application of this 
methodology would lend two 
primary strengths to our assay by 1) 
Figure 5.3. The equation used to correct for 
making the probe synthesis more the purity of the MS probes 
efficient by removing the resolution step and 2) allowing us to recycle our 
enantiomerically enriched half-esters obtained from PLE hydrolyses. 
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Scheme 5.7. Resolution of 2.32a and 2.32b by formation of a diastereomeric 
ammonium salt with a-methylbenzyl amine 
Synthesis of the probe 5.31a was initiated by performing a PLE hydrolysis of 
2.31a to 2.32a. Compound 2.32a was analyzed by chiral HPLC which confirmed that the 
half-ester was produced in 68% ee. Conversion to 5.31a was accomplished by activation 
of 2.32a as an acid chloride followed by quenching of the acid chloride with D6-ethanol. 
This gave 5.31a in 84% isolated yield. Compound 5.31b was synthesized using the same 
methodology (63% yield). Chiral HPLC analysis of 2.32b confirmed that the half-ester 
was produced in 63% ee. Racemic half-esters (±-2.32a and ±-2.32b) were also 
synthesized by saponification of 2.32a and 2.32b with NaOH. These racemic half-esters 
were esterified using the D5 / H5 diesters using the described acid chloride method. 
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selectivity with the correspnding chiral HPLC chromatograms 
Once the probes had been synthesized, we proceeded with a preliminary assay to 
determine if the proposed methodology would provide the expected result and whether 
ESI or MALDI-ToF mass spectrometry would be most convenient. To determine the 
validity of our proposed assay, PLE hydrolyses of probes 5.31a and 5.31b were 
performed using 10 mg of each probe in 1.5 mL of buffer. The resulting mixture of D5 
and H5 half-esters were then analyzed by chiral HPLC, ESI-ion trap mass spectrometry, 
and LDI-ToF mass spectrometry. Laser Desorption Ionization Time-of-Flight (LDI-ToF) 
was used to analyze the assay due to the interference caused by matrix in the low 
molecular weight region seen in MALDI-ToF. This was possible because the aromatic 
ring on our substrates is able to absorb the laser radiation and facilitate ionization. 3 
Analysis by ESI and LDI-ToF MS showed that the PLE hydrolysis of 5.31a proceeded 
with an observed 74% ee and 69% ee, respectively after correction (Scheme 5.8). 
Analysis by chiral HPLC revealed that the PLE hydrolysis of 5.31a proceeded with 67% 
ee. Hydrolysis of probe 5.31b in pH 7.4 phosphate buffer gave 66% ee and 58% ee after 
correction, respectively. Chiral HPLC analysis confirmed that the hydrolysis of 5.31b 
proceeded with 62% ee. Statistical analysis of the results from the hydrolysis of probes 
5.31a and 5.31b revealed less than four percent standard deviation for ESI-MS, LDI-
ToF-MS, and chiral HPLC. This means that both LDI-ToF and ESI MS are viable 
methods that give reliable results. These observations confirm that our assay provides 
valid data that can be used to evaluate the PLE hydrolysis of our MS probes (5.31a and 
5.31b). 
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The next task was to determine which method of analysis (ESI or LDI-ToF) gave 
the most reproducible results as compared to chiral HPLC. It has been observed that pH 
has an effect on the selectivity of some enantioselective enzymes. ' For this reason, it 
was decided to begin the assay by evaluating the mid buffering range of the phosphate 
buffer (pH 6.2 to 8.2) that is used as a solvent for the hydrolysis. The assay was 
performed in triplicate for pH 6.5, 7.0, 7.4, and 8.0. The results obtained from the three 
analytical methods (ESI-MS, LDI-ToF-MS, and chiral HPLC) were then compared 
graphically to determine how well the methods correlate (Figure 5.4). The trends 
observed in the graphs indicate that there was little variance in enantioselectivity over the 
pH range of the phosphate buffer. The same minor changes in enantiomeric composition 
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were observed with all three techniques which should allow either mass spectrometry 
technique to be utilized for analysis of our assays. It was decided that ESI-MS was the 
best technique to use to analyze our assays due to the ease of sample preparation. The 
LDI-ToF technique required more tedious sample preparation to remove salts that 
interfere with the laser desorption ionization process. The LC-MS technique allows us to 
use a divert valve to remove buffer and salts from our sample before it is injected into the 
mass spectrometer (Figure 5.5). With sound methodology for our assay now available, 
we proceeded to evaluate various cosolvents. 
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It is well known that inorganic buffers like phosphate and sulfate buffers suppress 
ion formation in mass spectrometry and can clog the inlet to an LC-MS system due to the 
non-volatile nature of the buffer salts. 3 For this reason, we wanted to determine if we 
could use a buffer that was compatible 
with mass spectrometry such as the 
TRIS buffer. We also wanted to 
determine if the buffer that was used 
had an affect on the enantioselectivity 
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the hydrolysis of probe 5.32b. A phosphate buffer control was also used. The general 
approach to the assay involved placing 10 mg of each probe in a microcentrifuge with the 
appropriate buffer. A PLE solution (50 mg / mL) was made and 4 units of enzyme were 
added to each tube. The assays were allowed to proceed for three days for probe 5.32a 
and five days for probe 5.32b. To analyze the samples, 200 uL of each sample was placed 
in an autosampler vial and diluted with 200 uL of one percent acetic acid in MeOH. An 
injection of 1 uL of the mixture was made into the LC-MS system. The eluant from the 
LC system was diverted for two minutes to elute the buffer before the remainder of the 
eluant was injected into the MS detector. We found that the first two to three days of 
hydrolyses proceeded with a similar selectivity to that seen in the phosphate buffer 
control (Figure 5.5). However, it was observed that a loss of selectivity was seen as the 
reaction proceeded beyond three days. This may have been due to buffer catalyzed 
racemic hydrolysis of the probes or reaction of the buffer with the probe. These 
experiments allowed for the conclusion that phosphate buffer was the better choice for 
buffering of our assays. 
Several literature sources have cited that polar aprotic cosolvents can induced an 
increase in enantioselectivity in various enzymatic hydroyses.4,20,47 We proceeded to 
apply our assay to evaluate several of the more commonly used cosolvents like DMSO, 
DMF, MeCN, THF, Dioxane, Diglyme, and Triglyme with probes 5.32a and 5.32b. 
Cosolvent compositions of 5% to 20% in pH 7.4 phosphate buffer were used. The results 
are described as an increase or decrease in enantioselectivity relative to controls that were 
performed in phosphate buffer (5.32a = 68% ee, 5.32b = 63% ee). The experimental 
results are shown in Figure 5.6. A slight increase in selectivity of PLE was seen with both 
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5.32a and 5.32b with most of the cosolvents. The exception was MeCN where we 
observed decreased enantioselectivity initially with probe 5.32a followed by an increase 
in selectivity with concentrations above 10%. The same result was obtained with the 
hydrolysis of 5.32b with MeCN resulted in a decrease in enantioselectivity with 
concentrations up to 15%, followed by a slight increase in enantioselectivity at 20% 
MeCN. The hydrolysis of probe 5.32b in MeCN cosolvents resulted in a decrease in 
enantioselectivity. The observed increase in enantioselectivity observed (6% for 5.32a 
and 14%o for 5.32b) with the polar aprotic cosolvents is synthetically insignificant which 
lead to evaluation of other cosolvents systems. 
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Figure 5.7. Results from the PLE hydrolysis of probes 5.31a and 5.31b in polar 
aprotic cosolvents 
Literature reports have reported that alcohol cosolvents are most effective as 
additives to improve the enantioselectivity of the PLE hydrolysis of malonate diesters. 
We began our alcohol cosolvent assay by examining mixtures of methanol, ethanol, 
isopropanol, and terf-butanol with pH 7.4 phosphate buffer. The solvent composition 
ranged from 5% to 30%o of each of the alcohols. When we began analyzing the results of 
the assay from probe 5.32a using the Select Ion Monitoring (SIM) mode for the MeOH 
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cosolvent reactions, we noticed that there were two resolved peaks in the LC-MS 
chromatogram that were isobaric (m/z = 267). The same sample was analyzed again 
using the full scan mode of the ion trap. We observed five identifiable peaks in the 
chromatogram when only two should have been present. When these peaks were 
subjected to MS" analysis by collision induced dissociation (CID), we found that the 
additional compounds were the result of transesterification with the methanol cosolvent 
(Figure 5.8). We saw the same result when ethanol was used as a cosolvent. We 
determined the transesterification was taking place by looking for the [M+Na]+ = 317 that 
corresponds to compound 2.31a. When this diester is hydrolyzed by PLE, we observe a 
ratio of m/z = 267 / m/z = 272 that was not representative of the enantiomeric 
composition of the hydrolysis. This was confirmed by chiral HPLC analysis of the same 
samples. Transesterification with primary alcohols clearly illustrates a limit of this assay. 
For this reason, we ceased the use of methanol and ethanol as cosolvents in these assays. 
G:\Docuire nts\...vrranslvl101J}71210135223 12/10/20071:5223 PH 
ST: 0.00- 10.00 SM: 1 
100 
<H 
c ! 1 2 
i i | i I i i 
i 
I i i i i | 
Time:r 
i i i i | i i i i | i i i i | i i i i I i I i i 
RT: Q.se 
1G0-] 
8 88: 
S 50-
$ 40 : 
& 20-
( 
- 1000 S!,i: 156 
r- i i / -> 0 0 
R I C
 V ^ O H 
5.33a 
1 2 
i 
" " I 
7 g 
1 l | l l l l 
3 
271.03 US 
.07121313 
ST: 0.00- 10.00 S1.I: 1 SB 
1C0-] 
RIC 
5.32a 
m/z = 284 [M+NH4]+ 
'
J!X^CH ( I GB„
 m/z=284[M+NH4]+ 
5.34a 
HI: 
1.S2EE 
253.00-
255.00 MS 
TransfsHCl 
.07121013 
5223 
I i i i i I i i i i—i—i—i—i—i—i—i—i—i—i—j— 
RT: 0.00 
tots 
I so-
I c-0-
i 
IZ 20 -
-10.00 SM: 153 
O O 
RIC / V ' x j v 
5.35a os» 
m/z = 303 [M+Na]+ 
- i— i—i—i—p—i—i—i—r - i— i -
0 1 2 
ML: 
1.S-0E8 
m/z= 
302.00-
M«.0O MS 
Trar,si.1 101 
07121013 
RT: 0.00-10.00 Sf.i: 1SB 
WO-, 
8 s«- RIC 
m/z= 317[M+Na]4 
H L: 
5.7 SEE 
nVz= 
3.1S.00-
30.00 
TransM 
US 
101 
07121013 
5223 
- 1 — I — I — I -
Figure 5.8. LC-MS chromatograms of the results of the PLE 
hydrolysis of probe 5.31a in 10% MeOH / pH 7.4 phosphate 
buffer cosolvent 
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We obtained the most interesting results with the isopropanol and tert-butanol 
cosolvent assays. Probe 5.32a showed an increase from 70% ee to 85% ee with the use of 
10% tert-butanol as a cosolvent. A similar result was seen with probe 5.32b, where an 
increase from 63% ee to 85% ee was seen with 30% tert-butanol. Interestingly 
isopropanol gave the best results of all of the evaluated cosolvents. We observed a 
substantial increase in the enantiomeric composition of probe 5.32a from 70% ee to 
103% ee (overestimation due to error from the MS measurement) when 10% isopropanol 
in pH 7.4 phosphate buffer was used as the solvent. When probe 5.32b was subjected to 
the assay with 30% isopropanol cosolvent, an increase in enantiomeric composition from 
63% ee to 90% ee was observed. To verify the results of these assays 100 mg of 2.31a 
and 2.32b were hydrolyzed in the appropriate cosolvent isopropanol cosolvent. The 
hydrolysis of 2.31a to 2.32a using 10% isopropanol in pH 7.4 phosphate buffer as the 
reaction medium resulted in > 97% ee, which confirmed the increase in enantiomeric 
composition seen in the MS assay (Scheme 5.10). As seen in previous reports, we 
observed a significant decrease in rate when > 30% cosolvent is used. In concentrations 
of the cosolvent over 30% the signals from the mass spectrometers was too weak to 
calculate an accurate enantiomeric composition. The overestimation of the enantiomeric 
composition seen in the MS assay is thought to be the result of the error associated the 
initial chiral HPLC determination of the probe composition and the error associated with 
the mass spectrometry assay. 
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Scheme 5.10. PLE hydrolysis of 2.31a to 2.32a in 10% /PrOH in pH 7.4 phosphate 
buffer with the corresponding chiral chromatograms 
The reasoning behind the modification of selectivity seen with cosolvent use is 
not understood. Matson, et al. has observed the occurrence of a buffer acting as an 
alternative nucleophile to water. This was considered as a possible explanation to the 
increase in selectivity seen with the PLE hydrolysis of probes 5.32a and 5.32b when 
isopropanol and tert-butanol were used as cosolvents. There was a small quantity of the 
isopropyl ethyl diester of probe 5.36a observed in the full scan LC-MS chromatogram 
(Figure 5.8). This lends evidence to isopropanol acting as an alternative nucleophile to 
water which would lead to transesterification of a single enantiomer of the half ester. 
However, there was no transesterification observed with the use of ter/-butanol as a 
cosolvent which also resulted in increased enantioselectivity with PLE. Experiments to 
determine if transesterification is the cause of the increase in selectivity will be discussed 
in Chapter VI. 
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Figure 5.9. LC-MS chromatograms of the results of the PLE 
hydrolysis of probe 5.31a in 10% iPrOH / pH 7.4 phosphate 
buffer cosolvent 
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We were very pleased with the increase from 70% ee to > 97% ee seen with the 
PLE hydrolysis of 2.31a to 2.32a. We had hoped that a similar result would be seen with 
the PLE hydrolysis of 2.31b to 2.32b. However, we were only able to increase selectivity 
from 63%) ee to 85%> ee with < 10% yield of 2.32b. While this is a significant increase, it 
is not of sufficient enantiomeric purity for to complete synthesis of our desired unnatural 
tyrosine analogues. Literature has shown that the PLE hydrolysis of methyl diesters yield 
higher selectivity than ethyl diesters.2'7" It is for this reason that the PLE hydrolysis of 
5.36 to 5.38 was evaluated in hopes that the selectivity would be > 97% ee. Synthesis of 
5.36 was initiated by generation of the enolate of dimethyl methyl malonate followed by 
quenching of the enolate with benzylchlorobenzyl ether (54% yield). Compound 5.37 
was subjected to a PLE hydrolysis in pH 7.4 phosphate buffer to give 5.38 in 75% yield. 
Chiral HPLC analysis of 5.38 showed that the hydrolysis proceeded in 80% ee. This is 
also a significant improvement in selectivity, but is still not of adequate optical purity. An 
MS probe was synthesized by converting 5.38 to an acid chloride, then quenching the 
acid chloride with CD3OD to give 5.39 in 82% yield. The absolute configuration of 5.38 
was determined by synthesis of a-methyl tyrosine methyl ester (5.41) from 5.38 (Scheme 
5.11) followed by comparison of the optical rotation to an authentic sample of a-methyl 
tyrosine methyl ester. The observed dextrorotary optical rotation matched that of the 
authentic sample of (S)-a-methyl tyrosine which allows for the conclusion that the PLE 
hydrolysis of 5.37 yields the i?-enantiomer of 5.38. 
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Scheme 5.11. Synthesis of MS probe 5.39 with the corresponding chiral HPLC 
chromatogams and synthesis of a-methyl tyrosine to determine the configuration 
of 5.38 
Probe 5.39 was subjected to hydrolysis in the same cosolvent systems used with 
probes 5.31a and 5.31b. This included isopropanol, ter?-butanol, and the polar aprotic 
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cosolvents used in the previous assays. We hoped to see the same increase in 
enantioselectivity with the methyl diester (probe 5.39) that we observed with the ethyl 
diester (5.31b). Surprisingly, it was observed that hydrolysis of probe 5.39 in low 
concentrations of cosolvents resulted in a decrease in enantioselectivity. The result was 
that the enantioselectivity of probe 5.39 seen with 10% isopropanol in pH 7.4 phosphate 
buffer cosolvent was decreased to the value seen in the hydrolysis of probe 5.31b in 
phosphate buffer (Table 5.1). It was observed that the hydrolysis of 5.39 in 30% 
isopropanol / 70% phosphate buffer yielded > 100% ee and the PLE hydrolysis of 5.39 in 
30% ter/-butanol / 70% phosphate buffer yielded 85% ee, by mass spectrometry. 
However, a scale-up of both reactions resulted in < 20% ee by chiral HPLC (Scheme 
5.11). The over estimation in enantioselectivity was due to low conversion of 5.39. The 
exact cause of this change in enantioselectivity is unknown and confirms that the results 
of hydrolyses with PLE in organic cosolvents are not well understood. 
Table 5.1. A comparison of the corrected MS reults from the PLE 
hydrolysis of probes 5.31b and probe 5.39. 
Cosolvent 
/-PrOH 
f-BuOH 
DMSO 
MeCN 
DMF 
Dioxane 
Diglyme 
Triglyme 
Control 
Probe 5.31b 
Corrected % ee 
10% 
71 
71 
72 
46 
67 
75 
71 
72 
63 
20% 
79 
77 
73 
45 
72 
77 
71 
75 
30% 
90 
85 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
10% 
64 
62 
76 
65 
67 
67 
70 
71 
80 
Probe 5.39 
Corrected % ee 
20% 
62 
61 
68 
71 
65 
69 
69 
70 
30% 
103 
85 
67 
n/a 
78 
n/a 
69 
70 
The result of the PLE hydrolysis of probe 5.39 in 10% /-PrOH (highlighted in 
blue) is the same as that seen in the PLE hydrolysis of 5.31b in buffer alone 
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Figure 5.10. Correlation of HPLC% ee and corrected 
MS % ee 
spectrometry assay and the 
values found by chiral HPLC. 
In addition to the points 
obtained from our assays, we synthesized +/-5.32a by saponification with NaOH in 
isopropanol and mixed this with the products from the PLE hydrolysis of probe 5.32a 
(68% ee) to generate enantiomeric compositions from 20-45% ee. The mixtures were 
analyzed by our mass spectrometry assay and by chiral HPLC to provided enough points 
in a broad enough range of enantiomeric composition for sufficient line fitting. The 
results of this line fitting are displayed in Figure 5.10. The excellent fit of the data to the 
line, the slope of the line, and the near zero Y-intercept illustrates the validity of our 
assay. The slight deviations seen are likely the result of the error associated with the Y-
axis of the graph. There are two sources of error associated with the values plotted on the 
Y-axis; the error from the initial determination of enantiomeric composition of the half-
ester used to make a probe and the error associated with the mass spectrometry 
measurements. This error results in an underestimation of enantiomeric composition by 
up to 5% to 8% ee, but the assay is still capable of determining conditions to optimize the 
selectivity of PLE for malonate diesters. 
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Conclusions 
The field of combinatorial asymmetric catalysis has seen much attention from 
scientists in academia and industry. The utility of this methodology is undisputable for 
optimization of chiral catalysts. In this chapter, a high-throughput mass spectrometry 
based assay has been developed that has allows for the evaluation of the 
enantioselectivity of PLE for three substrates under a variety of cosolvent conditions. 
This assay was used to find conditions that gave increased enantioselectivity for two of 
the diesters of interest.49 Furthermore, the data obtained from the MS assays was plotted 
against the data obtained from chiral HPLC to create a linear correlation graph. The 
regression analysis of this graph further validates that our assay is capable of determining 
the enantioselectivity of enzymes for malonate diesters over a broad range of 
enantioselectivities. This approach should allow us to synthesize mass spectrometry 
probes from any half ester of moderate selectivity from an enzymatic hydrolysis. Probes 
of lower enantiomeric composition will result in intensities that are closer to equal by 
mass spectrometry. The 5% to 8% ee error observed in the assay of probes 5.31a and 
5.3 lb should result in higher error with probes of lower enantiomeric composition, as 
compared to chiral HPLC. For this reason, better results should be observed with probes 
that are greater than 50% ee. However, empirical evidence is needed to determine the 
lower limit of probe enantiomeric composition that can be used for this assy. It is the 
intention of our research group to use this assay to further improve the enantiomeric 
composition of compound 2.32a for synthesis of the unnatural tyrosine analogues seen in 
Chapters II through IV. This assay will also be used to increase the selectivity of various 
enzymes for other malonate diesters of interest. 
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Experimental 
General 
All other chemicals and enzymes were obtained from Aldrich Chemical and used 
as received unless otherwise noted. Mass Spectrometry grade methanol was purchased 
from Aldrich. HPLC grade water was purchased from Fisher. Acetic Acid was purchased 
from Aldrich. Auto sampler vials and caps were purchased from VWR. Samples were 
analyzed using either a ThermoFisher LXQ ESI-Ion trap mass spectrometer coupled to a 
ThermoFisher Accela HPLC system or a Bruker Microflex MALDI mass spectrometer in 
the LDI mode. Chiral HPLC was performed using a LabAlliance Series III isocratic 
pump coupled to a LabAlliance Model 500 UV/Vis detector. HPLC chromatograms were 
recorded using the Peaksimple® data acquisition system and software. Chiral HPLC was 
performed using a Chiralcel OJ-H analytical column or a Chiralcel AD-H column from 
Chiral Technologies, Inc. 
Enzyme Assays (Generalprocedure) 
Approximately 10 mg of the probe under study (5.31a or 5.31b) was placed in a 
2.0 mL microcentrifuge tube along with 1.5 mL of reaction media (buffer or buffer / 
cosolvent mixtures). A 3 uL aliquot of a 50 mg/mL PLE solution (in 0.1 M phosphate 
buffer) was added (4.1 units total). The samples were loaded into an Eppendorf™ 
Thermomixer at 25 °C and 1400 RPM mixing rate. The samples were incubated and 
mixed continuously for three to five days for 5.31a and 5.31b respectively. Aliquots were 
taken at desired time intervals and analyzed by either LC-MS or LDI-ToF MS as 
described below. The observed % ee values were corrected for the optical purity of the 
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probe by dividing the observed % ee by the optical purity of the probe as determined by 
chiral HPLC analysis.50 
LDI-ToF MS 
A 200 uL aliquot of reaction media was placed in a glass vial and acidified with 
30 uL of 10% HC1 solution. The acidified media was then extracted with 200 uL of 
CH2CI2. A 2 (xL aliquot of the organic phase was spotted directly onto a polished steel 
Microscout® chip (Bruker Daltonics). The sample was allowed to dry at ambient 
temperature by gently passing a stream of air over the Microscout® chip. An average of 
800 laser pulses were collected for each sample and the intensities of the peaks were used 
for calculation of enantiomeric excess. 
ESI-ION TRAP MS 
A 200 uL aliquot of reaction media was placed in a glass autosampler vial and 
diluted with 200 \xL of methanol. The Accela autosampler was programmed to inject 1 
uL onto a Hypersil Gold RP HPLC column (50 x 2.1 mm, ThermoFisher). The mobile 
phase was 70:30 methanol:water at a flow rate of 100 uL / minute. The LC-MS system 
was programmed to divert the initial two minutes of flow to waste to desalt the sample. 
The data was collected for the chromatographic peak in SIM mode and the intensities 
were used to calculate enantiomeric excess. 
f/?)-2-(4-(benzvloxyniethvl)-3-ethoxv-2-methvl-3-oxopropanoic acid (2.31a): 
Compound 2.31a was synthesized using the procedure outlined in Chapter 2. The 
characterization data match that of authentic material. The % ee was determined by 
analytical chiral HPLC on either a Chriacel OJ-H (257 nm, flow rate = 1 mL / minute, 
158 
4% z'PrOH / 96% hexane) Rt(/?) = Rt w = 16.90, Rt(5) 19.20 or Chiracel AD-H (45°C, 257 
nm, flow rate = 1 mL/minute, 4% /PrOH / 96% hexane) Rt(R) = 13.65, Rt(S) 15.20. 
D5-Diethyl 2-(benzyIoxvmethvl)-2-methylmalonate (5.31a): An amount of 0.45 g (1.7 
mmol) of 2.32a was dissolved in 25 mL of CH2CI2 in a 50 mL round-bottom flask with a 
magnetic stirbar. Thionyl Chloride (1.8 mL, 25.2 mmol) was added and the solution was 
heated to reflux solvent for 19 hours. The solution was concentrated in vacuo to remove 
excess thionyl chloride and solvent. The acyl chloride was dissolved in 10 mL of dry 
CH2C12. A solution of 220 uL of Et3N in 1 mL of d6-ethanol was added dropwise to the 
stirring acyl chloride under a dry nitrogen atmosphere. The reaction was stirred overnight 
at ambient temperature. The reaction was diluted with 20 mL of ether and washed three 
times each with 10% HC1 and 1.0 M NaOH. The organic layer was dried over MgSCU, 
filtered, and concentrated by rotary evaporation to give 5.31a as a clear, viscous oil 0.43 
g (1.41 mmol 84% yield) TLC (30% ether / 70% hexane) Rf = 0.28. IR (cm"1) 1727, 'H-
NMR (300MHz, CDCl3) 1.21 (3H, t, J=7Hz), 1.52 (3H, s), 3.82 (2H, s), 4.16 (2H, q, 
J=7Rz), 4.53 (3H, s), 7.28 (5H, m). 13C-NMR (75MHz, CDC13) 14.2, 18.6, 55.0, 61.5, 
72.8, 73.6, 81.8, 127.6, 127.8, 128.5, 138.2, 170.8. HRMS: [C^H^DsOjNaf Calcd = 
322.1679, Obsd = 322.1670. 
(±)-D5/H5 -2-(4-(benzvloxvmethvl)-3-ethoxy-2-methvl-3-oxopropanoic acid (±-5.32a): 
An amount of 4.00g ( 13.6 mmol) of 2.31a was dissolved in 11 mL of Ethanol and 0.790 
g of KOH was added in a 50 mL round-bottom flask with a magnetic stirbar. After 48 
hours, the reaction was diluted with 20 mL of water and extracted three times with 20 mL 
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of ether. The aqueous layer was then acidified to pH 2 and extracted three times with 20 
mL of CH2CI2, the combined organic layers were dried over MgS04, filtered and 
concentrated in vacuo to give the racemic half ester 2.32a (2.21 g , 8.30 mmol, 61% 
yield). Then, ±-2.32 (0.446 g, 1.68 mmol) was esterified by the same procedure reported 
to prepare 5.31a to give 0.422 g (1.41 mmol, 84% yield) ±-5.31a diester. The racemic 
D5/H5 diester (0.357 g) was dissolved in a 80% z'PrOH / 20% H20 solution containing 
95.5 uL of a 50% w/v aqueous NaOH solution. The reaction was monitored by TLC and 
was complete after 48 hours. The reaction mixture was diluted with 20 mL of 1.0 M 
NaOH and extracted three times with Et20. The aqueous layer was acidified to pH 2 and 
extracted three times with CH2CI2, dried over MgS04, filtered and concentrated by rotary 
evaporation to give racemic D3/H5 half ester (±5.32a) (0.209 g, 0.775 mmol (based on 
average molecular weight), 65% yield). TLC (5% MeOH / 95% CH2C12) Rf= 0.317. 'H-
NMR (300MHz, CDC13) 1.23 (1.5H, \,J= 7 Hz), 1.54 (3H, s), 3.81 (2H, s), 4.20 (1H, q, 
J= 7 Hz), 4.55 (2H, s), 7.28 (5H, m). The % ee was determined by analytical chiral 
HPLC (Chiracel AD-H, 257 nm, flow rate = 1 mL / minute, 4% iPrOH / 96% hexane) 
R t w = 14.97, Rt(5) 17.62. 
(i?)-2-(4-(benzvloxv)benzvl)-3-ethoxv-2-methyl-3-oxopropanoic acid (2.32b): 
Compound 2.32b was synthesized according to the procedure outlined in Chapter 2. The 
% ee was determined by analytical chiral HPLC (Chiracel AD-H, 282 nm, flow rate = 1 
ml / minute, 4% IPTOH / 96% hexane) Rt(S) = 20.87, Rt(S) 30.18. 
(±) D5/H5-2-(4-(benzvIoxv)benzvl)-3-ethoxv-2-methyl-3-oxopropanoic acid (+/-
5.32b): An amount of 3.24 g (8.75 mmol) of 2.31b was dissolved in 20 mL of ethanol 
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and 701 uL of a 50% w/v aqueous NaOH solution was added in a 50 mL round-bottom 
flask with a magnetic stirbar. After 24 hours, the reaction was diluted with 40 mL of 
water and washed three times with Et20. The aqueous layer was then acidified to pH 2 
and extracted three times with CH2CI2, dried over MgSO/j, filtered and concentrated in 
vacuo to give the racemic (2.27 g, 6.62 mmol, 76% yield) half-ester (±2.32b). The 
characterization data was identical to that reported in the literature.51 Compound +/-2.32b 
was then esterified by the same procedure reported for 5.31b to give 0.391g (1.043 mmol, 
71% yield) of the racemic D5/H5 diester. The racemic D5/H5 diester (0.618g, 1.646 mmol) 
was then dissolved in 13 mL of a 80% z'PrOH / 80% water solution and 132 uL of 50% 
w/v aqueous NaOH solution was added. The reaction was monitored by TLC (5% MeOH 
/ 95% CH2CI2) and was completed after 48 hours. The reaction was diluted with 20 mL 
of 1.0 M NaOH and washed three times with Et20. The aqueous layer was then acidified 
to pH 2 and extracted three times with CH2CI2, dried over MgS04, filtered and 
concentrated in vacuo to give 0.49 g (0.078 Mol, 87% yield) of the racemic D5/H5 half 
ester (+/-5.32b). TLC (5% MeOH / 95% CH2C12) Rf = 0.51. 'H-NMR (300MHZ, CDCI3) 
1.26 (1.5H, t, J= 7 Hz), 1.40 (3H, s), 3.13 (1H, d, J= 14 Hz), 3.25 (1H, d, J= 14 Hz), 
4.20 (1H, q, J= 7 Hz), 5.01 (2H, s), 6.88 (2H, d, J= 8 Hz ), 7.08 (2H, d, J= 8 Hz )7.38 
(5H, m). 
D5- Diethyl 2-(4-(benzvloxv)benzvD-2-methvlmalonate (5.31b): An amount of 0.50 g 
(1.46 mmol) of 2.32b (from PLE hydrolysis) was dissolved in 15 mL of Methylene 
Chloride in a 25 mL round-bottom flask with a magnetic stirbar. Thionyl Chloride (2 
mL, 27.8 mmol) was added and the solution was brought to reflux solvent for 15 hours. 
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The solution was concentrated in vacuo and the crude acyl chloride was dissolved in 10 
mL of dry CH2Cl2.Tb.en, 220 uL of Et3N was dissolved in 1 mL of d6-ethanol and added 
dropwise to the stirring acyl chloride. The reaction stirred for 15 hours at ambient 
temperature under an N2 blanket. The reaction was diluted with 20 mL of Et20 and 
washed three times each with 10% HC1 and three times withl .0M NaOH. The organic 
layer was dried over MgS04, filtered, and concentrated in vacuo to give 5.31b as a white 
amorphous solid. TLC: (10% EtOAc / 90% hexane) Rf= 0.22. This gave 0.39 g (1.04 
mmol, 71% yield) of a white amorphous solid. Mp = 49° C, IR (cm"1) 1726 , 'H-NMR 
(300 MHz, CDC13) 1.24 (3H, t, J= 7 Hz), 1.33 (3H, s), 3.17 (2H, s), 4.18 (2H, q, J= 1 
Hz), 5.01 (2H, s) 6.86 (2H, d, J= 9 Hz), 7.04 (2H, d,J= 9 Hz) 7.37 (5H, m). 13C-NMR 
(75 MHz, CDCb) 13.1 (sept, J =20 Hz), 14.2, 19.8, 40.4, 55.0, 60.6 (quint, J = 22 Hz), 
61.5, 70.1, 114.6, 127.6, 128.0, 128.5, 128.7, 131.3, 137.1, 157.9, 172.1. HRMS: 
[C22H2iD505Na]+ calcd = 398.1992 obsd = 398.1983. 
Dimethyl 2-(4-(benzvloxv)benzvD-2-methyImalonate (5.37): Compound 5.37 was 
synthesized by a variation of a previous of literature procedure.52 A 250 mL 3-neck 
round-bottom flask was charged with 100 mL of dry THF, a stirbar, and 1.30 g (32.4 
mmol) of NaH (60% dispersion in mineral oil) under a nitrogen blanket. The flask was 
placed in an ice bath and allowed to stir for 15 minutes. A solution of dimethyl 
methylmalonate (3.95 g, 27 mmol in 5 mL of anhydrous THF) was added dropwise to the 
NaH suspension at 0 °C. Once H2 evolution had ceased, the solution was allowed to stir at 
ambient temperature for 30 minutes. A solution of l-(benzyloxy)benzyl)-4-
(chloromethyl)benzene (5.78 g, 27.0 mmol, in 30 mL of anhydrous THF) was added 
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dropwise. The resulting solution was heated to reflux solvent for 15 hours. The solution 
was then allowed to cool to ambient temperature and 1 mL of water was added to quench 
any remaining NaH. The resulting suspension was diluted with 100 mL of ether, washed 
three times with brine, three times with 10% HC1, dried over MgSC>4, filtered, and 
concentrated by rotary evaporation. The crude material was dissolved in 20 mL of MeOH 
and 20 mL of ddH20 was slowly added to precipitate the pure 5.37 which was isolated by 
vacuum filtration and dried over H2SO4 to give 5.01g (14.4 mmol, 54% yield) of a white 
amorphous solid. TLC (50% Et20 / 50% hexane) Rf = 0.40. 
(/?)-2-(4-(BenzvIoxv)benzvO-3-methoxv-2-methvl-3-oxopropanoic acid (5.38): An 
amount of 2.67 g (7.80 mmol) of 5.37 was dispersed in 600 mL of rapidly stirring 
phosphate buffer (0.1 N, pH 7.4). Then, 40 mg of PLE (702 units) was dissolved in 1.0 
mL of 3M (NH4)2S04 and added to the buffer solution. The pH of the reaction mixture 
was maintained using a 798 MPT Titrino® in the pH stat mode. The Titrino® was set to 
titrate to a volume of 7.50 mL (1 eq of 1.04 M NaOH). The hydrolysis proceeded for 96 
hours, after which time the solution was made basic by addition of 1.04 M NaOH. The 
aqueous solution was then extracted three times with 300 mL portions of ether and the 
aqueous layer was acidified using concentrated H2SO4 to a pH of 2. The aqueous layer 
was then extracted three times with CH2CI2 and four times with Et20. The organic layers 
were combined, dried over MgS04, filtered, concentrated by rotary evaporation, and 
purified by flash chromatography to give 1.93 g (5.88 mmol, 75% yield, 80% ee) of a 
white, amorphous solid. TLC (5% MeOH / 95% CH2C12) Rf = 0.33. [a]D24= -5.10° (c 
=8.00, CHCI3). Mp = 142 - 146 °C. IR (cm"1) 1734, 1707. 'H-NMR (300MHz, CDC13) 
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1.42 (3H, s), 3.13 (1H, d, J= 14 Hz), 3.25 (1H, d, J= 14 Hz), 3.76 (2H, s), 5.03 (2H, s), 
6.89 (2H, d, J= 9 Hz), 7.06 (2H, d, J= 9 Hz ), 7.38 (5H, m). 13C-NMR (75MHz, CDC13) 
20.4,41.2,53.0,55.1,70.2, 114.8, 127.7, 128.1, 128.2, 128.8, 131.3, 137.1, 158.2, 173.2, 
176.7. HRMS: [C,9H2o05Na]+ Calcd = 351.1203 Obsd = 351.1199. The % ee was 
determined by analytical chiral HPLC (Chiracel AD-H, 282 nm, flow rate = 1 ml / 
minute, 4% iPrOH / 96% hexane, 42 °C) Rt w = 20.52, Rt(S) 31.15. 
(V-)-2-(4-(Benzvloxv)benzvl)-3-methoxv-2-methvl-3-oxopropanoic acid (5.38): An 
amount of 5.01 g (14.6 mmol) of 5.37 was dissolved in 70 mL of MeOH and 1.17 mL 
(14.6 mmol) of a 12.50 M NaOH was added and the solution was allowed to stir at 
ambient temperature for 48 hours. The reaction was then diluted with 50 ml of 1.0 M 
NaOH, washed three times with Et20, acidified with concentrated H2SO4 at 0 °C, and 
extracted into Et20. The Et20 was dried over MgS04, filtered, and concentrated by rotary 
evaporation to give 3.68 g (11.2 mmol, 77% yield) of a white, amorphous solid. 
DrrDimethyl 2-(4-(benzvloxv)benzvD-2-methvlmalonate (5.39): An amount of 0.23 g 
(0.70 mmol) of (i?)-5.38 (from PLE hydrolysis) was dissolved in 10 mL of anhydrous 
CH2CI2 and 757 uL of SOCI2 (10.5 mmol) was added and the solution was brought to 
reflux solvent for 19 hours. The solution was concentrated in vacuo and the crude acyl 
chloride was dissolved in 1 mL of D3-methanol. Then, 1 mL SOCI2 and 10.5 uL of Et3N 
was added and the reaction was allowed to stir at room temperature for 17 hours. The 
solution was diluted with 10 mL of CH2CI2 and washed three times each with 10% HC1. 
The organic layer was dried over MgS04, filtered, and concentrated by rotary evaporation 
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to give 1.99g (0.58 mmol, 82% yield) of 5.39 as a white amorphous solid. TLC (30% 
EtOAc / 70% hexane ) Rf= 0.41, Mp = 75 - 78° C, IR (cm"1) 1720, 'H-NMR (300 MHz, 
CDC13) 1.36 (3H, s), 3.18 (2H, s), 3.73 (3H, s), 5.03 (2H, s), 6.88 (2H, d, J= 9 Hz), 7.03 
(2H, d, J= 9 Hz) 7.39 (5H, m). I3C-NMR(75 MHz, CDCI3) 19.9, 40.7, 52.7, 55.2, 70.1, 
114.7, 127.7, 128.1, 128.4, 128.7, 131.3, 137.2, 158.0, 172.6. HRMS: [C2oHi9D305Na]+ 
Calcd = 368.1548 Obsd = 368.1542. 
(5Vmethvl-3n4-(benzvloxv)phenvI)-2-(benzvloxvcarbonylamino)-2-
methylpropanoate (5.40): An amount of 1.00 g (3.05 mmol) of 5.38 was dissolved in 10 
mL of Dichloroethane and 722 uL (3.35 mmol) of DPP A and 1.37 uL (9.12 mmol) of 
Et3N was added and the solution was allowed to stir at room temp for 30 minutes. The 
solution was heated to reflux solvent for 1.5 hours, at which time 473 u.L (4.58 mmol) of 
benzyl alcohol was added and the solution was allowed to reflux for 17 hours. The 
mixture was then cooled and diluted with 20 mL of CH2CI2, washed two times with 10% 
HC1, filtered through a plug of silica gel, and concentrated by rotary evaporation. The 
residue was purified by flash chromatography (40% EtOAc / 60%) hexane) with 200 mL 
of silica gel to give 1.23 g (2.84 mmol, 93% yield, 80% ee) of a clear, viscous oil. TLC 
(40% EtOAc / 60% hexane) Rf = 0.44. [a]D235 = -27.1° (c = 10.3, MeOH). IR (cm"1) 
3352, 1719. 'H-NMR (300 MHz, CDCI3) 1.66 (3H, s), 3.16 (1H, d, J= 14 Hz), 3.39 (1H, 
d, J= 14 Hz), 3.77 (3H, s), 5.03 (2H, s), 5.11 (1H, d, J= 12 Hz), 5.22 (1H, d, J= 12 Hz), 
5.55 (1H, bs), 6.84 (2H, d, J = 9 Hz), 6.92 (2H, d,J= 9 Hz), 7.41 (10H, m). I3C-NMR 
(75 MHz, CDCI3) 23.6, 41.0, 52.7, 61.0, 66.5, 70.0, 114.7, 127.6, 128.1, 128.2, 128.3, 
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128.4, 128.6, 128.7, 131.0, 136.7, 137.1, 154.7, 157.9, 174.2. HRMS: ^ e ^ y N O s N a f 
calcd = 456.1781 obsd = 456.1773. 
(SVa-Methvi Tyrosine Methyl Ester (5.41): An amount of 0.50 g of Pd / C was 
carefully suspended in 5 mL of MeOH. Then, 1.26 g (2.85 mmol) of 5.40 was dissolved 
in 30 mL of MeOH and slowly added to the flask. The solution was degassed with 
hydrogen gas for 15 minutes placed under a Hydrogen blanket for 19 hours. The 
disappearance of 5.40 was monitored by TLC (40% EtOAc / 60% hexane). The reaction 
was filtered through a celite pad to remove the Pd/C and concentrated by rotary 
evaporation. The material was dissolved in 10 ml of 3N methanolic HC1 to form the 
chloride salt of a-methyl tyrosine and the excess MeOH was removed by rotary 
evaporation to give a clear, viscous liquid. The liquid was washed three times with Et20 
which resulted in the formation 0.69g (2.81 mmol, 99% yield) of a white amorphous 
solid. The dextrorotary direction of rotation [a]obs23°c = +0.42° (c = 7.1, MeOH) of 5.41 
matched that of an authentic sample [a]obs23 °c = +0.33 (c = 5.0, MeOH). 'H-NMR (300 
MHz, CD3OD) 1.47 (3H, s), 2.88 (1H, d, J= 14 Hz), 3.08 (1H, d, J= 14 Hz), 6.66 (2H, 
d, J= 8 Hz), 6.88 (2H, d, J= 9 Hz). 
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CHAPTER VI 
FUTURE DIRECTIONS 
Introduction 
It seems that each experiment preformed in the laboratory brings another question 
that would be interesting to answer. The work described in this dissertation is no 
exception to this. There have been many interesting discussions on the possible uses of 
the compounds that have been synthesized during the duration of this project. However, 
research is a story that is always in the process of being completed. This chapter will 
focus on what is needed to complete the work described in Chapters II though V with 
some possible expansions of the project. Methods that may be used to obtain compound 
2.32b in greater than 97% ee, including possible conversion of 2.32a into 2.32b will be 
discussed. This will include application of the mass spectrometry based assay that was 
outlined in Chapter 6.1 Also discussed is a potential method to increase the throughput of 
our mass spectrometry assay. Once compound 2.32b is obtained in sufficient optical 
purity, synthesis and testing of neurotensin (NT) analogues will proceed. Hopefully, 
future work on this project will allow for completion of this project and application of the 
described unnatural amino acids for use in NT peptidomimetic compounds. 
Future Directions 
Does Transesterification Influence the Enantioselectivity of Pig Liver Esterase? 
As demonstrated in Chapter V, use of various concentrations of isopropanol and 
ter/-butanol as cosolvents gave a significant increase in the enantioselectivity of the PLE 
hydrolysis of probes 5.31a, 5.31b, and 5.39.' Attempts have been made to establish 
predictive models for the enantioselectivity of enzymes in cosolvents. It was concluded 
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that any correlations seen with the dielectric constant or hydrophobicity (logP) of the 
cosolvents were enzyme and substrate specific and were not sufficient for establishing a 
model for other substrates. In our studies of PLE enantioselectivity it was also observed 
that the effects of each cosolvent were dependant on the substrate that was being studied 
(see Table 5.1, page 151). 
It is possible that some solvents, or even buffers, act as nucleophiles and assist in 
the observed increase in enantioselectivity of PLE. Some groups have observed the buffer 
acting as an alternate nucleophile to water. The buffer reacts with a single enantiomer of 
the product when formed in the enzyme active sight; leading to an the increase in 
enantioselectivity. It may be possible that the increase in enantioselectivity seen in the 
PLE hydrolysis of our diesters with isopropanol cosolvent is due, in part, to isopropanol 
acting as an alternative nucleophile to water (Scheme 6.1). Formation of the 5.36a has 
been observed when isopropanol was used as a cosolvent for the PLE hydrolysis of 
5.31a. Isolation of the isopropyl ethyl diester (5.36a), followed by analysis by chiral 
HPLC would allow us to determine if transesterification contributed to the observed 
increase in enantioselectivity. However, it is also worth noting that the increased 
selectivity seen when tert-butano\ was used as a cosolvent was not accompanied by any 
detectable transesterification. This means that although transesterification may play a role 
in increasing enantioselectivity, it is not the only contributing factor. It may be that the 
effect of cosolvents on enzymatic hydrolyses is far too complex to be narrowed to a 
single mechanism and will require extensive study, but this is beyond the scope of this 
dissertation. 
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2.31a 2.32a 5.36a 
Q 0 0 0 0 
v o">< " o ^ - - ^ ^ O ^ ^ X T O H + " ^ o >>v o' 
' 10% isopropanol/ _.,,., 1 ' 
OBn pH 7.4 phosphate > 9 7 % e e OBn OBn 
buffer 
Scheme 6.1. Transesterification observed in the PLE hydrolysis of 2.31a in 
10% z'PrOH / pH 7.4 phosphate buffer 
Increasing Enantioselectivity of PLE for 2.32b above 85% ee 
The effect of cosolvents on the enantioselectivity of PLE is well documented even 
though the mechanism remains unknown. In Chapter 5, it was demonstrated that the PLE 
hydrolysis of 2.31b to 2.32b in 30% isopropanol / 70% phosphate buffer could be 
obtained in 85% ee. It was also noted that concentrations of the cosolvents above 30% led 
to a low rate of conversion and low yield (less than 10%). Further work is needed to 
determine conditions that yield greater than 97% ee for the PLE hydrolysis of 2.31b. It 
may be possible to add ionic liquids to increase the rate of hydrolysis with higher 
concentrations of cosolvents. This may result in an increase in enantioselectivity above 
85% ee for 2.32b. If addition of ionic liquids and / or higher concentrations of cosolvents 
to the PLE hydrolysis of 2.31b fails to yield greater than 97% ee, it will be necessary to 
find other enzymes that are capable of producing high enantioselectivity for ester 
hydrolysis. Horse liver esterase, rabbit liver esterase, choline esterase, and Bacillus 
substilis esterase have proven to be enantioselective enzymes, and could be evaluated for 
hydrolysis of our diesters. " 
In addition to the numerous available esterases, there are also a number of lipases 
that have been shown to resolve chiral alcohols by cleavage of acetates or resolve chiral 
acids by cleavage of esters. ' Some lipases, such as pseudomonas lipase, have shown the 
ability to resolve prochiral diesters. ' Porcine pancrease lipase has been used for 
resolution of chiral diesters.1 These lipases can be evaluated for selectivity with 
prochiral malonate diester substrates using our mass spectrometry based assay for 
enantioselectivity. If the diester probes fail to yield notable enantioselectivity with 
lipases, the diesters can be converted to diacetates that may be enantioselectively 
hydrolyzed with lipases.14 The conversion of 2.31b or 5.57 to diacetates can be 
accomplished by reduction of the diester of interest to a diol by treatment with lithium 
aluminium hydride, followed by acetylation with acetic anhydride. 5 Similar diacetates 
have been hydrolyzed selectively by Lipases. The resulting diacetate can be evaluated 
with various lipases and esterases and if conditions are found that result in greater than 
97% ee, the half acetates can be can be converted to a series of unnatural amino acids. 
However, if the enantioselectivity is less than 97% ee, the half-acetate can be converted 
to a probe (6.4) that can be used in our mass spectrometry assay for enantioselectivity. 
This can be accomplished by treating 6.3 with D3-acetic anhydride. Cosolvents have the 
same effect on lipases that is seen with PLE.2'14 This should allow 6.4 to be used as a 
probe for media engineering of lipases under a variety of conditions. 
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R= CH3orCH2CH3 
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Amm©Add 
MS Assay 
Scheme 6.2. Conversion of a 2.31b or 5.37 into a diacetate subsequent synthesis 
of a D3-diacatate mass spectrometry probe (6.4) 
Obtaining Quantitative Information for the Mass Spectrometry Assay 
We would like to extend the mass spectrometry assay for enantioselectivity to 
give information on the rate and yield of the enzymatic reactions. One possibility that 
would allow us to monitor both rate and yield of the desymmetrization of a malonate 
diester is the isotopic dilution method for quantitation.16 This method requires the 
addition of an isotopomer as an external standard directly before analysis of the sample 
by LC-MS. The isotopomer should be ionized to the same extent as the molecule of 
interest, so if the concentration of the standard is known, the concentration of the analyte 
can be calculated. To use this method for our MS assay would require addition of an 
isotopomer of the diester probes or half ester product to the aliquots to be analyzed. This 
is convenient because the Hio or H6- diesters (2.31a, 2.31b, or 5.37) are intermediates in 
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synthesis of the Dj/Hs-diester probes and can be used as the needed isotopomer. As an 
example, use of the Hio diester (2.31b) would allow us to monitor the rate of the 
disappearance of the 5.31b (Scheme 6.3). The rate of the disappearance of the 5.31b 
should be equal to the rate of the reaction. This relationship should also exist for the yield 
of the reaction. However, if there is any decarboxylation of the 2.32b, the yield could 
appear to be higher than the actual yield of the reaction because the amount of 
decarboxylated half-ester would not be factored into the calculations for yield. To resolve 
this issue, an isotopomer of the half-ester could be used to directly monitor the rate and 
yield of the half ester probe. This would require the synthesis of a Ds-half ester that could 
be used as an external standard (Scheme 6.4). However this synthesis will require the use 
and waste of multiple deuterated materials. 
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Scheme 6.3. Example of the addition of an H]0-diester as an external probe 
and the representative mass spectra 
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Scheme 6.4. Synthesis of a Dg-half ester as an external probe 
If all of the methods described above fail to allow for the production of 2.31b in 
greater than 97% ee, it may be possible to convert 2.31a to 2.31b. Literature has shown 
that ring opening of (3-lactones synthesized from a-methyl serine with nucleophiles has 
led to the synthesis of various a-methyl amino acids. ' The nucleophile reacts almost 
exclusively at the (3-carbon which give an a-methyl amino acid. Smith et al. were able to 
successfully ring open 6.12 (Scheme 6.5) with a variety of organocuprates to yield 11 a-
methyl amino acids with proteinogenic and non-proteinogenic sidechains. It may be 
possible to convert 2.31a to a p-lactone (6.14) by hydrogenolysis of the benzyl protecting 
group followed by treatment with 0-(Benzotriazol-l-yl)-N,N,N',N'-tetramethyluronium 
hexaflourophosphate (HBTU).19 Treatment of 6.14 with 6.15 should result in the desired 
2.31b in greater than 97% ee. The procedure outlined by Smith et al. made use of 
catalytic amount of copper. However, it is possible that the organocuprate may react with 
ester moiety of the 6.14. For this reason, it may be necessary to use stoichiometric 
amounts of copper to transform 6.14 to 2.32b. If 2.32b can be obtained in greater than 
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97% ee through one of the methods outlined above, synthesis of the desired unnatural 
amino tyrosine analogues can proceed. 
2.32a 6.14 6.15 2.32b 
Scheme 6.5. Synthesis of a 2.32b from 2.32a through a p-lactone intermediate 
Synthesis of (S)-y4'4-Tyrosine 
In Chapter IV, it was noted that the attempted saponification of 4.47 did not yield 
4.50, but instead hydrolysis of the tert-b\\ty\ ester was observed to give 4.48 (see Scheme 
4.5 on page 105). A solution to this problem is to change the Wittig reagent to a tert-b\xiy\ 
ether instead of a tert-bvXy\ ester (total synthesis illustrated in Scheme 6.6). This should 
allow for the ester of 6.19 to be saponified. Compound 6.19 must be subjected to a 
Curtius rearrangement that is quenched with Fmoc-OH to generate 6.20 before the tert-
butyl ether is cleaved by treatment with H+ in the presence of a tert-bvXy\ ion scavenger 
such as anisole.20 Otherwise, a competing nucleophile may be generated that can react 
with the isocyanate that is formed in the Curtius rearrangement to give a cyclic 
carbamate. Compound 6.21 can be oxidized to the an acid by treatment with Jones 
reagent to yield the desired (5)-y4'4-tyrosine (6.22).21 
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Scheme 6.6 . Alternative synthesis of (S)- y4'-tyros ine (6.22) 
Synthesis and Evaluation of the Stability of Neurotensin Peptidomimetics 
Synthesis of neurotensin (NT) analogues can be conducted once conditions have 
been determined that yield acceptable optical purity for 2.32b and the desired unnatural 
tyrosine analogues have been synthesized. There are two options to obtain the desired 
neurotensin peptidomimetics: 1) the peptidomimetics can be synthesized commercially 
using our unnatural tyrosine analogues or 2) the peptidomimetics can be synthesized in 
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our laboratory using solid-phase peptide synthesis. The peptidomimetic can then be tested 
via a previously developed assay for neurotensin degradation. Since NT(8-13) is a small 
peptide and should be relatively easy to synthesize, I will discuss method that will allow 
for the completion of this research project in house. 
There are several published procedures for the solid phase synthesis of 
neurotensin.22'28 Chang et al. first used a 4-(hydroxymethyl)phenylacetamidomethyl-resin 
(PAM) for the solid phase synthesis NT analogues.29 It was found that the PAM resin 
gave double the yield of the more commonly used oxymethyl-copoly-(styrene-
divinylbenzene) resin. The reason for the increased yield was that the resin-amino acid 
linkage for PAM was 100 fold more stable during peptide synthesis than the oxymethyl-
copoly-(styrene-divinylbenzene) resin. For this reason, a PAM resin should be used for 
the solid phase peptide synthesis of our NT(8-13) analogues with the unnatural Tyr 
residues. A convergent synthetic strategy can be used to limit the number of steps, and 
increase the yield of the peptide synthesis. A convergent synthesis will increase the 
overall yield of the peptide synthesis by decreasing the total number of steps required as 
compared to a linear (one amino acid at a time) synthesis. For example, if each step in a 
linear peptide synthesis results in a 90 % yield, the six-residue NT(8-13) would be 
coupled with a 50 % overall yield. Therefore, each step that is removed from the 
synthesis by use of a convergent strategy should result in a 10% increase in overall yield 
of the peptide. This is particularly important because multiple NT analogues will be 
synthesized. Each cycle also requires 8 to 16 hours for coupling of each amino acid 
residue.30 Any step which limits the amount of time that the synthesis requires will make 
the entire peptide synthesis more efficient. Amino acid dimers, such as the 8-Arg -9-Arg, 
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can be synthesized in solution via Dicyclohexylcarbodiimide (DCC) amino acid coupling 
in the presence of N-hydroxybenzotriazole (HOBt) using Boc (ter/-Butoxycarbonyl) 
protected amino acids (Scheme 6.7). This will allow us to make bulk quantities of the 
required amino acid dimers that can be used in the synthesis of each NT(8-13) analogue. 
6.23 ^ \ 6.24 ^ " f ^ 6 2 5 
n M ^ ^ ^ a t B u N ^ /
 o t B u 
H 9 "J f HO HoBT
 H O r 
>T°Y N ^^O^NH + H2N^ C02-t-Bu " > f ° y N ^ N AC02-tBu 
° P h " (\ ° P h - = H 
Almost Quantitative 
Scheme 6.7. Example of a DCC peptide coupling of amino acids in the presence of HoBT 
Synthesis of our NT(8-13) analogues can be accomplished using methods similar 
to the those used by Bitterman et al.30 The Lue13 preloaded PAM resin is commercially 
available. The preloaded Leu residue can be deprotected by treatment with 50% TFA / 
CH2CI2 / Indole, followed by neutralization with N,N-Diisopropylethylamine (DIPEA). 
The He can be coupled to Lue by treatment of the Boc-Ile with 2-(7-Aza-lH-
benzotriazole-l-yl)-l,l,3,3-tetramethyluroniumhexafluorophosphate (HATU,3-5 eq) to 
activate the acid of lie , followed by addition of DIPEA and 8-16 hours of agitation. 
Complete acylation can be monitored by the Kaiser test (Ninhydrin test). The remainder 
of the amino acid residues can be coupled using the same procedure with exception of the 
Pro residue. The Pro residue must be coupled using Fmoc-Pro that is activated by bis-
(trichloromethyl)carbonate (BTC) in the presence of 2,6-lutidine. The F-moc group can 
be removed with piperidine / diazobicycloundecane (DBU) to facilitate the next coupling 
step. Once peptide synthesis is complete, the Boc-group can be removed by treatment 
with trifluoroacetic acid.30 Removal of the arginine and tyrosine protecting groups and 
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cleavage of the peptide from the resin can be facilitated by treatment with fluoric acid in 
the presence of a tert-butyl cation scavenger. The peptide can then be purified by 
reverse phase preparative HPLC and is ready to be subjected to degradation studies. 
Degradation studies can be conducted using established literature procedures.27' 
34
 For controls, native neurotensin and NT(8-13) can be used. Both are commercially 
available. This will allow us to compare the stability of our NT(8-13) analogues to the 
natural NT and NT(8-13) fragments. Our NT(8-13) will be incubated in a mixture of 
enzymes which exhibit high specific activity for the Pro-Tyr and Tyr-Ile peptides bonds. 
Pepsin and Chymotrypsin, as examples, hydrolyze peptide bonds on the amino-terminal 
side of aromatic amino acid residues. 3 To mimic in vivo conditions in the human body, 
our neurotensin analogues can be incubated in human serum (50% serum / 50% 
phosphate buffered Saline (PBS)) at 37 °C. At preset integrals an aliquot can be taken 
and reverse phase HPLC can be used to determine the amount of degradation that has 
taken place. ' ' The degradation products can be determined by LC-MS. 
Kokko et al. developed an in vitro degradation assay that utilizes MALDI-ToF 
mass spectrometry to monitor the degradation of neurotensin in rat serum.36 The 
neurotensin analog of interest will be incubated in rat serum, at 37 °C. At preset intervals 
a 20 uL aliquot will be removed and added to 80 uL of an alcohol solution (3:1 
MeOH/EtOH). This solution will then be vortexed for 30 seconds, followed by 
centrifugation for 10 minutes. Then, one uL of the solution will be mixed with one uL of 
an external standard (Kemptide, 1.30 nmol in saline) and added to six uL of matrix. Next, 
0.5 uL of the mixture will be spotted on a target plate and analyzed by MALDI-ToF MS. 
The masses observed in the mass spectrum should allow us to determine the degradation 
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products from our neurotensin analogues. We should be able to determine the rate of the 
hydrolysis by direct comparison of the intensities of the fragments to the intensities of the 
external standard. 
Conclusions 
Hopefully, with the future work outlined in this chapter, the enantiomeric 
composition of 2.32b can be improved to greater than 97% ee. This should allow for 
7 9 'X 'X 9 9 4 4 
complete synthesis of both enantiomers of the a-methyl, |3 ' -, (3 ' -, y ' - and y ' -
tyrosine analogues. Once the desired unnatural tyrosine analogues have been obtained, 
synthesis and testing of neurotensin peptidomimetics can proceed. Hopefully, the end 
result of this research project will be the development of neurotensin peptidomimetics 
that display increased in vivo stability and that retain the ability to interact with the 
neurotensin receptors with high affinity. This may allow for the exploration of new 
cancer drugs or new imaging agents that may specifically target cancerous cells. 
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206 
O N CO ^ 
n r M COCO 
rv 
m 
CO , _ i 
m 
o o CO U3 <t* cn en •«}-N v O U l l / 1 
7 6 5 
f l (ppm) 
O LT1 
en Ln 
LD LT1 
CO 
-3" CO 
co rv 
O 
r^ 
/-""' I I V I I 
^ ^ i H » H i i W W W W W « w ^ w » W M W ^ I W t f l W W t t i H » l i M i M I W » A ^ uJU^nwaMswwww^iwwjiXiMUifrgAiWMrttJUwn^^ 
230 210 190 170 150 130 110 
f l (ppm) 
90 80 70 60 50 40 30 20 10 0 
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A.21. a) 'H-NMR and b) 13C-NMR of compound 3.41a 
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A.22. a) 'H-NMR and b) 13C-NMR of compound 3.42a 
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A.23. a) 'H-NMR and b) 13C-NMR of compound 3.43a 
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A.24. a) 'H-NMR and b) 13C-NMR of compound 3.32b 
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A.25. a) 'H-NMR and b) 13C-NMR of compound 3.33b 
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A.26. a) 'H-NMR and b) 13C-NMR of compound 3.34b 
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A.27. a) 'H-NMR and b) 13C-NMR of compound 3.35b 
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A.28. a) 'H-NMR and b) 13C-NMR of compound 3.36b 
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A.29. a) 'H-NMR and b) 13C-NMR of compound 3.37b 
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A.30. a) 'H-NMR and b) l3C-NMR of compound 3.38b 
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A.31. a) ^-NMR and b) ,3C-NMR of compound 3.39b 
218 
^- ^ " r o r o r o r o r o m r o o c n C T > c o c o o o r-» •*• IN 
^H O O 
Lri u"i u-j 
1-1 
CO 
r-S 
o 
CO 
TH O in 
us ^ ro 
r*J pJ <N 
•3- rn 
T-H 1-H 
sv i i ^ V 
i / 
*v v^—, f H 
<3~ rs j 
I - M - . T1 ^ i 
13 12 11 10 7 6 5 
f l (ppm) 
I \/ /r^ V I \ I SI V \ / 
** IMl lMiMi i^^ LMAMJ MIMI tfiii^i mi J > (rtrii t Mm i m i tfim 
230 210 190 170 150 130 110 90 80 70 60 50 40 30 20 10 0 
fl (ppm) 
A.32. a) 'H-NMR and b) 13C-NMR of compound 3.40b 
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A.33. a) 'H-NMR and b) 13C-NMR of compound 3.41b 
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A.34. a) lH-NMR and b) l3C-NMR of compound 3.42b 
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A.35. a) lH-NMR and b) 13C-NMR of compound 3.43b 
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A.36. a) 'H-NMR and b) 13C-NMR of compound 4.43 
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A.37. a) 'H-NMR and b) 13C-NMR of compound 4.45 
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A.38. a) 'H-NMR and b) 13C-NMR of compound 4.46 
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A.39. a) 'H-NMR and b) 13C-NMR of compound 4.47 
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A.40. a) 'H-NMR and b) 13C-NMR of compound 4.48 
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A.41. a) 'H-NMR and b) 13C-NMR of compound 4.49 
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A.42. a) 'H-NMR and b) 13C-NMR of compound 4.53 
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A.43. a) 'H-NMR and b) 13C-NMR of compound 4.55 
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A.44. a) 'H-NMR and b) 13C-NMR of compound 4.56 
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A.45. a) 'H-NMR and b) 13C-NMR of compound 4.57 
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A.46. a) ' H - N M R and b) l3C-NMR of compound 4.58 
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A.47. a) 'H-NMR and b) 13C-NMR of compound 4.60 
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A.48. a) ' H - N M R and b) l3C-NMR of compound 4.61 
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A.49. a) 'H.NMR and b) l3C-NMR of compound 5.31a 
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A.50. a) 'H-NMR and b) 13C-NMR of compound 5.31b 
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A.51. a) 'H-NMR of compound +/- 5.32a 
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A.52. a) 'H-NMR of compound +/- 5.32b 
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A.53. a) 'H-NMR and b) 13C-NMR of compound 5.38 
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A.54. a) 'H-NMR and b) 13C-NMR of compound 5.39 
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A.55. a) 'H-NMR and b) 13C-NMR of compound 5.40 
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A.56. 'H-NMR of compound 5.41 
